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1 Chapter 1 
Introduction and Scope 
1.1 Introduction 
A diet rich in fruits and vegetables is associated with a long healthy life. 
Epidemiological data suggest that the dietary intake of fruits and vegetables has 
beneficial effects on a variety of diseases, such as different types of cancer, 
cardiovascular diseases, diabetes and the prevention of osteoporosis [1-4]. A 
large number of studies suggest that these protective effects are elicited by 
polyphenols present in fruits and vegetables [1-3]. 
Polyphenols are naturally occurring phytochemicals found in plant-based food, 
such as fruits, vegetables, legumes, whole grains, tea, coffee, wine and nuts 
and several thousand different polyphenolic compounds have been identified 
[2]. Based on their chemical structure polyphenols can be classified in phenolic 
acids (e. g. hydroxybenzoic or hydroxycinnamic acids), flavonoids, stilbenes, 
chalcones and lignanes [5]. Flavonoids are characterized by a 
2-phenylchromane basic structure. Depending on the degree of oxidation of the 
carbon atom at position C-2, -3 and -4, flavonoids are further divided in different 
subgroups: flavanols, anthocyanidines, flavanones, flavons, flavonols and 
isoflavones [6]. Stilbenes are characterized by an ethylene group substituted 
with two phenyl groups [5]. One stilbene derivate and exemplary chemical 
structures of flavonoids are shown in Fig.  1.1.  
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Fig.  1.1: Chemical structures of selected compounds investigated in this thesis. For the 
structures of the resveratrol oligomers please refer to Fig.  2.1. 
 
Dietary sources of the most extensively studied stilbene resveratrol are grapes, 
berries, peanuts and red wine. The average concentration of trans-resveratrol in 
red wine is reported to be 1.9 mg/L, ranging from non-detectable levels to 
14.3 mg/L [7]. In addition to the monomer, grapes and their products contain 
resveratrol oligomers, e. g. the dimer ε-viniferin or the tetramer hopeaphenol 
with concentrations up to 1.2 or 3.8 mg/L in red wines from North Africa [8].  
Main sources of the isoflavone and phytoestrogen genistein are soybeans 
(442 mg/kg) and soy-products, e. g. soymilk (18 mg/kg) [5]. 
Epigallocatechingallat (EGCG) is the gallic acid ester of the flavan-3-ol 
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epigallocatechin and can be found in the leaves of Camellia sinensis [5]. The 
concentration of EGCG in tea ranges between 3 and 48 mg/ 100 mL for black 
tea infusions and between 5 and 190 mg/ 100 mL for green tea infusions, 
respectively [9]. In plants, flavones and flavonols are mainly found as glycosides 
[10]. Apiin is the glycosylated form of the flavon apigenin occurring in parsley 
and celery [11, 12]. After hydrolysis, concentrations between < 1 and 191 µg/g 
fresh weight are reported for the aglycone apigenin (flavone) in celery [11]. The 
flavanone naringenin and its glycoside naringin can be found in citrus fruits [5]. 
Grapefruit juice contains 4.8 to 120 mg/ 100 mL naringin and < 0.2 to 15.8 mg/ 
100 mL of the aglycone [13], whereas the concentration in orange juice is 
considerably lower and ranges between 0.01 and 0.3 mg/ 100 g for naringin and 
between 0.1 and 0.17 mg/ 100 g for naringenin [14]. Nobiletin is a 
polymethoxylated flavon present in citrus peel [15]. Large amounts of peel are 
byproducts of juice productions and affords are made to process the peel to 
polyphenol-rich products [15]. Molasses are intermediate products of this 
process with a nobiletin concentration range of between 2200 and 71100 mg/ 
100 mL [15]. Several other polyphenols only occur in medical plants, for 
example wogonin, a monomethoxylated flavone, found in the root of Scutellaria 
baicalensis Georgi. The dried root is widely used in traditional Chinese medicine 
to treat liver diseases (jaundice), as well as hyperlipidemia, atherosclerosis and 
inflammatory diseases [16]. 
A large number of studies report a variety of biological actions elicited by these 
polyphenols including cardioprotective effects, anti-inflammatory actions and 
cancer preventive effects [3, 15-21]. 
A compound can only elicit a biological effect if it reaches the target cell or 
tissue in a sufficiently high concentration. Thus, the bioavailability plays a major 
role regarding the potential health effects of the dietary intake of polyphenols. In 
addition to distribution and excretion, the intestinal absorption and metabolic 
processes determine the systemically available amount of each polyphenol after 
the ingestion of polyphenol containing food [22]. Although there are exceptions 
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for some glycosides, polyphenols are in general believed to be only intestinally 
absorbed as aglycones [22, 23]. Therefore, glycosylated compounds have to be 
hydrolyzed by intestinal enzymes or colonic microflora prior to absorption [22]. 
Once absorbed, the polyphenols are metabolized by intestinal or liver phase II 
enzymes: Common conjugation reactions include methylation, sulfonation, and 
glucuronidation [22]. Despite an extensive metabolism upon absorption, 
polyphenol plasma concentrations in the µM range were detected after 
ingestion of polyphenolic compounds. Consumption of a black tea infusion 
containing 80-105 mg of EGCG resulted in maximal plasma concentrations of 
0.13-0.33 µM [24]. The bioavailability of flavanones and isoflavones seems to 
be better: The ingestion of grapefruit juice (199 mg total naringenin, sum of free 
and conjugated form) resulted in a plasma peak level of 6 µM for the flavanone 
after conjugate cleavage [25]. After consumption of a single soy meal containing 
3.6 µmol total genistein/kg bodyweight, maximal plasma concentrations of 4 µM 
after conjugate cleavage were observed 8 h after the meal [26]. However, due 
to extensive metabolic processes the majority of the bioavailable polyphenol is 
present in its metabolized form, dominantly as O-glucuronides [27]. Information 
about the biological activity of most metabolites is scarce and it cannot be 
assumed that it has the same biological activity as the parent compound [27]. 
Therefore, absorption and metabolism may be a limiting factor for the 
polyphenols to elicit their biological effects. Thus, the potency in vitro cannot be 
easily translated to the in vivo situation [27]. 
Several modes of action have been described for the anti-inflammatory effects 
of polyphenols: antioxidative and radical scavenging properties, a modulation of 
the gene expression of pro-inflammatory mediators and a modulation of the 
activity of enzymes of the arachidonic acid (AA) cascade [28]. The AA cascade 
comprises the formation of a multitude of biologically active lipid mediators, also 
referred to as oxylipins, from AA and other polyunsaturated fatty acids (PUFAs). 
Fig.  1.2 gives a simplified overview of the enzymatic and autoxidation pathways 
of the AA cascade and highlights selected metabolites and their physiological 
actions. 
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Fig.  1.2: Overview of the AA cascade. It should be noted that only few products are shown of 
the complex oxylipin pattern and the biological effects are summarized in a simplified 
fashion. 
 
The enzymatically formation of oxylipins in the AA cascade can be divided into 
three pathways: the cyclooxygenase (COX), the lipoxygenase (LOX) and the 
cytochrome-P-450 (CYP) branch [29]. Conversion of AA by COXs results in the 
formation of PGH2 which is subsequently processed by different prostaglandin 
synthases or thromboxane A synthase (TXAS) [29]. Prostaglandin-E-synthase 
(PGES) yields PGE2, a lipid mediator with a multitude of physiological actions, 
such as the mediation of pain, fever and inflammation (Fig.  1.2) [30]. PGI2, 
formed by prostacyclin synthase (PGIS), acts vasodilatory and inhibits platelet 
aggregation and is therefore an important regulator of vascular homeostasis 
and thrombosis [30]. Conversion of PGH2 by prostaglandin D synthase gives 
rise to PGD2, a bronchoconstrictor [31]. Prostaglandin F synthase catalyzes the 
reaction of PGH2 to PGF2α which plays, among others, a role in luteolysis, 
ovarian function, acute and chronic inflammation and cardiovascular diseases 
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[32, 33]. TxA2 formed by TXAS is the main COX product of platelets and acts 
platelet aggregating and as a vasoconstrictor [30]. The fate of the initially 
formed PGH2 depends on the enzymatic environment at the side of formation. 
COXs exist in different isoforms: COX-1 is a constitutively expressed isoform 
involved in the maintenance of physiological homeostasis, such as stomach 
acidity control and renal function [29]. The expression of COX-2 is inducible and 
increased in response to inflammatory mediators, such as the cytokines IL-1α/β 
or TNF-α [34]. 
Conversion of AA or other PUFAs by 5-,12- or 15-LOXs results in the formation 
of hydroperoxides, e. g. 5-HpETE, 12-HpETE and 15-HpETE, which can be 
reduced to the corresponding hydroxy-FAs (5-HETE, 12-HETE, 15-HETE) [35]. 
The 5-LOX product LTA4 is a precursor for the formation of the chemoattractant 
LTB4, anti-inflammatory lipoxins or cysteinyl-leukotriens (e. g. LTC4) which are 
potent contractors of airway smooth muscles and increased during acute 
asthma and rhinitis (Fig.  1.2) [35, 36]. Conversion of eicosapentaenoic acid 
(EPA) by acetylated COX-2 or CYP gives rise to 18-HEPE [37]. 15-LOX forms 
17-HDHA from docosahexaenoic acid (DHA) [37]. These and other hydroxy-
FAs can be further converted to a series of multiple hydroxylated FAs called 
resolvins and protectins which are believed to take part in the resolution of 
inflammation [37]. 
The third branch of the AA cascade includes the oxidation of PUFAs by CYPs. 
A product of the ω-hydroxylation by members of the CYP4 family is the 
vasoconstrictor 20-HETE [38]. R,S- and S,R-epoxy-FAs formed by members of 
the CYP2J and CYP2C families possess vasodilatory, anti-inflammatory and 
analgetic properties and are hydrolysed by the soluble epoxide hydrolase (sEH) 
to the corresponding dihydroxy-FAs [39, 40]. 
Products of autoxidative processes are hydroperoxy-FAs which react further to 
hydroxy-FAs, isoprostanes and R,R- and S,S-epoxy-FAs among other products 
(Fig.  1.2) [41-43]. In contrast to the enzymatic oxidation which is 
stereoselective, autoxidative products are formed in racemic mixtures. 
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1.2 Aim and Scope 
The central role in the physiological regulation of inflammation, blood pressure, 
coagulation, and pain makes the enzymes of the AA cascade a major target of 
pharmaceuticals [29]. COX-2 is the target of non-steroidal anti-inflammatory 
drugs (NSAIDs) and COX-2 selective inhibitors [30]. A large number of studies 
indicate that polyphenols also inhibit COX and influence the endogenous PG 
formation in vitro and it is suggested that some polyphenols mediate their anti-
inflammatory effects – in part – via this mechanism [21, 28, 44]. The differences 
between the in vitro test systems used make it hard to compare the efficacies of 
polyphenols obtained in the different studies. Most of these studies lack the 
direct comparison of the COX-2 inhibitory potency of the polyphenols with a well 
characterized COX-2 inhibitor. Therefore, it is difficult to estimate the biological 
relevance of the observed effects. Moreover, the in vitro potency of polyphenols 
cannot easily be transferred to the in vivo situation [27]. Thus, the relevance of 
in vitro activities has to be tested in vivo. Regarding the bioavailability of 
polyphenols, it is important to further improve the knowledge about absorption 
and metabolism. This may help to evaluate the in vivo relevance and to identify 
metabolites which may contribute to the biological action of the parent 
compound. 
Most studies investigating the biological actions of polyphenols present in 
grapes and wine mainly focus on resveratrol. Recent studies additionally 
included resveratrol oligomers, such as the dimer ε-viniferin and the tetramer 
hopeaphenol. These studies demonstrated that both oligomers act antioxidative 
and anti-inflammatory [19, 45, 46] and inhibit the growth of tumor cell lines [18, 
47, 48]. If the dietary intake of these compounds can elicit these actions, 
depends on their bioavailability. No information about the intestinal absorption 
and metabolism of resveratrol oligomers was available. Therefore, Chapter 2 
and 3 address these questions. In Chapter 2 a rapid LC-UV method for the 
quantification of resveratrol and its oligomers ε-viniferin, hopeaphenol, 
r2-viniferin and r-viniferin has been developed. This method was used as read-
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out for the investigation of the chemical and metabolic stability of these 
compounds. Glucuronidation is a major metabolic pathway for resveratrol and 
many other polyphenols [22]. The metabolic stability of ε-viniferin and 
hopeaphenol towards glucuronidation was studied and compared to that of 
resveratrol (Chapter 2). Chapter 3 aimed to investigate the intestinal absorption 
of ε-viniferin and hopeaphenol. The Caco-2 model, which is a commonly applied 
model to study intestinal absorption in vitro, was used to test if the oligomers 
can pass the intestinal gut barrier in a similar manner as resveratrol. 
Reliable analytical tools for the quantification of oxylipins in biological matrices 
are needed to elucidate if the dietary intake of polyphenols results in changes of 
oxylipin levels. Liquid-chromatography coupled to mass-spectrometry (LC-MS) 
is today’s most frequently used approach for the quantification of oxylipins. In 
addition to the instrumental analysis, sample preparation is an important 
parameter for the reliable quantification of oxylipins. Chapter 4 highlights the 
challenges of LC-MS based targeted metabolomics of the AA cascade, 
including new information about the effects of sample preparation on the 
oxylipin pattern. 
Oxylipins regulate several physiological processes and are known to be 
involved in the onset and progression of different diseases. PGs for example 
are elevated during inflammation and play, among others, a role in the 
pathogenesis of cancer, inflammatory bowel disease, sepsis and cardiovascular 
diseases [49-51]. A comprehensive analysis of oxylipins in animal models of 
diseases may help to better understand their role in health and disease and to 
identify potential drug targets. Although a large number of oxylipins are formed 
and there is a crosstalk between the different branches of the AA cascade [52, 
53], current studies investigating the role of oxylipins in animal models focus 
only on single analytes or pathways of the AA cascade. Moreover, if animal 
models are used to study effects of polyphenols on the activity of enzymes of 
the AA cascade, it has to be ensured that the selected model is characterized 
by changes in the oxylipin pattern. Accordingly, a model which aims to study 
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effects on COX-2 has to be characterized by increased PG levels. Otherwise, 
an inhibitory potential cannot be detected. For these reasons Chapter 5 and 6 
apply a targeted metabolomics approach (Chapter 4) to give comprehensive 
insights in oxylipin levels during different animal models of inflammatory 
diseases. Chapter 5 characterizes the time course of systemic lipid mediator 
levels during the development of chronic colitis in the DSS rat model. Moreover, 
changes in plasma and colonic tissue oxylipin levels were correlated with 
classical clinical and histopathological endpoints of inflammation. In Chapter 6 
two commonly used murine models of sepsis, the lipopolysaccharide (LPS) 
induced sepsis model and the cecal ligation and puncture (CLP) model, were 
comprehensively characterized and compared regarding their plasma and 
tissue oxylipin levels. 
Rapid analysis with an automated sample preparation is preferable for the 
investigation of the activity of single enzymes of the AA cascade. Chapter 7 
presents the development and characterization of a fast online-solid phase 
extraction-LC-MS method for the quantification of the COX products (TxB2, 
PGE2, and PGD2). This method was applied as read-out for three different in 
vitro test systems for the determination of COX-2 inhibitory effects. These test 
systems comprise an enzyme assay, the constitutively COX-2 expressing 
human cancer cell line HCA-7 and primary human monocytes stimulated with 
LPS. The COX-2 modulating drugs, celecoxib, indomethacin and 
dexamethasone, were used to characterize the assays. 
A large number of studies suggest a COX-2 inhibitory effect of polyphenols [20, 
21, 28]. Most of the studies were carried out in different in vitro test systems, 
making a comparison of compounds difficult. Moreover, most of the studies did 
not include a known COX-2 inhibitor as positive control, further complicating the 
evaluation of the potency of the observed effects. In Chapter 8 the COX-2 
inhibitory effects of a small library of polyphenols, including potent COX-2 
modulating polyphenols described so far as well as hopeaphenol and ε-viniferin, 
were studied for their effects on COX-2. The polyphenols were tested in a tiered 
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approach starting from a cell free enzyme assay to cellular systems. In all steps, 
the potency was directly compared with pharmaceuticals. Finally, the in vivo 
relevance was studied for the most potent polyphenols. LPS-induced murine 
sepsis was chosen as in vivo model of inflammation because among the 
inflammation models tested (Chapter 5 and 6), the increase in PG levels was 
most pronounced in this model. 
General conclusions, future perspectives and limitations of the presented 
studies are discussed in Chapter 9. 
 
  
INTRODUCTION AND SCOPE 
 
11 
 
1.3 References 
[1] Arts I. C. W., Hollman P. C. H. Am J Clin Nutr (2005) 81, 317S-325S 
[2]  Bahadoran Z., Mirmiran P., Azizi F. J diabetes Metab Disord (2013) 12, 
43 
[3] Nijveldt R. J., van Nood E., van Hoorn D. E. C., Boelens P. G., van 
Norren K., van Leeuwen P. A. M. Am J Clin Nutr (2001) 74, 418-425 
[4] Riboli E., Norat T. Am J Clin Nutr (2003) 78, 559S-569S 
[5] Belitz H. D., Grosch W., Schieberle P. Lehrbuch der Lebensmittelchemie 
(2008). Springer-Verlag, Heidelberg 
[6] Habermehl G., Hammann P. E., Krebs H. C., Ternes W. Naturstoffchemie 
(2008). Springer-Verlag, Heidelberg 
[7] Stervbo U., Vang O., Bonnesen C. Food Chem (2007) 101, 449-457 
[8] Guebailia H. A., Chira K., Richard T., Mabrouk T., Furiga A., Vitrac X., 
Monti J.-P., Delaunay J.-C., Mérillon J.-M. J Agr Food Chem (2006) 54, 
9559-9564 
[9] Bronner W. E., Beecher G. R. J Chromatogr A (1998) 805, 137-142 
[10] Hollman P. C. H., Arts I. C. W. J Sci Food Agr (2000) 80, 1081-1093 
[11] Crozier A., Lean M. E. J., McDonald M. S., Black C. J Agr Food Chem 
(1997) 45, 590-595 
[12] Nielsen S. E., Young J. F., Daneshvar B., Lauridsen S. T., Knuthsen P., 
Sandström B., Dragsted L. O. Br J Nutr (1999) 81, 447-455 
[13] Ho P. C., Saville D. J., Coville P. F., Wanwimolruk S. Pharm Acta Helv 
(2000) 74, 379-385 
CHAPTER 1 
 
12 
 
[14] Cerqueira e Silva L. C. R., David J. M., Borges R. S. Q., Ferreira S. L., 
David J. P., Reis P. S., Bruns R. E. J Anal Methods Chem (2014) 2014, 5 
[15] Manthey J. A., Grohmann K. J Agr Food Chem (2001) 49, 3268-3273 
[16] Tai M. C., Tsang S. Y., Chang L. Y. F., Xue H. CNS Drug Rev (2005) 11, 
141-150 
[17] Aggarwal B. B., Bhardwaj A., Aggarwal R. S., Seeram N. P., Shishodia 
S., Takada Y. Anticancer Res (2004) 24, 2783-2840 
[18] Empl M. T., Macke S., Winterhalter P., Puff C., Lapp S., Stoica G., 
Baumgärtner W., Steinberg P. Vet Comp Oncol (2014) 12, 149-159 
[19] Ha D. T., Kim H., Thuong P. T., Ngoc T. M., Lee I., Hung N. D., Bae K. J 
Ethnopharmacol (2009) 125, 304-309 
[20] Murakami A., Ohigashi H. Int J Cancer (2007) 121, 2357-2363 
[21] Pan M.-H., Lai C.-S., Ho C.-T. Food Funct (2010) 1, 15-31 
[22] Manach C., Scalbert A., Morand C., Remesy C., Jimenez L. Am J Clin 
Nutr (2004) 79, 727-747 
[23] Hollman P. C., de Vries J. H., van Leeuwen S. D., Mengelers M. J., Katan 
M. B. Am J Clin Nutr (1995) 62, 1276-1282 
[24] Scalbert A., Williamson G. Am J Clin Nutr (2000) 130, 2073S-2085S 
[25] Erlund I., Meririnne E., Alfthan G., Aro A. J Nutr (2001) 131, 235-241 
[26] King R. A., Bursill D. B. Am J Clin Nutr (1998) 67, 867-872 
[27] González R., Ballester I., López-Posadas R., Suárez M. D., Zarzuelo A., 
Martínez-Augustin O., Medina F. S. D. Crit Rev Food Sci Nutr (2011) 51, 
331-362 
INTRODUCTION AND SCOPE 
 
13 
 
[28] Garcia-Lafuente A., Guillamon E., Villares A., Rostagno M. A., Martinez J. 
A. Inflamm Res (2009) 58, 537-552 
[29] Buczynski M. W., Dumlao D. S., Dennis E. A. J Lipid Res (2009) 50, 
1015-1038 
[30] Simmons D. L., Botting R. M., Hla T. Pharmacol Rev (2004) 56, 387-437 
[31] Hardy C. C., Robinson C., Tattersfield A. E., Holgate S. T. N Engl J Med 
(1984) 311, 209-213 
[32] Basu S. Med Res Rev (2007) 27, 435-468 
[33] Samuelsson B., Goldyne M., Granstrom E., Hamberg M., Hammarstrom 
S., Malmsten C. Annu Rev Biochem (1978) 47, 997-1029 
[34] Morita I. Prostag Oth Lipid M (2002) 68-69, 165-175 
[35] Haeggström J. Z., Funk C. D. Chem Rev (2011) 111, 5866-5898 
[36] Holgate S. T., Polosa R. Nat Rev Immunol (2008) 8, 218-230 
[37] Serhan C. N., Petasis N. A. Chem Rev (2011) 111, 5922-5943 
[38] Kroetz D. L., Xu F. Annu Rev Pharmacol Toxicol (2005) 45, 413-438 
[39] Imig J. D. Physiol Rev (2012) 92, 101-130 
[40] Morisseau C., Inceoglu B., Schmelzer K., Tsai H.-J., Jinks S. L., Hegedus 
C. M., Hammock B. D. J Lipid Res (2010) 51, 3481-3490 
[41] Milne G. L., Musiek E. S., Morrow J. D. Biomarkers (2005) 10, 10-23 
[42] Nakamura T., Bratton D. L., Murphy R. C. J Mass Spectrom (1997) 32, 
888-896 
[43] Yin H., Brooks J. D., Gao L., Porter N. A., Morrow J. D. J Biol Chem 
(2007) 282, 29890-29901 
CHAPTER 1 
 
14 
 
[44] González-Gallego J., García-Mediavilla M. V., Sánchez-Campos S., 
Tunón M. J. Br J Nutr (2010) 104, S15-S27 
[45] He S., Lu Y., Jiang L., Wu B., Zhang F., Pan Y. J Sep Sci (2009) 32, 
2339-2345 
[46] Huang K.-S., Lin M., Cheng G.-F. Phytochemistry (2001) 58, 357-362 
[47] Kang J. H., Park Y. H., Choi S. W., Yang E. K., Lee W. J. Exp Mol Med 
(2003) 35, 467-474 
[48] Kim H., Chang E., Bae S., Shim S., Park H., Rhee C., Park J., Choi S. 
Arch Pharm Res (2002) 25, 293-299 
[49] Cohen J. Nature (2002) 420, 885-891 
[50] Ricciotti E., Fitzgerald G. A. Arterioscler Thromb Casc Biol (2011) 31, 
986-1000 
[51] Stenson W. F. Scand J Gastroenterol Suppl (1990) 25, 13-18 
[52] Meirer K., Steinhilber D., Proschak E. Basic Clin Pharmacol Toxicol  
 (2013) 114, 83-91 
[53] Peri K. G., Varma D. R., Chemtob S. FEBS Letters (1997) 416, 269-272 
 
 
 15 
 
2 Chapter 2 
Development of a Rapid LC-UV Method for the 
Investigation of Chemical and Metabolic Stability of 
Resveratrol Oligomers * 
 
Resveratrol, piceatannol, ε-viniferin, r-viniferin, r2-viniferin and hopeaphenol are 
naturally occurring polyphenols, associated with potentially beneficial health 
effects. We developed a rapid LC–UV-method allowing the simultaneous 
determination of these six compounds in biological samples in less than 
2.5 minutes with standard LC equipment. Utilizing this method for the 
assessment of the stability of the six analytes, we demonstrated that all stilbene 
polyphenols disappear rapidly in Dulbecco’s Modified Eagle Medium (half life 
piceatannol: 0.4 h, resveratrol: 1 h). By contrast the tetramer hopeaphenol was 
stable over the maximum incubation time of 72 hours. In incubations with liver 
microsomes, ε-viniferin was rapidly glucuronidated, although to a lower extent 
than resveratrol. Hopeaphenol was not glucuronidated at all. Given that 
glucuronidation is the major metabolic pathway for polyphenols, hopeaphenol 
might exhibit significantly different pharmacokinetic properties than other 
polyphenols. Taking together chemical and metabolic stability and biological 
activity of hopeaphenol, these findings warrants further investigation of this 
polyphenol. 
* Reprinted with permission from Willenberg I., Brauer W., Empl M. T., Schebb 
N. H. J Agr Food Chem (2012) 60 (32), 7844-7850. Copyright (2012) American 
Chemical Society. 
Author contributions: IW: Contributed to research design, performed experiments and wrote the 
manuscript; WB: Performed stability experiments; MTE: Contributed to research design and 
manuscript writing; NHS: Designed research, performed experiments and wrote the manuscript. 
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2.1 Introduction 
The polyphenols resveratrol (trans-3,5,4'-trihydroxystilbene), piceatannol (trans-
3',4',3,5-tetrahydroxystilbene), ε-viniferin, r-viniferin, r2-viniferin and 
hopeaphenol are secondary metabolites occurring in grapes and various plant 
species, especially in the Vitaceae but also in the Dipterocarpaceae family [1-3]. 
The structures of the compounds are depicted in Fig.  2.1. 
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Fig.  2.1: Structures of the analytes: r2-viniferin (1), hopeaphenol (2), ε-viniferin (3), r-viniferin 
(4), trans-resveratrol (5) and trans-piceatannol (6). Shown is the conformation as 
previously reported. 
 
With the exception of r-viniferin and r2-viniferin all of them have been detected 
in red wine. For example, the mean stilbene polyphenol concentration in 
different wines from northern Africa was found to be 26 mg/mL, with a mean of 
1.7 mg/L resveratrol, 0.2 mg/L ε-viniferin and 1.4 mg/L hopeaphenol [4]. In 
recent years many studies reported a variety of biological effects exhibited by 
these substances [5, 6]. In particular resveratrol has been extensively studied 
and is known to exert antioxidative, cardioprotective and anticarcinogenic 
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effects [7]. The potential health-promoting effects of piceatannol include 
antioxidant and cell cycle modulatory activities [8]. Only limited information 
about the biological activity of the resveratrol oligomers, ε-viniferin, r-viniferin, 
r2-viniferin and hopeaphenol is available. Few studies report, aside from 
antioxidant and anti-inflammatory properties, effects on the growth and 
proliferation of different tumour cell lines (i. e. leukaemia, colon, breast and 
prostate cancer cells) [2, 5, 6]. Due to their potency to drastically inhibit the 
growth of human tumor cell lines, the resveratrol oligomers may represent a 
new class of natural anti-carcinogens [9]. In order to study these biological 
effects and their underlying molecular mechanisms in more detail, cell culture 
experiments are indispensable. However, several studies demonstrate that 
polyphenols, including resveratrol, rapidly degrade under cell culture conditions 
[10, 11]. Therefore, it is necessary to evaluate the stability of resveratrol 
oligomers in cell culture medium before biological endpoints can be further 
investigated using cell culture systems. For the assessment of the chemical 
stability, analytical methods are needed, allowing the quantitation of resveratrol 
and its oligomers. Numerous methods are described for the quantitation of 
resveratrol by liquid chromatography (LC) [12, 13], but only a few methods for 
the quantitation of resveratrol oligomers have been published [1, 14, 15]. 
Furthermore, these methods have a limited spectrum with regard to the 
compounds detected, e. g. none of the methods allows the quantitation of 
r-viniferin and r2-viniferin. For that reason we developed a rapid LC-UV method 
for the fast simultaneous quantitation of resveratrol, piceatannol, ε-viniferin, 
r-viniferin, r2-viniferin and hopeaphenol in biological samples. This method was 
used to assess the chemical stability of resveratrol and its oligomers in cell 
culture medium under different conditions. As a second application, we 
employed the developed method to investigate the metabolic stability of the 
resveratrol-oligomers towards conjugation with glucuronic acid in vitro. 
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2.2 Experimental 
2.2.1 Chemicals and biological materials 
Trans-piceatannol (99%) and trans-resveratrol (99%) were purchased from 
Sigma-Aldrich (Schnelldorf, Germany). The dimer ε-viniferin (90%) and the 
tetramer hopeaphenol (95%) were obtained from Actichem SA (Montauban, 
France). The two other tetramers, namely r-viniferin and r2-viniferin with a purity 
level of at least 90%, were a kind gift from the laboratory of Dr. Winterhalter of 
the University of Braunschweig, Germany. The chemical structures of the 
analytes are displayed in Fig.  2.1. Dulbecco’s Modified Eagle Medium (DMEM) 
was purchased from Biochrom AG (Berlin, Germany) and all other chemicals 
from Sigma-Aldrich (Schnelldorf, Germany). The ingredients of the DMEM were 
in accordance with the suggestion of the American Type Culture Collection 
(ATCC). Microsomes were obtained from BD Biosciences (Woburn, MA, USA). 
Preparations of pooled human liver microsomes (HLM) from 25 mixed gender 
donors and pooled rat liver microsomes (RLM) from 150 male Sprague Dawley 
rats at a concentration of 20 mg protein/mL were used. The activity of the 
microsomal preparations was characterized by monitoring their ability to 
conjugate the standard UGT substrate 4-(trifluoromethyl)-umbelliferone (TFMU) 
as previously described [16]. HLM showed an activity of 56 ± 4 nmol/min/mg 
and RLM an activity of 71 nmol/min/mg. 
2.2.2 LC-UV analysis 
LC-UV analysis was performed on an Agilent 1100 system (Waldbronn, 
Germany). Separation was carried out on a 75 mm x 4.6 mm i.d., 2.7 µm, HALO 
RP-18 with “fused core” particles. The analytes (injection volume 10 µL) were 
separated by a binary gradient at a flow rate of 2.0 mL/min of 0.1% acetic acid 
(HAc) as solvent A and 95/5 acetonitrile (ACN)/water (v/v) acidified with 0.1% 
HAc as solvent B. The following gradient was used: 0.0-0.2 min isocratic 30% 
B, 0.2-1.8 min linear 30-70% B, 1.8-1.9 min linear 70-100% B, 1.9-2.5 min 
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isocratic 100% B, 2.51 min return to initial conditions of 30% B. The column was 
reconditioned during the next injection cycle of the autosampler (about 1 min). 
The analytes were detected by a photodiode array (PDA) detector operating at 
a detection frequency of 5 Hz with a slit of 4 nm. Piceatannol, hopeaphenol and 
r2-viniferin were detected at a wavelength of 283 nm, resveratrol at 305 nm and 
the signal of ε-viniferin und r-viniferin was detected at 325 nm. 
Quantitation was performed by external calibration of the LC-UV signal of 
standards utilizing one of the resveratrol oligomeres as internal standard (IS). 
For the determination of resveratrol, piceatannol, ε-viniferin and r-viniferin, 
hopeaphenol (2 µM) was used as IS. For the quantitation of hopeaphenol and 
r2-viniferin the closely eluting ε-viniferin (1 µM) was used as IS. For calibration, 
the polyphenols were sequentially diluted (0.3, 0.5, 1, 2, 3, 5, 8, 10 µM) in 50/50 
ACN/water containing IS and 0.1% acetic acid. The acid was added to ensure 
the stability of IS and analytes. The analyte to IS area ratios were fitted in a 
linear way reciprocally weighted by concentration. 
Sample preparation was carried out by mixing equal volumes of IS solution 
(4 µM hopeaphenol or 2 µM ε-viniferin, in ACN with 0.2% HAc) and incubation 
samples. The resulting mixtures were gently vortexed and centrifuged at 21,000 
x g for 10 min at 4 °C. The supernatant was transferred to brown glass vials and 
immediately analyzed by LC-UV. Recovery rates were determined in DMEM 
spiked with 3 µM, 5 µM and 10 µM of the polyphenols. These samples were 
analyzed within the same day as the other samples. All analyses were carried 
out as triplicates and results are presented as mean with the standard deviation 
(SD). 
2.2.3 Determination of chemical stability during incubation in cell culture 
medium 
The stability of the stilbene polyphenols was determined in DMEM (pH 7.4) in a 
Polysterol 96-well plate (Techno Plastic Products, Trasadingen, Switzerland) to 
mimic cell culture experimental conditions. Each well was filled with 100 µL of 
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polyphenol solution (10 µM) in DMEM and the plate was incubated in four 
different conditions: i) at 4 °C in the dark, ii) at 23 °C in the dark, iii) at 37 °C in a 
cell culture incubator (5% CO2) in the dark, iv) at 23 °C on a laboratory bench at 
room light (2 m away from a commercial fluorescent tube). In addition, 
experiments were also carried out at 23 °C in the dark in DMEM medium 
adjusted to pH 4.0 with HAc and pH 9.0 with 1 M tris(hydroxymethyl)-
aminomethane. After 0.25, 0.5, 1, 3, 6, 9, 24, 48 and 72 h, 75 µL were sampled 
per well and analyzed by LC-UV. For the unstable piceatannol, sampling was 
performed additionally after 2.5, 5, 10, 15, 20, 25, 30 and 60 min. In order to 
generate cis-isomers for the characterisation of degradation products the 
stilbene polyphenols were subjected to daylight for 10 min (piceatannol) to 30 
min (resveratrol, ε-viniferin, r-viniferin, and r2-viniferin) as previously described 
[17].  
2.2.4 Glucuronidation assays 
The glucuronidation assay was carried out as previously described [16]. In brief 
resveratrol, ε-viniferin, and hopeaphenol were incubated with microsomes in a 
total volume of 200 µL of 100 mM potassium phosphate buffer (pH 6.9). In a 
generic scheme, 10 µL of microsome solution containing 12.5 µg protein were 
mixed with 96 µL buffer and 40 µL of alamethicin solution (125 µg/mL) and 
placed on ice for 15 min. Alamethicin forms pores in the microsomal membrane 
and therefore increases the substrate accessibility of the uridine 5’-diphosphate-
glucuronosyltransferases (UGTs) [18]. Subsequently 4 µL of the substrate 
(concentration in the assay: 20 µM), 20 µL magnesium chloride and 10 µL of 
the β-glucuronidase inhibitor saccharolactone (concentration in the assay: both 
10 mM) were added and the mixture pre-incubated for 5 min at 37 °C on a 
heated shaker. The reaction was initiated by the addition of 20 µL of uridine 
5’-diphosphoglucuronic acid (UDPGA, 20 mM) and the reaction tubes incubated 
for further 40 min. The reaction was then stopped by the addition of 200 µL of IS 
solution (4 µM hopeaphenol for ε-viniferin; 2 µM ε-viniferin for hopeaphenol and 
resveratrol in ACN acidified with 0.2% HAc) followed by a centrifugation step 
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and LC-UV analysis. For control incubations buffer was added instead of 
UDPGA solution. 
2.3 Results and Discussion 
2.3.1 LC-UV method 
A new ultra fast LC-UV method was developed, to enable rapid analysis of 
resveratrol and its analogs and oligomers in biological samples. The separation 
was carried out on a 2.7 µm “core-shell” particle reversed-phase column. In 
addition to the advantages of sub-2.7 µm particle size, the not entirely porous 
stationary phase allows a more efficient mass transfer between stationary and 
mobile phase because of a shorter diffusion path in the shell type particles [19]. 
The flow rate was set to 2.0 mL/min to compensate for the large void volume of 
the standard LC equipment used. As shown in Fig.  2.2, this setup led to a very 
high chromatographic resolution in an analysis time of less than 2.5 minutes. 
The mobile phase gradient was optimized to fully separate analytes from the 
void volume (22 s, 0.7 mL) of the system, where polar matrix compounds elute. 
Applying a shallow gradient from initial 30% to 70% organic solvent in 1.6 min 
allows the baseline separation of all six analytes (Fig.  2.2). Piceatannol and 
resveratrol eluted first in narrow peaks, followed by the tetramer hopeaphenol 
which showed a relatively broad peak. Finally ε-viniferin, r2-viniferin and 
r-viniferin eluted in very narrow peaks (for retention times see Tab. 2.1). 
Thereafter, the column was washed with two void volumes of organic solvent 
and reconditioned with three void volumes during the autosampler injection 
cycle of the next sample (about 1 min).  
The polyphenols were detected close to their absorbance maxima as 
determined in the LC solvent using the PDA detector. Piceatannol, hopeaphenol 
and r2-viniferin were monitored at a wavelength of 283 nm, resveratrol at 
305 nm and ε-viniferin and r-viniferin at 325 nm.  
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Fig.  2.2: Typical chromatographic separation of a standard solution of resveratrol (5), 
piceatannol (6) and four resveratrol-oligomers (1-4). Shown are the chromatograms at 
283 nm (A), 305 nm (B) and 325 nm (C) used for quantitation of an injection (10 µL) 
of a 3 µM standard solution. 
 
With this setup, a limit of detection (LOD) of 0.03 µM (0.3 pmol on the column) 
was determined for r2-viniferin and r-viniferin eluting in very narrow peaks with a 
full width at half maximum (FWHM) around 0.5 s (Tab. 2.1). With a broader 
peak width the LOD increased to 0.1 µM (1 pmol) for resveratrol and ε-viniferin 
and 0.3 µM (3 pmol) for hopeaphenol. This sensitivity is almost comparable to a 
recent LC-UV method for resveratrol-oligomers utilizing sub-2 µm particle-filled 
columns and a high pressure LC system, leading to LOD values between 
5-50 µg/mL (0.2-0.55 pmol) [1]. With an analysis time of 2.5 min (about 3.5 min 
total running time) our method is more than twice as fast, while only using 
standard equipment (max pressure <250 bar). Moreover this method is the first 
for the quantitative measurement of r-viniferin and r2-viniferin described so far. 
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Tab. 2.1:  Performance of the new LC-UV method. The observed retention times (tR) , peak 
width at half maximum height (w0.5), the resulting number of theoretical plates (N), 
the limit of detection (LOD) and the dynamic range for each analyte are shown. 
 
Analyte 
tR 
(min)a 
W 0.5 
(s)b 
N 
(-) 
LOD 
(µM)c 
Dynamic 
range 
(µM)d 
r2 Slope 
(1/µM) 
Inter-
cept 
(-) 
Piceatannol 
0.60 
± 0.03 
1.32 
± 0.48 
4.2·103 
 
0.3 
 
1-10 0.999 0.63 -0.06 
Resveratrol 
0.89 
± 0.03 
1.38 
± 0.48 
8.2·103 
 
0.1 
 
0.3-10 0.999 1.21 -0.02 
Hopeaphenol 
1.11 
± 0.06 
1.98 
± 0.84 
6.3·103 
 
0.3 
 
1-10 0.999 0.49 0.03 
ε-viniferin 
1.43 
± 0.02 
0.78 
± 0.18 
6.7·104 
 
0.1 
 
0.3-10 0.999 2.56 -0.03 
r2-viniferin 
1.55 
± 0.01 
0.60 
± 0.06 
1.3·105 
 
0.03 
 
0.1-10 0.998 3.71 -0.10 
r-viniferin 
1.77 
± 0.03 
0.48 
± 0.06 
2.5·105 
 
0.03 
 
0.1-10 0.994 0.85 0.04 
a Mean of the 3 µM standard solution over 6 months (n = 6) 
b Injection of 3 µM standard solution (n = 3) 
c Signal-to-noise-ratio of at least 3:1 
d 10 µM was the highest concentration tested; linear range >10 µM 
 
In order to test the influence of matrix compounds on the separation and 
detection, DMEM was spiked with the polyphenols and analyzed after mixing 
with the internal standard and a centrifugation step. For all analytes the present 
method shows a good accuracy, with a mean recovery rate of 98 ± 6%. 
Moreover, the method precision was acceptable with an inter-sample variation 
of below 6.5% (Tab. 2.2). These results clearly demonstrate that increased 
analysis speed is not detrimental to analytical performance. Allowing the 
analysis of more than 400 samples in a single day, the developed LC-UV 
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method is ideally suited for stability studies, which require the analysis of large 
sets of samples. 
Tab. 2.2: Recovery rates determined in spiked DMEM. The mean of the recovery rate (rec.) 
and the intra-day RSD of the analysis of 3 independent spiked samples are shown. 
 
 
Spiked content 
3 µM 5 µM 10 µM 
 
Rec. 
(%) 
RSD 
(%) 
Rec. 
(%) 
RSD 
(%) 
Rec. 
(%) 
RSD 
(%) 
Piceatannol b 103 5.2 91.6 1.2 84.4 1.8 
Resveratrol 
97.1a 
97.8b 
3.9 a 
9.9 b 
103 a 
107 b 
2.7 a 
6.3 b 
101 a 
103 b 
8.1 a 
2.2 b 
Hopeaphenol a 96.9 0.40 94.7 5.0 94.3 4.7 
ε-viniferin b 97.1 5.8 106 5.8 101 2.4 
r2-viniferin b n.d.c n.d.c n.d.c n.d.c 97.9 6.8 
r-viniferin 
116 a 
98.9 b 
9.6 a 
6.5 b 
114 a 
107 b 
6.9 a 
6.3 b 
118 a 
102 b 
4.8 a 
3.6 b 
a Internal Standard ε-viniferin (1 µM) b Internal Standard hopeaphenol (2 µM)  
c not determined (limited amount of reference compound available) 
 
2.3.2 Chemical stability of resveratrol, analogs and oligomers in cell culture 
medium 
The stability of piceatannol, resveratrol, hopeaphenol, ε-viniferin, r-viniferin and 
r2-viniferin was analyzed in DMEM, a standard medium used to culture various 
cell lines. The compounds were incubated for up to 72 h under different 
conditions and their stability was assessed by LC-UV. As shown in Fig.  2.3 A, 
piceatannol, resveratrol, ε-viniferin, r-viniferin and r2-viniferin were rapidly 
degraded in the dark at a pH of 7.4 and a temperature of 23 °C. With a half life 
(t1/2) of about 25 min piceatannol was the most unstable compound, followed by 
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resveratrol with a t1/2 of about 1 h. Among the oligomers, r-viniferin showed the 
shortest half life (t1/2 ~5 h), whereas the tetramer r2-viniferin was as stable as 
the dimer ε-viniferin with a half life of about 15 h. 
 
Fig.  2.3: Stability of the analytes during incubation in DMEM medium. At room temperature, 
pH 7.4 (A), at room temperature under room light, pH 7.4 (B), at 4°C in the dark 
(fridge), pH 7.4 (C) and in DMEM medium adjusted to pH 9.0 (D). Shown is the 
mean and SD of three incubations. 
 
By contrast, the concentration of the tetramer hopeaphenol was virtually 
unchanged. Even after an incubation time of 72 h, 84 ± 3% of the initial 
concentration were detected. When incubated at a higher temperature of 37 °C 
in a cell incubator under a 5% CO2 atmosphere, a similar stability pattern of the 
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compounds was observed (t1/2 piceatannol ~20 min; t1/2 resveratrol ~2.5 h; t1/2 
r-viniferin ~5 h; t1/2 ε-viniferin ~19 h; t1/2 r2-viniferin ~21 h; t1/2 hopeaphenol >72 
h). In accordance to these findings, a decrease in the temperature had only 
minor effects on the stability of the polyphenols (Fig.  2.3 C). Interestingly, the 
stability of r2-viniferin was markedly increased at low temperatures (t1/2 ~24 h) 
when compared to the other polyphenols, which disappeared at a similar rate as 
higher temperatures (Fig.  2.3 C). Based on these results, one could conclude, 
that temperature only slightly influences the stability of resveratrol and its 
analogs and oligomers in DMEM. In contrast to that, the pH strongly influences 
the stability of the test substances. As already known for many other 
polyphenolic compounds [20, 21], the stability of piceatannol, resveratrol, 
ε-viniferin, and hopeaphenol decreased at a pH of 9 (Fig.  2.3 D). Although 
hopeaphenol was still the most stable compound among the analytes, with a 
half life of about 30 h, it nevertheless was subjected to a significant degradation 
under alkaline conditions. A decrease in pH to a value of 4.0 increased the 
stability of all compounds, and ≥90% of the initial concentration of all 
polyphenols was recovered after 72 h. 
A faster loss of the compounds was observed at a pH of 7.4 and a temperature 
of 23 °C when the DMEM was subjected to room light (fluorescent tube) 
radiation during incubation. In this case, none of the polyphenols had a half life 
of longer than 4 h (Fig.  2.3 B), a finding which is consistent with previous 
results showing that trans-stilbene derivatives degrade under light [7, 22]. It is 
interesting to note, that under these conditions, r2-viniferin was the most stable 
compound, followed by ε-viniferin. 
Despite the complete disappearance of the peaks of the test compounds during 
incubations at different conditions in the dark, no new peaks of degradation 
products could be observed for piceatannol, resveratrol, ε-viniferin and 
r2-viniferin at the monitored wavelengths (283 nm, 305 nm and 325 nm). Only 
r-viniferin gave rise to a new peak at a retention time of 1.56 + 0.01 min. The 
area of this peak increased between 0.5 and 9 hours during incubation at pH 
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7.4. At pH 9 the peak already appeared after 0.25 hours of incubation. In both 
cases longer incubation led to a decrease of the peak area, and after 48 hours it 
disappeared completely similar to its precursor r-viniferin (Fig.  2.4). 
 
Fig.  2.4: Formation of degradation product of r-viniferin at a retention time of 1.56 min. (A) 
Chromatogramm (285 nm) of a 6 h incubation of r-viniferin at room temperature at 
the dark at pH 9. (B) Area of the newly formed compound peak over the incubation 
time at pH 7.4 and pH 9. 
 
It is well known, that trans-stilbene polyphenols are converted to their cis-
isomers in the light [7, 22]. In order to generate cis-isomers, light radiation was 
used as previously described for resveratrol [17]. All stilbene polyphenols were 
converted in the light, yielding a single product peak in LC-UV. The retention 
times of the products were: resveratrol 1.21 ± 0.01 min, piceatannol 0.82 ± 0.01 
min, ε-viniferin 1.30 ± 0.01 min and r-viniferin 1.65 ± 0.01 min. Peaks of these 
tentatively identified cis-isomers of resveratrol, ε-viniferin and r-viniferin were 
detected during incubation in DMEM medium in the light, but vanished rapidly 
during further incubation. Thus, it is unlikely that even under light exposure the 
observed disappearance of the polyphenols in DMEM medium is driven by cis-
trans-isomerization.  
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Recently Yang et al. [11] reported a complete degradation of resveratrol by 
auto-oxidative processes at 37 °C in the dark. They showed that after a 24 h 
incubation of 200 µM resveratrol in Base Modified Eagle Medium at 37 °C, 96% 
of the compound was degraded, with a considerable hydrogen peroxide 
formation. Consistent with our results no degradation products could be 
detected by LC-UV. This may be explained by the complexity of polyphenol 
auto-oxidation, leading to various products and adducts [7, 10, 20, 22, 23]. 
Among the stilbene monomers piceatannol is more susceptible to auto-
oxidation than resveratrol, as is to be expected for a polyphenol with a catechol 
moiety [21]. By contrast, dimerization has a stabilizing effect, and ε-viniferin 
shows a significantly slower degradation than its monomer resveratrol (Fig.  
2.3). Among the tetramers bearing one trans-stilbene moiety (Fig.  2.1), 
r2-viniferin is significantly more stable towards auto-oxidation than r-viniferin. 
The stilbene moiety seems to be a key factor for the instability in DMEM. 
Hopeaphenol, the only substance tested which does not exhibit this structural 
feature, is stable under physiological conditions (Fig.  2.3 A-C). Only prolonged 
incubation under alkaline conditions (Fig.  2.3 D) and light radiation causes a 
degradation of this compound. When taking this chemical stability into account, 
hopeaphenol holds a unique place among resveratrol and its oligomers. 
Regardless of the nature of the underlying degradation processes in DMEM, the 
half life of stilbene polyphenols particularly that of resveratrol and piceatannol, is 
short. Therefore, care should be taken in the design of cell culture experiments 
investigating biological effects of polyphenols utilizing different cell culture 
media. In particular, the concentration of the stilbene polyphenols should be 
monitored in the medium throughout the incubation period. 
In vivo, considerable amounts of resveratrol are detected as conjugates in 
serum and urine, suggesting that chemical degradation of stilbene polyphenols 
seems to be less relevant in the living organism. The difference of the 
degradation behavior of the test compounds in the cell culture medium used in 
our study when compared to the in vivo situation may be explained by a 
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stabilization of the stilbene polyphenols by extensive protein binding [7, 24]. 
This assumption is substantiated by the finding, that only about 50% resveratrol 
were degraded when incubated for 24 hours in DMEM containing 10% fetal calf 
serum [10], whereas in our experiments it disappeared completely. 
2.3.3 Metabolic stability of resveratrol and its oligomers 
To date, no information about the metabolism of resveratrol oligomers is 
available. Glucuronidation is the major metabolic pathway of resveratrol and 
many other polyphenols. Therefore, we applied the new rapid LC-UV method, to 
characterize the metabolic stability of ε-viniferin and hopeaphenol, and compare 
it to that of resveratrol. The polyphenols were incubated with rat liver 
microsomes (RLM) and human liver microsomes (HLM) at a substrate 
concentration of 20 µM. The conjugation rate was determined based on 
substrate consumption (Fig.  2.5). At a reduced pH of 6.9, all polyphenols were 
sufficiently stable over the incubation time of 40 minutes in phosphate buffer. 
More than 77 ± 2% of resveratrol, 95 ± 2% of ε-viniferin and 97 ± 1% of 
hopeaphenol of the initial amount was recovered in control incubations without 
UDPGA (Fig.  2.5). As described previously, resveratrol was quickly conjugated 
by both RLM and HLM [25, 26]. After 40 min incubation with RLM, less than 1% 
unconjugated substrate remained, and HLM conjugated 65% of resveratrol 
(remaining substrate 35 ± 2%). The dimer ε-viniferin was also significantly 
glucuronidated by both RLM and HLM, albeit to a lesser extent than resveratrol. 
After 40 min incubation with the same amount of microsomal protein, 15 ± 4% 
(RLM) and 54 ± 2% (HLM) of ε-viniferin remained unconjugated. To our 
surprise, the tetramer hopeaphenol was, under identical conditions, not 
glucuronidated at all. With a recovery rate of the unchanged substrate of 
94 ± 1% compared to 97 ± 2% for incubations with RLM and HLM, respectively, 
almost the same amount of hopeaphenol was detected as in control incubations 
without UDPGA (Fig.  2.5). 
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Fig.  2.5: Glucuronidation of resveratrol, ε-viniferin and hopeaphenol (each 20 µM) by human 
liver microsomes (HLM) and rat liver microsomes (RLM). Shown is the remaining 
concentration of the substrate after 40 min incubation with 0.25 mg/mL microsomal 
protein in presence and absence of the co-substrate UDPGA. Shown is the mean 
and SD of three independent experiments. 
 
In spite of a high absorption rate, the bioavailability of resveratrol is very low 
[27, 28]. Extensive intestinal and hepatic metabolism of resveratrol by 
sulfonation and glucuronidation leads to a rapid conjugation of this polyphenol 
[7, 22, 27]. For instance, only trace amounts of free resveratrol (<5 ng/mL) is 
detectable in the plasma after a dietary relevant single oral dose of 25 mg in 
humans [28]. Even an ultra high single dose of 5 g resveratrol to human 
volunteers led only to a plasma concentration of 533 ng/mL (2.5 µM) [29]. In 
contrast to that, the plasma concentration of glucuronide and sulfate conjugates 
exceeded the concentration of the unchanged compound by a high order of 
magnitude [27, 28]. Although few studies describe a biological activity of the 
conjugates [7, 22, 27], the vast majority of potentially beneficial effects on the 
regulation of cellular pathways have been exclusively described for the parent 
compound. Poor oral bioavailability and thus a lack of effectiveness, is a 
common phenomenon described for many biologically active polyphenols [30]. 
Our finding that hopeaphenol is barely glucuronidated by human and rat liver 
enzymes sets it clearly apart from most naturally occurring polyphenols. Upon 
absorption, its slow phase II metabolism might lead to an improved 
bioavailability in comparison to other stilbene-derivatives and polyphenols. 
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However, it is questionable if a compound with a molecular weight of 907 g/mol 
is efficiently absorbed in mammals after oral intake. 
Except for hopeaphenol, the tested polyphenols disappear rapidly in DMEM 
medium under cell culture conditions, probably caused by degradation through 
auto-oxidation. These findings demonstrate the necessity of cell culture 
experiments with polyphenols being always accompanied by a monitoring of the 
stability of the test compounds under assay conditions. Only if the polyphenol is 
stable for a given incubation time, a reliable correlation between observed 
biological effects and the substance can be deduced. With the new ultra fast 
LC-UV method, using only basic LC equipment, we developed a tool for the 
rapid assessment of the stability of resveratrol its analogs and oligomers. 
2.4 Conclusions 
Our findings show for the first time, that oligomerisation stabilizes stilbene 
polyphenols in cell culture medium. Among all tested compounds, the tetramer 
hopeaphenol has a unique stability with almost all of the initial concentration 
beeing recovered after a 72 h incubation period. Our initial investigation of the 
glucuronidation of the resveratrol-oligomers demonstrates that ε-viniferin, 
similar to resveratrol and many other polyphenols, is rapidly conjugated. 
Surprisingly, the tetramer hopeaphenol was not glucuronidated by liver UGTs, 
which might lead to an improved bioavailability upon absorption. If one takes the 
chemical and metabolic stability, as well as the high potency of hopeaphenol on 
inhibiting tumor cell growth into account, it is apparent, that especially this 
compound qualifies for further investigation. Current data clearly implies that 
hopeaphenol could be a promising natural anti-carcinogen, which also might 
contribute to the beneficial effects associated with moderate wine consumption. 
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3 Chapter 3 
Investigation of the Absorption of Resveratrol 
Oligomers in the Caco-2 Cellular Model of Intestinal 
Absorption * 
 
Resveratrol oligomers are biologically active polyphenols found in wine. No 
information about the bioavailability of these polyphenols is available. In order to 
elucidate if the reseveratrol oligomers can pass the intestinal barrier, the 
transport of the dimer ε-viniferin and the tetramer hopeaphenol was studied in 
the Caco-2 transwell system. A flux through the cell monolayer could neither be 
observed for ε-viniferin nor for hopeaphenol (apparent permeability coefficient 
(Papp) <1 x 10
-6 cm/s). In contrast, resveratrol showed a Papp of 11.9 x 10
-6 cm/s. 
Nevertheless, about 16-30 % of the oligomers were found in the lysed cellular 
fraction. This leads to the conclusion that the intestinal absorption rate of the 
two resveratrol oligomers ε-viniferin and hopeaphenol is low and negligible when 
compared to resveratrol. Therefore, it is unlikely that the oligomers could elicit a 
systemic biological effect after dietary intake. However, the compounds may act 
locally on the intestinal epithelium. 
 
* Reprinted from Food Chemistry, vol. 167, Willenberg I., Michael M., Wonik J., 
Bartel L. C., Empl M. T., Schebb N. H., Investigation of the Absorption of 
Resveratrol Oligomers in the Caco-2 Cellular Model of Intestinal Absorption, pp. 
245-250, Copyright (2015), with permission from Elsevier. 
Author contributions: IW: Designed research, performed experiments and wrote the manuscript; 
MM: Developed online-SPE-LC-MS method and performed transport experiment as part of her 
master thesis under the supervision of IW; JW: Helped with the stability experiments; LCB: 
Helped with the cell culture experiments; MTE: Contributed to research design and manuscript 
writing; NHS: Designed research and wrote the manuscript. 
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3.1 Introduction 
Resveratrol oligomers are stilbenoid polyphenols consisting of two to eight 
subunits of resveratrol (Fig.  2.1) [1]. The structural characteristics of resveratrol 
oligomers are diverse and they are synthesized by many plant species, with the 
families of Dipterocarpaceae and Vitaceae producing the biggest diversity of 
molecules [1, 2]. Just like resveratrol [3], some resveratrol oligomers seem to be 
synthesized, at least in grapevine plants (Vitaceae family), following contact 
with pathogens and might therefore act as phytoalexins [4]. Grapevine plants 
and edible products derived therefrom (e.g. wine) act as the major dietary 
source for resveratrol derivatives as well as resveratrol itself [5-7]. The 
resveratrol dimer ε-viniferin (Fig.  2.1) and the tetramer hopeaphenol (Fig.  2.1) 
are found in wine at concentrations of 0.58-4.3 mg/L [8] and 0.3-3.1 mg/L [6], 
respectively. Similar to many other polyphenols in the diet, hopeaphenol and 
ε-viniferin show antioxidative and anti-inflammatory properties [9-12]. Moreover, 
they have strong effects on the viability and proliferation of mammalian tumor 
cells in vitro. The potency of ε-viniferin to inhibit the growth of tumor cells 
depends on the used cellular model and is comparable to that of resveratrol [13-
15]. In contrast to that, hopeaphenol is much more potent than both the 
monomer and the dimer [16-18], with for instance IC50 values of 1.8 µM and 8.8 
µM in various canine tumor cell lines [19]. Similar to resveratrol [5], the 
antiproliferative effects of both oligomers involve the activation of apoptotic 
signaling cascades and the induction of a cell cycle arrest in the case of 
hopeaphenol [14, 18-20]. Because of their high biological activity, resveratrol 
oligomers are discussed as a potential new class of natural anticarcinogens and 
chemopreventive compounds [18, 21]. However, no information about the 
bioavailability of these molecules is available. Since dietary compounds can 
only elicit biological effects upon intestinal absorption, information about such 
processes is crucial for the evaluation of their potential impact on human health. 
We therefore investigated the absorption of ε-viniferin as an example of a 
resveratrol dimer as well as hopeaphenol as a paradigm of a tetramer and 
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compared it to that of resveratrol in the Caco-2 transwell system, a widely used 
in vitro model for human intestinal drug absorption. 
3.2 Experimental 
3.2.1 Chemicals and biological materials  
Caco-2 cells were purchased from the American Type Culture Collection 
(ATCC; distribution by LCG, Wesel, Germany). trans-resveratrol (≥99% purity) 
was purchased from Sigma-Aldrich (Schnelldorf, Germany) and the dimer 
ε-viniferin (≥90% purity) as well as the tetramer hopeaphenol (≥95% purity) 
were obtained from Actichem SA (Montauban, France). The chemical structures 
of the analytes are displayed in Fig.  2.1. Acetonitrile (HPLC grade) and acetic 
acid were obtained from Carl Roth (Karlsruhe, Germany). Dulbecco’s Modified 
Eagle Medium (DMEM), fetal bovine serum (FBS) and all cell culture reagents 
were purchased from Biochrom (Berlin, Germany). β-glucuronidase (GUS) from 
Helix pomatia (HP-2 specific activity: GUS ≥100.000 u/mL, sulfatase: 
≤7.500 u/mL), formononetin and all other chemicals were obtained from Sigma-
Aldrich. 
3.2.2 LC-UV analysis and sample preparation  
Quantification was carried out by liquid chromatography with ultraviolet 
absorbance detection (LC-UV) with automated sample preparation by online-
solid phase extraction (SPE) in backflush mode [22, 23]. The LC system 
included a SIL-10-ADVP autosampler (Shimadzu, Langenfeld, Germany), a 
Spectra System P4000 pump (Thermo Fisher, Bremen, Germany) as gradient 
pump 1, two LC-10-ADvp LC pumps (Shimadzu) as gradient pump 2, a high-
pressure two-position “Cheminert” six-port valve (VICI, Schenkon, Switzerland), 
a CTO-10ASvp column oven (Shimadzu) set to 40 °C and a SPD-10ADVP dual 
channel UV-detector (Shimadzu). Separation was carried out on a 125 x 4.6 
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mm “Sphere Clone” C18-reversed phase column (Phenomenex, Torrance, CA, 
USA) filled with 3 µm particles and equipped with a C-18 4 x 3 mm pre-column 
(Phenomenex). The same type of pre-column was used as stationary phase for 
the online-SPE. An aqueous solution of 0.1% (vol) acetic acid was used as 
solvent A and 95/5 acetonitril/water (v/v) acidified with 0.1% acetic acid was 
used as solvent B. At the beginning of each analysis 10 µL of sample were 
transferred to the SPE column with a flow of 1.5 mL/min of solvent A. During 
this procedure, the polyphenols were extracted, while salts and proteins were 
washed to waste. After 0.5 min the six-port valve was switched and the analytes 
were eluted in the reverse direction (backflush) onto the separation column with 
the flow of pump 2 (1.0 mL/min). After 2.5 min, the analytes were transferred 
completely to the analytical column and the six-port valve was switched back to 
loading position. This allowed flushing the SPE column with solvent B 
(1.0-4.0 min) and its equilibration for the next run, while the polyphenols were 
separated by the gradient delivered by pump 2. The following solvent gradient 
was used: 0.0-4.0 min isocratic 25% B, 4.0-8.0 min linear from 25-70% B, 
8.1-12.0 min isocratic 100% B and re-equilibration for 4 min at 25% B. 
Resveratrol, ε-viniferin and formononetin were detected at a wavelength of 305 
nm and hopeaphenol at a wavelength of 285 nm as previously described [24]. 
 
Fig.  3.1: Typical online-SPE-LC-UV chromatogram of a separation of resveratrol (1), 
hopeaphenol (2), ε-viniferin (3) and the IS (4). Black: signal at 305 nm; gray: signal 
at 285 nm. 
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Quantification was performed by an external calibration using formononetin as 
internal standard (IS). For calibration, the analyte to IS area ratios were linearly 
fitted, quadratic-reciprocally weighted by concentration. Instrument controlling 
and data analysis was performed with Excalibur 2.0 (Thermo Fisher). Under 
these conditions, all analytes as well as the IS were baseline separated (Fig.  
3.1) and the limit of detection (LOD) for the polyphenols ranged from 0.05 to 
0.2 µM with a linear range of more than three orders of magnitude (Tab. 3.1). 
Tab. 3.1:  Performance of the online-SPE-LC-UV method. The observed retention times (tR), 
the limit of detection (LOD) and the dynamic range for each analyte are shown. 
 
Analyte 
tR
a 
(min) 
LOD 
(µM) 
Dynamic 
rangeb 
(µM) 
r2 
Slopec 
(1/µM) 
Interceptc 
Resveratrol 
4.66 
± 0.02 
0.12 0.23-30 >0.99 0.44 0.009 
Hopeaphenol 
5.28 
± 0.04 
0.23 0.47-30 >0.99 0.23 -0.005 
ε-viniferin 
6.25 
± 0.01 
0.05 0.12-30 >0.99 0.33 -0.010 
Formononetin 
(IS) 
7.40 
± 0.24 
- - - - - 
a mean ± SD of the 3 µM standard solution over 2 months (n = 4). 
b 30 µM was the highest concentration tested; linear range ≥30 µM. 
c mean of 3 calibrations over 2 months. 
 
The only necessary preparation step was mixing equal volumes of the biological 
samples with 10 µM IS solution in acetonitrile. As shown in Tab. 3.2, the 
accuracy for the quantification in different cell culture media was excellent 
(100 ± 10%). Only in spiked medium treated overnight with 10 000 u GUS, the 
recovery rate was barely acceptable (about 70%), probably caused by 
degradation of the analytes during incubation with the crude enzyme 
preparation. With the sensitivity, dynamic range and accuracy in biological 
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samples depicted in Tab. 3.1 and Tab. 3.2, the online-SPE-LC-UV method is 
ideally suited for the quantification of resveratrol, ε-viniferin and hopeaphenol in 
cell culture experiments. 
Tab. 3.2: Recovery rates of resveratrol, hopeaphenol and ε-viniferin in cell culture media. 
 
 
Recoverya (%) 
TRIS-buffered 
medium 
CO3
2--buffered 
medium, 
10% FBS 
TRIS medium 
after GUS 
treatment 
Resveratrol 103 ± 4.5 97.0 ± 5.6 73.1 ± 13 
Hopeaphenol 104 ± 2.8 96.3 ± 1.8 65.3 ± 5.0 
ε-viniferin 95.0 ± 1.5 92.9 ± 5.4 75.2 ± 5.0 
a mean ± SD of 3 experiments, analyte concentration: 10 µM 
3.2.3 Investigation of chemical stability of the polyphenols 
The stability of the polyphenols was determined in different DMEM preparations 
(pH 7.4) in a 96 well plate (TPP, Trasadingen, Switzerland) to mimic the 
conditions of the transport experiments in vitro. Each well was filled with 100 µL 
of DMEM containing 10 µM resveratrol, ε-viniferin and hopeaphenol and the 
plate was incubated at 37 °C in a humidified incubator (5% CO2). After 0, 1, 3, 
6, 8, 24 and 48 h, 75 µL of each well were sampled and analyzed by the online-
SPE-LC-UV method described above. The experiments were carried out in 
standard DMEM supplemented with 10% FBS as well as in DMEM without FBS 
and phenol red containing 50 mM TRIS buffer adjusted to pH 7.4 as a 
replacement for the usual carbonate buffer. 
3.2.4 Cell culture 
Caco-2 cells were cultured in DMEM supplemented with 10% FBS, 1% non-
essential amino acids, 2 mM glutamine and 100 IU/mL penicillin and 100 µg/mL 
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streptomycin. Cultures were maintained in a humidified incubator at 37 °C, with 
an atmosphere containing 5% CO2. Stock cultures were split at subconfluent 
densities (70-80%) by using trypsin/EDTA and seeded at a density of 13 x 105 
cells/cm2 into new culture vessels. For the transport experiment the 
subconfluent cells were seeded at a density of 1 x 105 cells/well in inserts 
(“ThinCerts”, Greiner Bio One, Frickenhausen, Germany) with a permeable 
membrane, a pore size of 0.4 µm and a growth area of 1.13 cm2. The inserts 
were placed in 12-well tissue culture plates with 0.5 mL of medium in the apical 
compartment and 1.5 mL medium in the basolateral compartment. The medium 
was changed 3 times a week. 
3.2.5 Transport experiments 
The transport experiments were performed 23-27 days post seeding in DMEM 
medium adjusted to pH 7.4 containing 50 mM TRIS buffer and without added 
phenol red or FCS. The integrity of the Caco-2 cell monolayer was 
characterized by trans-epithelial electrical resistance (TEER) measurements 
performed with an epithelial volt-ohm-meter (“EVOM2”, WPI, Berlin, Germany). 
Moreover, lucifer yellow (LY; 100 µM in the apical compartment) was used as a 
marker for paracellular diffusion. In order to investigate the integrity of the cell 
layer, the cells were incubated for 6 h with 100 µM LY in the apical chamber. 
Thereafter, 15 µL medium of the basolateral chamber were mixed with 85 µL 
fresh medium and the fluorescence was measured with a microplate reader 
(Tecan, Crailsheim, Germany) at an excitation wavelength of 427 nm and an 
emission wavelength of 535 nm. The limit of quantification was 0.02 µM LY, 
which corresponds to an apparent permeability coefficient (Papp) of 8.00 x 10
-8 
cm/s. No LY could be detected in the basolateral chamber 21 days post seeding 
and in the following days. The time course of the TEER and the permeability of 
LY are depicted in Fig.  3.2. For the experiment, only inserts which exceeded a 
resistance of 300 Ω/cm2 were used and all transport experiments were carried 
out with a concentration of 20 µM of the polyphenols (resveratrol, ε-viniferin or 
hopeaphenol) in the apical chamber. 
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Fig.  3.2 Characterization of the Caco-2 cultivation on permeable membranes. Shown is the 
time course of the trans-epithelial electrical resistance (TEER, black line, right axis) 
and the apparent permeability coefficient (Papp) of the paracellular diffusion marker 
Lucifer Yellow (LY, gray bars, left axis). After day 21 no LY was detected in the 
basolateral chamber (papp ≤ 1.00 x 10
-8
 cm/s). Values represent the mean and SD of 
three independent determinations. 
 
After 0, 1, 3 and 6 h, 60 µL of each well were taken as samples from the 
basolateral side and 20 µL from the apical side. After the last sampling point 
(6 h), the whole medium was collected from both chambers and the cells were 
lysed by incubation with 1% Triton X-100 solution for 10 min. In order to liberate 
polyphenols bound as conjugates, sample medium collected of both 
compartments was additionally incubated over night with 1000 u/mL GUS. All 
solutions were kept at -20 °C until analysis by online-SPE-LC-UV. The apparent 
permeability coefficient (Papp) was calculated according to Formula 1. 
Formula 1: Calculation of the apparent permeability coefficient 
 
 
Δc is the concentration (µM) in the receiver compartment, V is the volume of the 
receiver compartment, Δt is the duration of the transport experiment (s), c0 is 
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the initial concentration in the donor compartment (µM) and A is the surface 
area of the membrane (cm2) [25]. 
In order to assure that the integrity of the monolayer is not affected by 
resveratrol, ε-viniferin and hopeaphenol, the transport experiments were 
performed additionally in the presence of LY (100 µM in the apical 
compartment). After 6 h of incubation no LY could be detected in the basolateral 
chamber, indicating that the polyphenols did not comprise the integrity of the 
monolayer. 
3.3 Results and Discussion 
3.3.1 Stability of the polyphenols 
The central aim of our study was to investigate the intestinal absorption of 
resveratrol, ε-viniferin and hopeaphenol in vitro. For these kinds of studies, it is 
a necessary prerequisite that the compounds are chemically stable during the 
whole duration of incubation. However, previous studies show that particularly 
resveratrol is not stable in standard DMEM, with a half-life of less than one hour 
[24, 26, 27]. In order to increase the stability of the polyphenols in the used cell 
culture environment, we followed two strategies. In the first approach, FBS was 
added to the cell culture medium. Similar to non-covalent binding of compounds 
to plasma proteins in vivo, the formation of polyphenol protein adducts could 
improve stability in cell culture medium [24]. Secondly, TRIS-buffered medium 
was used since bicarbonate ions are postulated to play a key role in the 
degradation of resveratrol [27]. As shown in Fig.  3.3, resveratrol, ε-viniferin and 
hopeaphenol were stable in both media, with a recovery of more than 90% after 
48 h incubation.  
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Fig.  3.3: Stability of resveratrol, hopeaphenol, ε-viniferin in cell culture media under cell 
culture conditions (37 °C, 5% CO2). (A) TRIS-buffered DMEM (B) DMEM (CO3
2-
-
buffered) with 10% FBS. 
 
This is more than sufficient to perform studies on the absorption of these 
compounds. For the transport studies only FBS-free medium was used, 
because the non-covalent FBS adducts might hamper the diffusion of the 
compounds into the cells. 
3.3.2 Intestinal absorption of resveratrol, ε-viniferin and hopeaphenol 
The intestinal absorption of resveratrol and its oligomers was investigated for 
each compound individually using the Caco-2 transwell system. Long-term cell 
cultures of the human colorectal adenocarcinoma cell line Caco-2 show 
phenotypical similarities to small intestinal epithelium of man. Confluent Caco-2 
monolayers grown on permeable membranes have become the standard model 
for the in vitro investigation of the intestinal absorption of xenobiotics [28]. For 
this reason we used the Caco-2 transwell system to evaluate the bioavailability 
of resveratrol oligomers in our experiments. 
The incubation of resveratrol in the Caco-2 transwell system showed that the 
compound rapidly crossed the Caco-2 monolayer (Tab. 3.3).  
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Tab. 3.3:  Distribution of 20 µM of each polyphenol after 1, 3 and 6 h incubation in the apical 
chamber of the Caco-2 transwell system. The table show the absolute amounts 
(nmol) detected in the apical and basolateral chamber and those of the cell lysates. 
For the cell culture medium, the amount of the free compound (n=6) and its 
conjugated form (amount after cleavage-free amount, n=3) is presented. All results 
are presented as mean ± SD. Moreover, the total recovery of the initially added 
amount of 10 nmol is calculated. 
 
compartment resveratrol ε-viniferin hopeaphenol 
 1 h 
apical 
free  4.3 ± 0.26 7.3 ± 0.80 7.5 ± 0.47 
conjugate  0.71 ± 0.50 n.d. n.d. 
basolateral 
free  0.99 ± 0.17 n.d. n.d. 
conjugate  1.2 ± 0.21 n.d. n.d. 
cell lysate 
free  0.58 ± 0.01 0.68 ± 0.12 1.1 ± 0.22 
conjugate  0.16 ± 0.03 n.d. n.d. 
Recovery (%) 80 ± 12 80 ± 9.2 86 ± 6.9 
 3 h 
apical 
free  0.74 ± 0.06 6.1 ± 0.70 6.4 ± 0.36 
conjugate  2.3 ± 0.30 n.d. n.d. 
basolateral 
free  1.3 ± 0.14 n.d. n.d. 
conjugate  4.2 ± 0.45 n.d. n.d. 
cell lysate 
free  0.10 ± 0.01 0.86 ± 1.6 2.4 ± 0.64 
conjugate  0.20 ± 0.06 n.d. n.d. 
Recovery (%) 88 ± 10 70 ± 8.3 88 ± 10 
 6 h 
apical 
free  n.d. 5.6 ± 0.39 5.5 ± 0.47 
conjugate  4.2 ± 0.15 n.d. n.d. 
basolateral 
free  0.59 ± 0.08 n.d. n.d. 
conjugate  4.3 ± 0.16 n.d. n.d. 
cell lysate 
free  n.d. 1.6 ± 0.14 3.0 ± 0.13 
conjugate  n.d. n.d. n.d. 
Recovery (%) 91 ± 3.9 72 ± 5.2 85 ± 6.0 
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After 1 h incubation 0.99 ± 0.17 nmol of free resveratrol were detected on the 
basolateral side corresponding to an apparent transport rate of 11.9 ± 0.2 x 10-6 
cm/s. This rapid and high flux of resveratrol through the cell layer is consistent 
with earlier studies describing a Papp of 11.3-11.9 x 10
-6 cm/s [29-31]. After three 
hours of incubation, a slightly higher amount of free resveratrol (1.3 ± 0.14 
nmol) was detected, which, after 6 h, decreased to 0.59 ± 0.08 nmol free 
resveratrol on the basolateral side (Tab. 3.3). This can be explained by the 
rapid phase II metabolism of resveratrol by the Caco-2 cells. Consistent with 
this finding, a high amount of resveratrol glucuronides and sulfonates (4.3 nmol 
± 0.08) was detected on the basolateral side after 6 h incubation time. This 
translates to 49% of the added amount of resveratrol passing through the Caco-
2 monolayer after 6 h. By contrast, ε-viniferin and hopeaphenol could not be 
detected on the basolateral side, neither in their free form nor after conjugate 
cleavage (Tab. 3.3). Taking the limit of detection of the method into account, 
this corresponds to a Papp of lower than 0.3 x 10
-6 cm/s for ε-viniferin and 1.4 x 
10-6 cm/s for hopeaphenol. Compounds which are completely absorbed in the 
human intestine typically exhibit Papp-values of >70 x 10
-6 cm/s in the Caco-2 
transwell system, whereas compounds with poor absorption (<20%) have Papp 
values of < 10 x 10-6 cm/s [32]. It therefore has to be concluded, that it is 
unlikely that either resveratrol oligomer will be absorbed from the human 
intestinal epithelium after dietary intake. Nevertheless, it is impossible to 
exclude that a low portion of the ingested amount might cross the intestinal 
barrier, since an extrapolation from the Caco-2 model to the actual in vivo 
situation is not entirely accurate [25]. 
After 6 h of incubation 43 ± 2% of resveratrol were detected in form of its 
conjugates in the basolateral chamber, while 42 ± 2% were found conjugated in 
the apical chamber (Tab. 3.3, Fig.  3.4). 
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Fig.  3.4: Distribution of the total amount (10 nmol added to the apical chamber) of either free 
or conjugated polyphenols after 6 h of incubation time in the apical and basolateral 
chamber as well as in the cell lysate. 
 
Since phase II enzymes are located intracellularly, the resveratrol conjugates 
detected in the apical compartment must have been released from the Caco-2 
cells. It is somewhat striking that the whole amount of resveratrol recovered 
after 6 h (91%) has been absorbed at least once into the cells. However, no 
resveratrol or conjugated resveratrol was detected in the cells, indicating an 
efficient outward transport. This mechanism might be mediated by MRP2 on the 
apical side and MRP3 on the basolateral side [33, 34]. 
After 6 h of incubation, a significant portion of the added amount of ε-viniferin 
and hopeaphenol was found in the cellular fraction (Fig.  3.4). 16 ± 1% of 
ε-viniferin were found in or on the cell surface and 56 ± 1% could be recovered 
in the medium on the apical side. An even higher amount of hopeaphenol was 
found to be in or non-covalently bound on the cells (30 ± 1%), with 55 ± 5% 
being found in the medium. For both compounds, the cellular levels increased 
during the incubation period in a time-dependent manner (Tab. 3.3). 
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The amount of detected resveratrol oligomeres did not increase after conjugate 
cleavage. Thus, neither ε-viniferin nor hopeaphenol seem to be a substrate for 
the glucuronosyltransferases and sulfotransferases expressed by Caco-2 cells 
[35]. This finding supports the high metabolic stability of hopeaphenol towards 
glucuronidation and the low conjugation rate of ε-viniferin [24]. Slow phase II 
metabolism may provide a mechanistical explanation why such high amounts of 
ε-viniferin and hopeaphenol are found in or on the cells. On the contrary, 
resveratrol, which is an excellent substrate for human glucuronosyl- and 
sulfotransferases [36, 37] is rapidly conjugated and transported out of the cells. 
3.4 Conclusions 
Neither ε-viniferin nor hopeaphenol passed the Caco-2 cell monolayer in 
significant amounts. Together with low concentration in grapes and, wine and 
other foodstuff, it seems unlikely that a biological relevant amount of these two 
resveratrol oligomers would cross the human intestinal barrier. As is the case 
with other fairly large polyphenols such as proanthocyanidins [38, 39], the 
bioavailability of ε-viniferin and hopeaphenol after dietary intake has to be 
regarded as low. Since compounds can only elicit biological effects when they 
reach the cells in their target tissue in sufficiently high concentrations, the 
overall relevance of the described health-promoting effects of resveratrol 
oligomers in vitro may seem rather limited. However, the high levels of 
ε-viniferin and hopeaphenol found in or on the Caco-2 cells indicate that the 
compounds could possibly reach high concentrations in the intestinal epithelium 
after ingestion of dietary supplements enriched in resveratrol oligomers e.g. 
extracts from grapevine-shoots. Assuming that these compounds reach the 
intestine unchanged, one could therefore postulate a potential but locally 
confined biological activity in the gastrointestinal tract. 
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4 Chapter 4 
Targeted Metabolomics of the Arachidonic Acid 
Cascade – Current State and Challenges of LC-MS 
Analysis of Oxylipins * 
 
Quantification of eicosanoids and oxylipins derived from other polyunsaturated fatty 
acids in biological samples is crucial for a better understanding of the biology of 
these lipid mediators. Moreover, a robust and reliable quantification is necessary to 
monitor the effects of pharmaceutical intervention and diet on the arachidonic acid 
(AA) cascade, one of today’s most relevant drug targets. Low (sub-nanomolar) 
concentrations and a large number of structurally similar analytes, including 
regioisomers, require high chromatographic resolution and selective and sensitive 
mass spectrometry analysis. Currently, reversed phase liquid chromatography in 
combination with detection on sensitive triple quadrupole instruments, operating in 
selected reaction monitoring mode, is the main method of quantitative oxylipin 
analysis. A lack of standardized sample collection, handling and preparation 
procedures, degradation of the analytes during sample preparation and purity and 
availability of standards (internal standards) are the major problems of targeted 
metabolomics approaches of the AA cascade. Major challenges for instrumental 
analytical methods are the detection of esterified oxylipins and separation and 
individual detection of oxylipin-isomers. Solving these problems would help to 
further knowledge of the biology of lipid mediators and is an important task for bio-
analytical research. 
 
* Reprinted from Analytical and Bioanalytical Chemistry, vol. 407, issue 10, 2015, pp. 
2675-2683, Targeted Metabolomics of the Arachidonic Acid Cascade – Current State 
and Challenges of LC-MS Analysis of Oxylipins, Willenberg I., Ostermann A.I., Schebb 
N.H., with kind permission from Springer Science and Business Media. 
Author contributions: IW: Designed research, performed experiments and wrote manuscript; 
AIO: Designed research performed experiment, and wrote manuscript; NHS: Designed research 
and wrote the manuscript. 
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4.1 Introduction 
Lipid mediators have an important function in biology. In particular, eicosanoids 
(C20) and oxidative products of other long chain polyunsaturated fatty acids 
(PUFAs) regulate a large variety of cellular and physiological functions [1]. In 
mammals, these oxylipins are formed enzymatically via three pathways: i) 
constitutively expressed cyclooxygenase 1 (COX-1) and inducible COX-2, ii) 5-, 
12- and 15-lipoxygenases (LOX) and iii) cytochrome P450 monooxygenases 
(CYP), particularly CYP2J and CYP2C. They are also formed non-enzymatically 
by (aut)oxidation. The products initially formed can be further converted by 
several other enzymes, for example by microsomal prostaglandin E synthase 
(mPGES) or by soluble epoxide hydrolase (sEH) leading to a pleiotropy of 
oxylipins formed in the arachidonic acid (AA) cascade (Fig.  1.2). In several 
cases, the product pattern of the four processes overlaps. For example, 
15-HETE is not only generated by 15-LOX, but also by COXs and autoxidation, 
with distinct differences in stereochemistry [2]. Moreover, the route of formation 
of several mediators has not yet been discoverd, e.g. that of 18-HEPE, being 
the major hydroxy-FA metabolite in several cultured cells incubated with EPA 
[3].  
More than half of the currently sold pharmaceuticals directly target the AA 
cascade [4], for example non-steroidal anti-inflammatory drugs (NSAIDs), 
including aspirin and selective COX-2 inhibitors (e.g. celecoxib), and 5-LOX 
inhibitors and leukotriene (LT) antagonists. Approximately 30 years after the 
Nobel Prize to J. Vane, S. Bergström and B. Samuelsson for the discovery of 
the importance of prostaglandins (PGs), the biological functions of non-classical 
eicosanoids and oxylipins other than PGs and LT are becoming clearer. For 
example, multiple hydroxylated docosahexaenoic acids (DHA) and EPAs have 
been discovered as a new class of inflammation resolving lipid mediators [5, 6]. 
The vasodilatory action of epoxy-FAs (Fig.  1.2) on endothelial cells is well 
established and a large number of studies describe anti-inflammatory and 
analgesic effects, although an epoxy-FA receptor has not been discovered. 
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Although AA, DHA and EPA-derived epoxides have similar biological activity, 
the effects in cancer are different, with AA derived epoxy eicosatrienoic acids 
(EpETrEs) promoting angiogenesis, whereas n3-PUFA derived epoxides 
suppress tumor growth [7]. 
To investigate and understand the function of the many different oxylipins in 
physiology, analytical methods are needed to quantify their levels in biological 
samples. The most promising strategy is the parallel quantification of a 
comprehensive pattern of products of the AA cascade derived from both 
n6-PUFAs, for example AA, and n3-PUFAs, for example EPA and DHA. By 
monitoring the activity of an enzyme or pathway of the cascade using several 
products instead of only one main product, the up and down regulation of 
distinct pathways can be deduced with higher certainty. Moreover, routes of 
formation and crosstalk between the branches of the AA cascade can be 
determined [8]. Because many pharmaceuticals modulate the AA cascade, 
quantification of oxylipins is also crucial for the determination of in vivo target 
engagement of established drugs, for example aspirin, and new experimental 
drugs, for example sEH inhibitors. This article briefly summarizes the current 
state of LC-MS based targeted metabolomics of the AA cascade and focusses 
on the challenges of the quantification of oxylipins in biological matrices. 
4.2 Current state of oxylipin analysis 
4.2.1 Instrumental analysis 
Current targeted metabolomics LC-MS approaches for the AA cascade have 
impressive characteristics: One method enables parallel analysis of 141 lipid 
mediators derived from different n6- and n3-FAs. Of these, 102 can be 
quantified against standards using 30 stable isotope labelled internal standards 
(IS) in a run time of only 25 min with high sensitivity (limit of detection (LOD) 
0.1-1 pg on column) [9]. Several other approaches have similar performance, 
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e.g. parallel quantification of 104 oxylipins with the use of 11 IS in 26 min and 
LODs between 1.8 and 340 pg on column [10], or quantification of 88 analytes 
(6 IS) in 21 min and LOQs between 0.06 and 15.96 pg on column [4, 11, 12]. 
For methods established in other labs the total number of covered analytes is 
not clear because the articles are focused on groups of analytes, e.g. resolvins, 
or only report oxylipins above the LOQ [5, 13, 14]. However, analysis times (of 
about 25 minutes) and sensitivities (LODs between 0.01 and 0.21 pg on 
column) are comparable [5, 13, 14]. 
All of these methods use reversed phase (RP) LC coupled to a highly sensitive 
triple-quadrupole (QqQ) MS instrument using negative electrospray ionization 
(ESI) of the slightly acidic analytes (fatty acid derivatives). For the analysis of 
oxylipins in biological samples the following challenges have to be addressed 
by the LC-MS method: (i) low (< nM) concentration of the analytes, (ii) huge 
concentration differences between the least and the most abundant oxylipin 
within a single sample (>103-fold), requiring a broad linear detector response 
[15, 16], (iii) correct identification of the LC-MS peaks and (iv) simultaneous 
quantification of a multitude of chemically and structurally similar analytes with 
numerous isomers present in all samples, e.g. regioisomers of hydroxy-FAs or 
PGE2 and PGD2 (Fig.  1.2). Although the sensitivity and linear detector 
response of modern QqQ-MS fulfill the demands of i-ii, confirming the identity of 
the analytes (iii) requires meaningful fragment spectra to be obtained [14, 17]. 
Because all oxylipins can occur in form of several isomers, identification only by 
retention time and selected reaction monitoring (SRM) of the analyte’s transition 
can lead to false conclusions. Therefore, many groups use QTRAP instruments 
for oxylipin analysis, enabling operating the second analytical quadrupole to be 
operated as a linear ion trap to obtain high quality fragment spectra. Selective 
detection (iv) requires both, a highly efficient chromatographic separation and 
detection in SRM mode. This can be observed for the analysis of 8-, 9- and 
12-HETE (Fig.  1.2, Fig.  4.1). Despite high chromatographic resolution using a 
modern <2µm particle filled column, 8- and 12-HETE coelute. In consequence, 
quantification can only be achieved by detecting unique fragment ions in SRM. 
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For 9- and 12-HETE the opposite is true: The MS/MS spectra of both 
compounds are very similar and provide no specific SRM transitions. Therefore, 
these hydroxy-FAs have to be separated chromatographically.  
 
Fig.  4.1: Separation of regioisomers of hydroxy-AA (8-, 9- and 12-HETE) by means of RP-18 
LC and ESI-MS/MS. (A) Co-elution of 8- and 12-HETE which can be detected 
independently, based on specific SRM transitions. (B) Chromatographic separation 
of 9- and 12-HETE. Both show interfering SRM transitions because of almost 
identical collision induced dissociation MS/MS spectra of their [M-H
+
]
-
 ions (C). 
 
The narrow oxylipin peaks resulting from modern LC-methods require rapid 
switching times and sensitivity at short dwell times of the MS. To keep cycle 
CHAPTER 4 
 
58 
 
times of the MS short, but simultaneously providing enough data points per 
peak, all current methods use software assisted features for example scheduled 
or dynamic multiple reaction monitoring (MRM). Nevertheless, the narrow 
elution windows of a large number of analytes still require dwell times of less 
than 10 ms. It will be interesting if other MS detector types become available for 
targeted oxylipin analysis. High resolution MS (HRMS) could improve signal to 
noise ratio, but does not enable the numerous constitution isomers to be 
distinguished, meaning detection in SRM mode is mandatory for this analysis. It 
will be interesting to determine whether modern qTOF instruments can provide 
sufficient sensitivity and linear detector response. For orbitrap instruments, the 
major question is whether the cycle time for SRM detection could be short 
enough for quantification of the narrow LC peaks. The first report of oxylipin 
analysis using an orbitrap instrument is promising: The comparison of the 
quantitative performance between the orbitrap and a QqQ-MS showed similar 
results with respect to linear detection ranges, with LODs for the orbitrap 
ranging between 10 and 30 pg of the oxylipins [18]. If these instruments proof 
able to match the rapid, sensitive and robust quantification of QqQ-MS, the 
combination of quantification with HRMS and continous detection of fragment 
spectra would greatly enhance instrumental oxylipin analysis. 
As well as improvements to LC-MS instruments, derivatization could lead to 
better separation efficacy and particularly improved MS detection. Gelb and 
coworkers introduced a derivatization strategy which converts the carboxy 
moiety of the oxylipins to an amide with positively charged N-(4-aminomethyl-
phenyl) pyridinium (AMPP) [19], enabling detection in positive ESI mode. This 
strategy could also improve sensitivity on today´s instruments, although they 
have a more efficient ion transmission in negative ESI than the instruments 
used by Gelb and coworkers.  
Derivatization to pentafluorobenzyl (PFB) esters was used by Blair and 
Coworkers allowing efficient normal phase chiral separation of oxylipins (see 
below). Furthermore, dedicated ion formation by electron capture atmospheric 
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pressure chemical ionization (APCI) increased both selectivity and sensitivity 
through decreasing background signals [2]. APCI is generally acknowledged to 
be less prone to matrix effects compared to ESI. Hence, a similar derivatization 
is promising to circumvent the massive problems resulting from ion suppression 
in RP-LC-ESI(-)-MS of oxylipins in biological samples [12]. New derivatization 
agents with specific ionization, e.g. electrochemistry-assisted ionization [20], or 
novel ionization techniques, for example dielectric barrier discharge ionization-
MS [21], could further improve selectivity, sensitivity and robustness of oxylipin 
detection by mass spectrometry. 
4.2.2 Sample preparation 
Extraction of free oxylipins from a biological matrix, like plasma or tissues, is not 
trivial. The analytes have a broad polarity range and are prone to degradation 
by autoxidation (all oxylipins) and by base (PGs) or acid (epoxy-FAs) treatment. 
When analyte concentrations are well above the LOQ of the instrument – which 
is rarely the case – it is possible to directly inject the sample after dilution and/or 
protein precipitation with or by organic solvents. However, most analyses 
require pre-concentration. For this purpose liquid-liquid extractions (LLE) [22] or 
most frequently solid phase extractions (SPE) [4, 9, 10, 13, 14] are used. In 
contrast to similar instrumental analyses of oxylipins, SPE procedures differ 
substantially from lab to lab. Stationary phases range from RP-18 [14] and 
mixed mode phases with RP-8 and anion exchange properties [13] to polymeric 
phases [4, 9, 10]. As might be expected, these methods have a dissimilar 
performance leading to different oxylipin patterns for the same sample, 
particularly for epoxy-FAs (Fig.  4.2) [12]. The ESI-interfering matrix in plasma is 
most efficiently removed by specific SPE procedures using anion exchange 
stationary phases [13] (carboxy acid moiety of the oxylipins) or polar and non-
polar washing steps (water and n-hexane) before elution of the medium to non-
polar oxylipins with methyl formate on the tC-18 column [14]. The latter 
procedure on classical RP material overall outperforms the other procedures, 
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with respect to recovery of IS, reduction of ion suppressing matrix and 
extraction efficacy of oxylipins from the biological matrix (Fig.  4.2). 
 
Fig.  4.2: Concentrations of selected oxylipins in pooled human EDTA plasma using different 
well established solid phase extraction (SPE) methods for sample preparation: (A) 
prostanoides and hydroxy-FA of AA and (B) dihydroxy-FAs and epoxy-FAs of AA 
and DHA. All results are shown as mean ± SD (n=5). The following protocols were 
used: SepPak – tC18 phase, washing with water and n-hexane, elution with methyl 
formiate [14]; AnionEx – C8 phase with anion exchange properties, washing with 
methanol/water (v:v, 1:1), elution with ethyl acetate/n-hexane (75:25) acidified with 
1% acetic acid [13]; StrataX – polymeric phase with polar groups washing with 10% 
methanol, elution with methanol [9]; Oasis – polymeric phase with polar groups, 
washing with 5% methanol acidified with 0.1% acetic acid, subsequent elution with 
methanol and ethyl acetate [4].Instrumental analysis was carried out as described [4, 
11]. The complete evaluation of the performance of the procedures can be found in 
[12]. 
 
An adequate sample preparation which eliminates as much matrix as possible 
is essential because insufficient removal of interfering matrix compounds is 
highly problematic for quantitative oxylipin analysis: In all methods, a single 
internal standard (IS) is used for a whole group of structurally similar analytes 
eluting at different retention times. Thus, the IS cannot compensate for all 
matrix effects, leading to matrix dependent over- and under-calculations of the 
oxylipin concentration. In addition to further optimization of the sample 
preparation procedures, the availability and use of more heavy isotope labeled 
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IS would much improve robustness, accuracy and precision of oxylipin analysis 
in biological samples. 
4.3 Pitfalls and Limitations 
4.3.1 (Biological) variation of oxylipin concentration 
Reports on human serum and plasma oxylipin concentrations document strong 
(interindividual) variations between samples from different subjects [15, 23]. 
These variations impede the recognition of biologically significant differences in 
lipid mediator levels between groups of different (patho)physiological conditions. 
Moreover, significant effects of pharmacological or nutritional intervention can 
vanish within high standard deviations and/or standard errors. Part of the 
variation is obviously based on biological differences, e.g. different habits of 
human subjects. For example physical exercise elicits change in the systemic 
levels of epoxy- and dihydroxy-FAs [24]. Little is known about the changes in 
oxylipins during the circadian rhythm; however it is clear that the nutritional 
status strongly affects the levels of circulating lipids and lipid mediators. Even a 
single moderate dose of n3-PUFA causes changes in plasma hydroxy-, epoxy- 
and dihydroxy-FA levels [25]. Thus, sample collection from human subjects 
should be as standardized as possible (e.g. fixed fasting period, day time, 
physical activity). 
Another major problem contributing to poor precision in the analysis of 
biological samples is the formation and degradation of oxylipins after sample 
collection. Even short storage of blood before further processing has massive 
effects on the plasma concentration of several oxylipins (Fig.  4.3). Moreover, if 
the sample sits for few minutes in the centrifuge, after centrifugation and before 
the plasma is collected and frozen, the levels of some oxylipins are significantly 
reduced (appendix Fig.  11.4).  
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Fig.  4.3:  Ex-vivo degradation/formation of oxylipins in human whole blood after blood 
withdrawel. Blood of a healthy human volunteer was collected in EDTA tubes, 
pooled and left for 5 min, 30 min, 60 min or 120 min either at room temperature (RT) 
or on ice. After centrifugation (1200 g, 15 min, 4 °C), the plasma was immediately 
frozen (-80 °C) and the oxylipin concentration was analyzed within 5 days (Oasis 
SPE [4, 11, 12]). The resulting concentrations after different periods of time in 
sample preparation are compared to those with direct sample preparation (t(5min, 
RT)). The results clearly show, that after 60 min storage of whole blood the levels of 
several oxylipins are massively reduced (e.g. 15-HETE and 14(15)-EpETrE) while 
other analytes are formed ex-vivo (e.g. PGE2). Shown are mean ± SD (n=4). More 
results about the effect of storage during sample preparation of human blood can be 
found in appendix (Fig.  11.1, Fig.  11.2, Fig.  11.3). 
 
Prolonged storage in the freezer can also lead to degradation and loss of the 
analytes as revealed for several DHA and EPA derived resolvins and 
prostanoides [5]. In a few studies COX and sEH inhibitors as well as protease 
and esterase inhibitors are added to the samples to prevent enzymatic 
formation and/or degradation [26]. More frequently antioxidants, for example 
radical scavenging butylated hydroxytoluene (BHT) and chelating 
ethylenediaminetetraacetic acid (EDTA), are used to prevent oxylipin 
degradation or formation (e.g. 11-HETE, 9-HETE, isoprostanes) by autoxidation 
during sample preparation [4, 10, 11, 26]. However, the benefit of these 
procedures has not yet been systematically evaluated for a comprehensive set 
of oxylipins. Overall, artificial (ex-vivo) formation and/or degradation of the lipid 
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mediators is one of the major challenges in the analysis of biological samples 
which can only be addressed by strict standard operating procedures (SOPs) 
including rapid sample processing and optimized storage conditions (-80 °C, 
short time). For few oxylipins, ex-vivo formation and/or degradation can be 
excluded and/or measured by additional determination of their endogenously 
formed metabolites, e.g. 11-dehydro-TxB2 [27] together with TxB2 or 
bicycloprostaglandin E2 as stable degradation product of PGE2 [28].  
4.3.2 Plasma or serum? 
Both, plasma and serum should be regarded as appropriate matrices for 
quantitative oxylipin analysis of circulating oxylipins [5, 16]. For plasma, the 
anticoagulant should be chosen carefully: EDTA seems to be the best choice 
because for example heparin is known to cause artifacts [29]. For serum it has 
to be kept in mind that coagulation is in part mediated by the AA cascade and 
causes massive (ex-vivo) formation of several oxylipins including TxB2 and 
12-HETE (Fig.  1.2). Moreover, detectability of low concentrated mediators, for 
example resolvins is improved [5]. Regarding variability, it remains to be 
evaluated whether plasma or serum enables the determination of oxylipin 
concentrations in blood with a higher precision. 
4.3.3 Accuracy and inter-lab comparability 
In addition to high intersample variations, huge differences between the mean 
concentrations of the lipid mediators were found in different studies, e.g. for 
human plasma or serum (summarized in [15]). This indicates that the accuracy 
of current methods is a further problem. Because of the above summarized 
difficulties of oxylipin analysis and their nature as endogenously formed lipid 
mediators (biomarkers), validation procedures as suggested for drugs, e.g. by 
European Medicines Agency (EMA), are not or only in part applicable. With 
respect to accuracy, current methods have been used to determine, for 
example, the recovery in spiked plasma [10] or in (matrix free) saline phosphate 
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buffer [4]. Interestingly, others failed to recover oxylipins from buffer, probably 
because of low solubility of oxylipins in the aqueous solution [10]. Regardless of 
how rigid recovery rates in (spiked) quality control samples are determined, the 
quantification relies on the availability and purity of reference standards. In most 
cases these compounds have to be synthetized or are obtained commercially 
(currently from a single company). For the latter, the affordable quantities are so 
low that purity cannot be checked by standard chemical methods. Thus, a 
mistake in the concentration provided by the manufacturer leads directly to 
systemic errors. Matching LC-MS response from batch to batch and comparing 
peak areas of regioisomers in selected ion monitoring mode under isocratic LC 
conditions are the only possible ways to verify manufacturer information. To 
improve quality of the results in the future it will be important to agree on criteria 
which have to be fulfilled for a fit-for-purpose-validation in oxylipin analysis. With 
an exchange of samples, standards between groups and inter-laboratory tests 
this would help improve comparability.  
4.4 Analytical challenges 
4.4.1 The free, the bound, and the total… – or the analytical challenge in 
detecting esterified oxylipins 
Although a significant portion of oxylipins is incorporated in lipids, it is believed 
that their paracrine and autocrine action is mainly mediated by their free, i.e. 
non-esterified form [16]. The esterified (bound) oxylipins can readily be 
liberated, e.g. by phospholipases [30]. In plasma, the concentrations of 
esterified epoxy-FAs and hydroxy-FAs exceed the concentrations of the free 
ones by approximately 50 to 350-fold and 10 to 40-fold, respectively [13, 16]. 
Esterified oxylipins are commonly quantified after saponification (base 
hydrolysis) [13, 16, 31-33]. For this purpose, the samples are incubated with 
sodium hydroxide (1.00-3.75 M) either overnight at 4 °C [31] or at 60 °C for 
20-30 min [13, 16]. Other methods incubate the extracted lipids with 0.1 M 
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sodium carbonate at 4 °C overnight [33] or perform transesterification of lipids to 
methyl esters (0.35 M sodium methoxide solution for 60 min at 60 °C) with 
subsequent hydrolysis by the addition of water (60 min) [32]. The performance 
of the different cleavage-procedures has not been systematically compared. 
However, alkaline treatment degrades a large number of oxylipins, particularly 
PGs, e.g. β-hydroxy-keto prostanoids, e. g. PGE2, PGD2, or thromboxanes [31, 
32] and thus information on their concentration is lost. Harsh alkaline treatment 
could even lead to the formation of conjugated FAs from PUFAs [34] and thus is 
prone to produce artifacts of the polyunsaturated analytes. In contrast, a 
moderate saponification could lead to incomplete liberation of esterified 
oxylipins. All current cleavage techniques yield a combined sum of free and 
esterified oxylipins and provide no information on how the analytes are bound in 
the samples. Yet, it is highly relevant to know whether a mediator is bound to 
the sn2-position of a phospholipid of the cell membrane, and thus rapidly 
releasable by phospholipases upon inflammatory stimuli or if it is bound in a 
triacylglyceride (fat) with unknown biological fate. One way of addressing this 
problem would be to separate the different lipid classes of a lipid extract before 
hydrolysis, as commonly performed for fatty acid analysis [35]. Another 
possibility is the direct detection of the esterified oxylipins, as recently 
successfully performed, e.g. for C16:0/12-HETE-phosphatidylethanolamine [36]. 
Combining all oxylipins and possible lipids results in a fairly large number of 
analytes. Thus, the integration of targeted oxylipin metabolomics in lipidomics is 
one of the biggest challenges for analytical chemistry of oxylipins. However, the 
low (total) concentration of the lipid mediators makes it doubtful whether the 
sensitivity of today´s instruments is sufficient for their detection if they are 
distributed in several individually detected lipids. 
4.4.2 Detection of stereoisomers  
A major task for instrumental analytical methods, and one which is important to 
address, is the differentiation between stereochemical configurations. Cis-trans 
isomers of epoxides (Fig.  1.2) can be well resolved by RP chromatography. 
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The enzymatically formed cis-isomers elute first, followed by the trans-epoxides 
formed by (aut)oxidation [37] (same SRM transition as the cis-isomer, eluting 
1-3 min later). Although quite large peaks of trans-epoxides are found in 
biological samples, particularly after conjugate cleavage, these metabolites are 
not included in most current methods. Thus, the concentrations of trans-
epoxides are not evaluated, which makes it impossible to assess their effect as 
lipid mediators. In particular, the important question of whether and to what 
extend trans-epoxy-FAs contribute to the biological effects attributted to cis-
epoxy-FAs cannot be evaluated. 
The robust and efficient RP chromatography fails to separate formed 
enantiomers. Thus, for example the lipid mediator referred to as 14(15)-EpETrE 
(or 14(15)-EET), is in fact 4 compounds, which are generated via CYP 
conversion and (aut)oxidation processes and can be hydrolyzed by sEH at 
isomer specific rates [37] (Fig.  1.2). With the exception of the epoxides, almost 
all oxylipins are chiral, and have different biological activity. 
Whereas enzymatic routes form products at a distinct enantiomer ratio, 
aut(oxidation) processes result in the formation of racemats. Therefore, chiral 
separation can be very helpful to differentiate between the routes of formation. 
Moreover, in several cases, different enzymatic routes of formation can be 
distinguished on the basis of the enantiomer ratio, e.g. (±)15-HETE (Fig.  1.2). 
Whereas the formation of 15-(S)-H(p)ETE is catalyzed by 15-LOX, 
15(R)-H(p)ETE is formed by aspirin acetylated COX-2 [2]. As revealed for this 
example, chiral separation would greatly assist in distinguishing the route of 
formation of the lipid mediators which is poorly understood for several oxylipins, 
e.g. for the dominantly formed and bioactive 18-HEPE (Fig.  1.2). Several chiral 
chromatographic separation methods have been developed as recently 
summarized by Mesaros and Blair [19]. However, because chiral-LC cannot 
achieve the robustness and (overall) separation power of RP chromatography, it 
is comparatively rarely used. Thus, targeted oxylipin metabolomics would 
greatly benefit from progress in chiral LC-MS approaches [38]. A promising 
TARGETED METABOLOMICS OF THE ARACHIDONIC ACID CASCADE 
 
67 
 
further tool for enantiomer separation might be ion mobility spectrometry using a 
chiral modifier [39] at the front end of the MS or (chiral) supercritical fluid 
chromatography. Of all challenges for instrumental analytical chemistry 
mentioned in this article, the integration of chiral separation in the routinely used 
targeted metabolomics techniques would have the largest effect on our 
understanding of the biology of oxylipins. With the data resulting from these 
methods, one could not only monitor the activity of distinct enzymatic and 
(aut)oxidative pathways in vivo, but also identify the biologically most active 
isomers. 
4.5 Conclusions 
Highly sensitive LC-MS methods have been developed which enable an 
impressive understanding of the biological importance of the lipid mediators 
formed in the AA cascade. However, numerous questions remain to be 
answered, e.g. determining the mechanisms of the effects of dietary n3-PUFA 
intake on human health. Comprehensive investigation of hydroxy-n3-PUFAs, 
resolvins and n3-epoxides by methods summarized in this article, could enable 
researchers to address this question. 
With today´s “ultra-high-performance” liquid chromatography and high end 
QqQ-MS the instrumentation for highly sensitive and specific detection of 
oxylipins is available. Moreover, new HRMS instruments entering the field may 
bring about much progress in targeted lipid mediator analysis. With these 
instruments it is easy to generate peaks, areas and numbers. However, it will 
still be a challenge to obtain meaningful results, i.e. accurate concentrations in 
biological samples. In particular, the optimization of sample collection, 
stabilization and preparation seems to be required. With respect to instrumental 
analysis the greatest challenges are the differential detection of stereoisomers 
and analysis of esterified oxylipins. To achieve this progress in targeted oxylipin 
metabolomics, it is crucial that analytical chemistry is regarded as an integral 
part of medical and biological research. Thoroughly developed methods and 
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their continuous improvement require time and (grant) money. Although, not all 
method developments may address fundamental scientific questions (such as 
the detection of esterified oxylipins), in particular improvements to sample 
preparation, a fit-for-purpose validation and interlab comparison seem to be of 
particularly high importance for the field. 
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5 Chapter 5 
Effect of Acute and Chronic DSS Induced Colitis on 
Plasma Eicosanoid and Oxylipin Levels in the Rat * 
 
Eicosanoids and oxylipins are potent lipid mediators involved in the regulation of 
inflammation. In order to evaluate their role and suitability as biomarkers in colitis, 
we analyzed their systemic levels in the acute and chronic phase of dextran sulfate 
sodium (DSS) induced colitis. Male Fischer 344 rats were treated in three cycles with 
4% DSS in the drinking water (4 days followed by 10 days recovery) and blood was 
drawn three days prior to the first DSS treatment and on day 4, 11, 32 and 39. 
Histopathological evaluation of the colon tissue after 42 days showed that the 
animals developed a mild to severe chronic colitis. Consistently, prostaglandin 
levels were massively (2-fold) elevated in the colonic tissue. LC-MS based targeted 
metabolomics was used to determine plasma oxylipin levels at the different time 
points. In the acute phase of inflammation directly after DSS treatment, epoxy-fatty 
acid (FA), dihydroxy-FA and hydroxy- FA plasma concentrations were uniformly 
elevated. With each treatment cycle the increase in these oxylipin levels was more 
pronounced. Our data suggest that in the acute phase of colitis release of 
polyunsaturated FAs from membranes in the inflamed tissue is reflected by an 
uniform increase of oylipins formed in different branches of the arachidonic acid 
cascade. However, during the recovery phases the systemic oxylipin pattern is not 
or only moderately altered and does not allow to evaluate the onset of chronic 
inflammation in the colon. 
 
* Reprinted from Prostaglandins & Other Lipid Mediators, Willenberg I., Ostermann A.I., 
von Keutz A., Steinberg P., Schebb N.H., Effect of Acute and Chronic DSS Induced 
Colitis on Plasma Eicosanoid and Oxylipin Levels in the Rat, 
doi:10.1016/j.prostaglandins.2015.04.002, Copyright (2015), with permission from 
Elsevier. 
Author contributions: IW: Designed research, performed experiments and wrote manuscript. 
AIO: Designed research, performed experiments; AvK: Performed experiments; PS: Designed 
research and wrote the manuscript; NHS: Designed research and wrote the manuscript. 
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5.1 Introduction 
Ulcerative colitis (UC) is a chronic, tissue-destructive disease with unknown 
etiology and high prevalence in Europe with up to 500 affected persons per 
100 000 [1]. Recent research indicates that UC derives from excessive 
inflammation [2, 3]. The arachidonic acid (AA) cascade is a central pathway in 
the paracrine and autocrine regulation of inflammation [4, 5]. The conversion of 
AA (20:4n6) by cyclooxygenases (COXs) and lipoxygenases (LOXs) leads to 
highly potent lipid mediators such as prostaglandins (PG) and leuktorienes (LT). 
Recent years have shown that products derived from other polyunsaturated 
fatty acids (PUFA), particularly docosahexaenoic acid (22:6n3, DHA) and 
eicosapentaenoic acid (20:5n3, EPA) – generally named oxylipins – also play 
key roles in the regulation of inflammation [6]. Another class of lipid mediators, 
the anti-inflammatory epoxy-FAs, are formed by cytochrome P450 
monooxygenases (CYP). They are inactivated by hydrolysis to dihydroxy-FAs 
by soluble epoxide hydrolase (sEH) [7]. A large number of currently sold anti-
inflammatory drugs target PG formation by COX inhibition. The first line 
treatment of mild and moderate UC is 5-aminosalicylic acid (5-ASA, 
Mesalazine) [8]. One mode of action of 5-ASA is a competitive inhibition of 
COXs [9]. However, the use of other COX inhibitors, i.e. non-steroidal anti-
inflammatory drugs (NSAID), is controversial because of the central role of PGs 
in epithelia protection and homeostasis [10-12]. New studies in rodents suggest 
that inhibiting sEH and stabilizing epoxy-FAs in the CYP branch of the AA 
cascade could be a promising treatment of UC [13, 14]. Moreover, studies in 
animals and humans suffering from UC demonstrate that n3-PUFAs, which are 
believed to act mainly based on a modulation of the endogenous oxylipin 
pattern, act in a preventive/curative way on colitis [15-17]. However, only few 
data regarding the changes in oxylipin pattern occurring during UC are 
available. Particularly, information on the effect of colonic inflammation on 
systemic markers, i.e. oxylipins circulating in plasma, is scarce. Therefore, the 
aim of the present study was to characterize the effects of dextran sulfate 
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sodium (DSS) induced colitis on oxylipin plasma levels in acute inflammation, 
healing/regeneration and onset of chronic colitis. 
5.2 Experimental 
5.2.1 Chemicals 
DSS (36-50 kDa) was purchased from MP Biomedicals (Heidelberg, Germany). 
LC-MS grade acetonitrile (ACN), acetic acid (HAc) and methanol (MeOH) were 
from Fisher Scientific (Nidderau, Germany). Oxylipin standards and internal 
standards were obtained from Cayman Chemicals (local distributor: Biomol, 
Hamburg, Germany). Further standards such as EpODEs and DiHODEs were a 
kind gift from the laboratory of Bruce Hammock (UC Davis, California, USA). 
1-(1-(Ethyl-sulfonyl)piperidin-4-yl)-3-(4-(triﬂuoromethoxy)phenyl)urea 
synthesized as described [18] was used as internal standard 2 (IS 2). All other 
chemicals were from Sigma Aldrich (Schnelldorf, Germany). 
5.2.2 DSS induced colitis model 
Male Fischer 344 rats (95-115 g, 6 weeks) were obtained from Charles River 
Laboratories International Inc. (Sulzfeld, Germany) and kept in type IV 
polycarbonate cages (EHRET, Emmendingen, Germany). The bedding 
consisted of poplar granules (Lignocel select, Rosenberg, Germany), which 
were changed once a week. Before starting the DSS treatment the animals 
were allowed to acclimatize in our laboratory for two weeks. The animals had 
access to standard chow (#1324 Altromin, Lage, Germany) and water ad libitum 
and were kept at a 12 hour light/dark cycle.  
Colitis was induced by three cycles of a four-day treatment with DSS in drinking 
water (4% w/v) followed by 10 days of recovery (Fig.  5.1) as described [19]. 
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Fig.  5.1 DSS treatment regime of rats to induce acute and chronic colitis. Animals received 
4% DSS in the drinking water for four days followed by a recovery phase with tap 
water for ten days. This cycle was repeated thrice. Animals of the control group 
received tap water over the whole period of time. Red arrows indicate blood 
sampling time points. At day 42 animals were sacrificed and colon tissue was 
sampled. 
 
Five hundred microliters EDTA-blood were collected from the retrobulbar 
venous plexus three days prior first DSS treatment as well as on days 4, 11, 32 
and 39. The obtained blood was centrifuged (1 500 x g, 10 min, 4°C) and the 
plasma was stored at -80°C until it was analysed. On day 42 the animals were 
killed by cardiac puncture after anesthesia with xylazine/ketamine (66/5 mg/kg 
bw). The gut was transferred to ice cold phosphate buffer saline and after 
measuring the colon length, the proximal colon, distal colon and rectum 
sections [20] were sampled. The intestine was opened longitudinally, cleaned 
with ice-cold buffered and cut into pieces. One piece of the distal colon 
(50-100 mg) was immediately frozen at -80°C for oxylipin analysis. The other 
piece and a sample of the proximal colon and rectum were fixed in 4% formalin 
at room temperature for the histopathological examination. Samples were 
prepared and scored as described [21] regarding the severity of inflammation 
(0 = none, 1 = minimal, 2 = mild, 3 = moderate, 4 = severe inflammation) and 
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the extent of inflammation (0 = none, 1 = mucosal, 2 = mucosal and 
submucosal, 3 = mucosal, submucosal and muscular, 4 = mucosal, 
submucosal, muscular and serosal layers involved). The health status of the 
animals was daily inspected, and the disease activity index (DAI) was 
determined based on body weight loss, faeces consistency and macroscopically 
visible blood in faeces [17, 22]. The study was approved by the animal welfare 
service of the state of Lower Saxony (Oldenburg, Germany). 
5.2.3 LC-MS analysis of oxylipins 
Quantification of oxylipins in plasma and colon tissue was carried out by LC-MS 
as described [23]. In brief, following addition of internal standards, 250 µL 
plasma were extracted utilizing Oasis HLB solid phase cartridges (Waters, 
Eschborn, Germany). Colon tissue (75 ± 25 mg) was homogenized in 500 µL 
MeOH/water 50/50 (v/v) with a ball mill (Retsch, Haan, Germany) for 10 min at 
30 Hz. After centrifugation the supernatant was transferred to a preconditioned 
SPE column; the column was filled with wash solution and further processed 
like plasma samples. The residue of the evaporated solid phase extract was 
dissolved in 50 µL methanolic solution of IS2 and 5 µL were separated on an 
Agilent Zorbax Eclipse Plus C-18 reversed phase column (2.1 x 150 mm, 
particle size 1.8 μm) with a gradient of 0.1% aqueous HAc as solvent A and 
ACN/MeOH/HAc (800/150/1, v/v/v) as solvent B. Mass spectrometric detection 
was carried out on an AB Sciex 6500 QTRAP instrument (AB Sciex, Darmstadt, 
Germany) in scheduled selected reaction monitoring mode following negative 
electrospray ionization (ESI). Instrument controlling was performed with Analyst 
1.6.2 and data analysis was carried out with Multiquant 2.1.1 (AB Sciex). A list 
of all oxylipins covered by the method can be found in the appendix (Tab. 11.1). 
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5.3 Results 
5.3.1 Disease activity index (DAI) and histopathological examination 
The time course of the DAI (weight loss, stool consistency and blood in feaces) 
during the DSS treatment and the results of the histopathological analysis of the 
colon are shown in Fig.  5.2. 
 
Fig.  5.2 Characterization of the acute and chronic phase of DSS induced colitis. (A) Disease 
activity index (DAI) of the DSS treated animals (blue line) in comparison to the 
control group (gray line). (B) Colon length of the DSS-treated and control group at 
day 42. Histopathological scoring of severity (C) and extent of inflammation (D) in 
different colon sections. Blue bars represent the DSS-treated group, gray bars the 
control group. Data is shown as mean ± SEM. (B-C) Statistically significant 
differences between the DSS-treated and the control group are indicated by 
asterisks; * p < 0.05, ** p< 0.01 calculated by the Mann-Whitney U test. 
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In treated rats, the DAI increased after the first 4-day treatment period with 
DSS, reaching a maximum at day 7 during the recovery phase. Following the 
second DSS treatment cycle (day 15-18) the DAI raised more rapidly to a 
maximum of 1.5 at day 18 and 19. Thereafter, during the second recovery 
phase the DAI decreased and reached a plateau at 0.7-0.8. Following the third 
treatment cycle the DAI remained at an even higher level (0.8-1.0), an indication 
of chronic inflammation. The DAI of the control animals was always below 0.35 
(Fig.  5.2 A). At the end of the experiment (day 42) the colon length was not 
significantly different between the groups (DSS treated group: 12.2 ± 0.4 cm, 
control group: 13.7 ± 1.0 cm, Fig.  5.2 B). The histopathological examination of 
the colon at day 42 clearly showed that the DSS treatment caused a medium to 
severe chronic inflammation with a predominant lymphoplasmacytic infiltration, 
particularly in the distal colon and rectum. The scores of severity and extent of 
inflammation are shown in Fig.  5.2 C-D. The inflammation was much more 
pronounced in the distal colon and rectum compared to the proximal colon. 
5.3.2 Prostaglandin (PG) levels in colonic tissue 
Concentrations of PGs in the distal colon tissue are shown in Fig.  5.3. The 
most abundant PGs in the distal colon were found to be PGE2, PGD2 and 
6 keto-PGF1α. Tissue levels of all detected PGs were dramatically elevated in 
the DSS-treated group undergoing a chronic colitis. For example, the PGE2 
level was significantly higher in the DSS-treated group (6.5 ± 0.5 pmol/mg) 
when compared to the control group (2.8 ± 0.6 pmol/mg; p<0.01). The same 
trend was observed for PGD2 and 6-keto-PGF1α. The tissue levels of COX 
products of other PUFA were also elevated by chronic colitis (Fig.  5.3). 
Interestingly, the PGD metabolites were formed to a greater extent if compared 
to the corresponding PGE metabolites. However, both groups of PGs were 
increased about two-fold following the DSS treatment. For example, the PGE3 
tissue level was significantly higher in the DSS group than in the control group 
(27 ± 3 fmol/mg vs. 12 ± 2 fmol/mg; p<0.01) and this was also the case for 
PGD3 (53 ± 8.4 fmol/mg vs. 25 ± 5.9 fmol/mg; p<0.05). The colonic tissue levels 
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of TxB2 were 915 ± 132 fmol/mg in the DSS group and 805 ± 196 fmol/mg in the 
control group, and, thus, were unaffected by the treatment with DSS. 
 
Fig.  5.3: Prostaglandin concentration in the distal colon tissue of the DSS treated animals at 
day 42 (blue bars, n=5) in comparison to the control group (gray bars, n=4). 
Statistically significant differences between the DSS-treated and the control group 
are indicated by asterisks; * p < 0.05, ** p< 0.01. Statistical differences were 
analyzed by t-test, only 6-keto-PGF1α showed skew distribution and was analyzed by 
the Mann-Whitney U test. 
5.3.3 Systemic oxylipin levels 
The concentrations of oxylipins detected in plasma during the repeated 
treatment with DSS (Fig.  5.1) are shown in Tab. 5.1 and time courses of 
selected metabolites are presented in Fig.  5.4. For the plasma PGE2 
concentration only slight to moderate changes (not statistically significant) were 
observed during the onset of the chronic colitis (Fig.  5.4 F). 
Epoxy-FAs of most PUFAs were slightly but not statistically significantly 
increased after the first DSS treatment cycle at day 4. During the recovery 
phase (day 11) the concentrations of epoxy-FAs decreased and were similar or 
even slightly lower than those of the control group.  
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Tab. 5.1:  Plasma concentration of oxylipins at different time points during DSS induced colitis. 
Statistically significant differences between the DSS-treated (n=5) and the control 
(ctrl.) group (n=4) were calculated by two-way Anova with Bonferroni post-test.  
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Tab. 5.1 continued 
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Following the third DSS treatment (day 32) the epoxide levels were massively 
increased reaching statistical significance for 9(10)-EpODE, 12(13)-EpODE, 
15(16) EpODE, 9(10)-EpOME, 12(13)-EpOME and 19(20)-EpDPE when 
compared to the control group. During the recovery phase (day 39) the levels 
dropped again and were similar to those of the control group (Fig.  5.4 A-B). 
 
Fig.  5.4: Time course of plasma concentration of selected oxylipins during repeated DSS 
treatment: (A) 14(15)-EpETrE, (B) 19(20)-EpDPE, (C) 14,15-DiHETrE, (D) 19,20-
DiHDPE, (E) 5-HETE and (F) PGE2. The gray background indicates the periods of 
DSS treatment (4% in drinking water). The concentration of oxylipins detected in 
plasma can be found in Tab. 5.1. 
 
A consistent time course was observed for the dihydroxy-FAs. After the first 
DSS treatment (day 4) all dihydroxy-FA levels, except for 17,18-DiHETrE, were 
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elevated (significantly in the case of 12,13-DiHODE, 12,13-DiHOME, 
19,20-DiHDPE, 5,6-DiHETrE, 8,9-DiHETrE and 14,15-DiHETrE). During the 
recovery phase the concentrations decreased again and were similar to those 
of the control group. Directly after the third treatment with DSS (day 32), the 
levels of all detected dihydroxy-FAs, except for 17,18-DiHETE, were massively 
elevated and went back to baseline during the recovery phase (day 39) (Fig.  
5.4 C-D). The effects of the DSS treatment on plasma hydroxy-FA 
concentrations were similar. After the first treatment with DSS (day 4) the levels 
of most hydroxy-FAs were increased, e. g. 20-HETE and 5-HEPE. However, 
15-HETE, 11-HETE, 8-HETE and 12-HETE were detected at lower 
concentrations in the DSS-treated group than in the control group. During the 
first recovery (day 11) concentrations of most hydroxy-FAs in the DSS-treated 
group were found to be similar to those in the control group. After the third acute 
phase (day 32) the levels of all hydroxy-FAs of the treatment group were 
elevated, the increase reached statistical significance in the case of 9-HOTrE, 
13-HOTrE, 9-HODE, 13-HODE, 8-HETE and 5-HETE. As already described for 
the epoxy- and dihydroxy-FAs, all hydroxy-FA levels decreased to a similar 
concentration range as the ones from the control group at day 39 during the 
third recovery phase (Fig.  5.4 E). 
5.4 Discussion 
In the present study a commonly used rodent model of colitis with similarities to 
human UC [24] was applied to investigate the effect of acute and chronic colitis 
on systemic oxylipin levels. Colonic inflammation was elicited by repeated 
treatment with DSS in the drinking water (Fig.  5.1). In line with earlier studies in 
the rat model [19], the observed DAI shows that repetitive DSS treatment is 
effective to induce cycles of acute colitis, leading to a chronic inflammation after 
42 days (Fig.  5.2). This conclusion is based on the histopathological findings, 
showing an intense inflammation particularly in the distal colon sections. 
However, the effect of chronic inflammation in Fischer 344 rats seems to have a 
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minor effect on colon length when compared to the results in mice [15] and 
Sprague Dawley rats [25]. The oxyilipin levels in the distal colon tissue display 
the expected increase in PGs in response to chronic inflammation with a 
pronounced increase of the levels of PGE2, PGD2 and other PUFA analogs (Fig.  
5.3). Playing a dominant role in the regulation of coagulation rather than in 
inflammation, the TXA2 degradation product TXB2 was not elevated in response 
to inflammation. The elevation of the tissue PG levels is comparable to earlier 
studies in mice and rats, in which an increased PGE2 formation in response to 
colitis was reported [11, 26]. 
Acting predominantly as paracrine and autocrine lipid mediators [4, 5], the effect 
of colitis on the systemic non-esterified oxylipins in plasma was less 
pronounced. Among the PGs, only PGE2 and PGD2 as well as TxB2 exceeded 
the limit of quantification. Thus, PGs formed in the intestine tissue do not reach 
the blood in considerable concentrations (<0.2 nmol/L; 70 pg/mL) or they are 
rapidly degraded and excreted. The determined concentration of the PGs varied 
massively in both groups, thereby making a biologically meaningful 
interpretation of the determined levels difficult. This variation is most probably 
caused by formation/degradation of PGs, especially PGE2, during blood 
collection and sample preparation as discussed elsewhere [4]. 
For the epoxy-, dihydroxy-, and hydroxy-FAs overall, the same trend in the 
plasma levels was observed. In response to each cycle of acute colonic 
inflammation, their plasma concentrations were elevated, reaching a maximum 
1-2 days after the DSS induced tissue damage. This indicated that these 
oxylipins are released from damaged/inflamed colon tissue into the blood in 
considerable concentrations. The uniform increase of the different oxylipins 
suggests that the acute colitis generally increases the formation of products of 
the AA cascade, rather than having a distinct effect on the pathways, such as 
CYP, LOX enzymes and autoxidation. This is consistent with earlier reports 
showing that the release of PUFA, e.g. by phospholipase A2, is a rate limiting 
step in the generation of LOX and COX products in intestine tissue in DSS 
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induced colitis [12]. In addition to a release of epoxy-, dihydroxy-, and hydroxy-
FAs from the inflamed colon tissue, it also has to be taken into account that 
acute colitis could lead to an elevated release of PUFAs and subsequent 
formation of the oxylipins in the blood or another tissue. However, the latter 
route of formation seems to be unlikely, since free fatty acids circulate in blood 
under physiological conditions transporting energy from the fat tissue e.g. to the 
muscles [27]. 
During recovery and healing of acute colitis, the plasma concentration of the 
oxylipins rapidly declines, and the oxylipin plasma concentration does not allow 
to gain information regarding (the onset of) chronic inflammation. However, the 
increase of epoxy-, dihydroxy-, and epoxy- FA becomes more pronounced with 
the DSS treatment cycles (Fig.  5.1, Fig.  5.4, Tab. 5.1). This can be explained 
in two ways: (i) the acute phase during repeated inflammation becomes more 
and more severe and/or (ii) in each inflammation phase oxylipins are formed 
from released PUFAs and a significant portion of them is re-esterified. In the 
following acute phase these oxylipins are directly released by phospholipases. 
5.5 Conclusions 
Overall the changes in the plasma oxylipin pattern support the relevance of the 
release of PUFAs from phospholipids during the acute phase of DSS induced 
colitis [12], as the plasma concentrations of several epoxy-, dihydroxy- and 
hydroxy-FAs are massively elevated during acute colitis. Taking into account 
that several of these oxylipins are potent lipid mediators, e.g. epoxy-FAs [7], our 
data suggest that oxylipins formed from AA and other unsaturated FAs play a 
key role in the biology of colitis. However, the rather unspecific increase of 
oxylipins derived from different enzymatically pathways make it difficult to 
pinpoint one branch of the AA cascade as potential target for pharmacological 
therapies. Finally, it has to be concluded that the plasma oxylipin concentration 
seems not to be a suitable biomarker to analyze the chronic phase of colitis. 
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6 Chapter 6 
Characterization of Changes in Plasma and Tissue 
Oxylipin Levels in LPS and CLP Induced Murine Sepsis * 
Objective: The present study aimed to comprehensively investigate the changes 
in lipid mediators during murine sepsis induced by lipopolysaccharide (LPS) or 
cecal ligation and puncture (CLP). 
Methods: 24 h after induction of sepsis in male C57BL/6 mice by LPS or CLP, 
plasma and liver, lung, kidney and heart tissues were sampled. Lipid mediator 
levels in plasma and tissue were quantified by means of LC-MS. Moreover, 
aspartate transaminase (AST), alanine transaminase (ALT), lactate 
dehydrogenase (LDH) and urea and creatinine levels were determined in plasma. 
Results: Elevation of liver function plasma parameters within 24 h revealed that 
both models were successful in the induction of sepsis. LPS-induced sepsis 
resulted in dramatic increase of plasma PGE2 (2100% change in comparison to 
control) and other cyclooxygenase metabolites, whereas this effect was less 
pronounced in CLP induced sepsis (97% increase of PGE2). Plasma epoxy-fatty 
acids (FAs) and dihydroxy-FAs and most of the hydroxy-FAs were elevated in 
both models of sepsis. Changes of tissue oxylipin concentrations were organ 
dependent. Whereas only few changes were detected in the lung and liver tissue, 
epoxy-FAs were elevated in the kidney. In the heart tissue a trend towards lower 
levels of hydroxy-FAs and epoxy-FAs was observed. 
Conclusion: Both murine models of sepsis are characterized by changes of 
oxylipins formed in all branches of the arachidonic acid (AA) cascade. The more 
pronounced effects in the LPS model make this model more suitable for the 
investigation of the AA cascade and its pharmacological modulation in sepsis. 
 
* Willenberg I., Song R., Shushakova N., Gueler F., Schebb N. H. (2015) 
Submitted for publication. 
Author contributions: IW: Designed research, performed experiments and wrote manuscript; SR: 
Performed experiments; NS: Performed experiments; FG: Designed research, helped writing 
the manuscript. NHS: Designed research and wrote the manuscript. 
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6.1 Introduction 
Sepsis is a severe medical condition with high incidence and mortality [1-3]. 
Sepsis arises when a host is not able to contain an infection and is 
characterized through a complex deregulation of inflammation resulting in 
multiple organ failure [4]. Aside from cytokines the pro-inflammatory 
prostaglandins (PGs), especially PGE2, play a role in sepsis [5]. Plasma PG 
levels are increased in several animal models of sepsis [6-9] and patients [10, 
11]. PGs modulate a variety of biological functions and are enzymatically 
formed from arachidonic acid (AA) or other polyunsaturated fatty acids (PUFAs) 
by cyclooxygenases (COXs) and several PG-synthases [12]. For example, 
PGE2 plays a role in the regulation of immune response, blood pressure, 
inflammation and pain [13]. PGI2 is a potent vasodilator and inhibitor of platelet 
aggregation and therefore important for cardiovascular homeostasis [13]. 
6-keto-PGF1α is its inactive, non-enzymatically formed hydrolysis product and 
used as marker for the in vivo production of PGI2 [13]. 13,14-dihydro-15-keto-
PGF2α is a plasma metabolite of PGF2α, which is involved in several 
physiological processes, such as luteolysis, oviarian function, parturition as well 
as in acute and chronic inflammation and cardiovascular diseases [14, 15]. 
Apart from the COX branch, PUFAs are converted in the AA cascade 
enzymatically by lipoxygenases (LOXs) and cytochrome P450 
monooxygenases (CYPs) or non-enzymatically via autoxidation. Conversion by 
enzymes of the CYP2C or CYP2J families results in the formation of epoxy-FAs 
with vasodilatory, anti-inflammatory, and analgetic properties. They are 
subsequently hydrolyzed by soluble epoxide hydrolase (sEH) to the less 
biologically active dihydroxy-FAs [16, 17]. ω-hydroxylation of AA by members of 
the CYP4A or CYP4F families form 20-HETE, acting as a vasoconstrictor [18]. 
The primary products of LOXs are hydroperoxy-FAs, which can be 
subsequently reduced to the corresponding hydroxy-FAs, such as 5-, 12- or 
15-HETE or the eicosapentaenoic acid (EPA) derived 5-, 12- or 15-HEPE [19]. 
These hydroxy-FAs can be used as markers for 5-, 12- or 15-LOX activity. 
Under physiological conditions, 5-HpETE can be further processed by 5-LOX to 
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LTA4 which serves as precursor for several highly biological active lipid 
mediators, such as the chemoattractant LTB4 or the anti-inflammatory LXA4 
[19]. Moreover, resolvins and related compounds, which are believed to be 
involved in the resolution of inflammation, are formed by the action of COX and 
LOX and primary products such as 18-HEPE and 17-HDHA are used as marker 
for this pathway [20]. Oxygenated FAs can be formed via autoxidation. Whereas 
enzymatic oxidation is stereoselective, autoxidation results in the formation of 
racemic mixtures. Primary autoxidation products are hydroperoxides, which can 
be reduced to hydroxy-FAs, such as 9- or 11-HETE [21]. Further reaction of the 
initially formed hydroperoxides results in the formation of F2-isoprostanoids, 
such as 5-iPF2α-IV, which are used as markers of oxidative stress in vivo [22]. 
Previous studies investigating the role of lipid mediators, generally referred to 
as oxylipins, in sepsis focused only on single or few compounds [7-9, 23]. 
Although there is a crosstalk between different pathways [24, 25], 
comprehensive information about sepsis related changes in all pathways is 
scarce. Particularly, no data on differences in oxylipin pattern induced by 
different animal models of sepsis is available. Initiation of sepsis in animal 
models can be achieved via three strategies: (i) administration of exogenous 
toxins (such as lipopolysaccharide (LPS)), (ii) administration of viable 
pathogens or (iii) by an alteration of the intestinal barrier [4, 26]. LPS-induced 
sepsis and polymicrobial sepsis induced by cecal ligation and puncture (CLP) 
are the most commonly used animal models. LPS-induced sepsis can be simply 
and robustly achieved by i.p. injection and is characterized by a rapid and 
massive elevation of systemic cytokines, such as TNF-α, IL-1β and IL-6 and PG 
levels [8, 26]. Notably, in clinical sepsis the increase of systemic cytokine levels 
is more prolonged and the concentrations are lower. Thus, LPS-induced sepsis 
gives insights in septic processes albeit there are limitations regarding the 
complex physiological response in septic patients [4, 26]. The CLP model is 
considered to be the gold standard in sepsis models [4]. In CLP surgery the 
intestinal barrier is damaged, allowing bacterial translocation which leads to 
peritonitis and eventually multiorgan failure. The cytokine release after CLP 
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surgery is prolonged and resembles the cytokine profile observed in septic 
patients [4, 26, 27]. 
This study aims to comprehensively investigate and compare the role of lipid 
mediators in these two models of sepsis. For this purpose, both oxylipin plasma 
as well as tissue levels were analyzed using a targeted metabolomics approach 
and correlated with clinical chemistry parameters indicating multiorgan failure 
due to acute sepsis. 
6.2 Experimental 
6.2.1 Chemicals 
LPS from E.coli O111:B4 was purchased from Sigma (Schnelldorf, Germany, 
L 2630 Lot#043M4104V). Oxylipin standards and internal standards were 
purchased from Cayman Chemicals (local distributor: Biomol, Hamburg). Epoxy 
octadecadienoic acids (EpODEs) and dihydroxy octadecadienoic acids 
(DiHODEs), 1-(1-methanesulfonyl-piperidin-4-yl)-3-(4-trifluoromethoxy-phenyl)-
urea (TUPS) were a kind gift from the laboratory of Bruce Hammock (UC Davis, 
California, USA). LC-MS grade acetonitrile (ACN), acetic acid (HAc) and 
methanol (MeOH) were obtained from Fisher Scientific (Nidderau, Germany). 
n-hexane (HPLC grade) was from Carl Roth (Karlsruhe, Germany). All other 
chemicals were from Sigma (Schnelldorf, Germany). 
6.2.2 In vivo studies 
C57BL/6 male mice (H2b, 11-13 weeks of age) were obtained from Charles 
River (Sulzfeld, Germany). Animals were cared for in accordance with the 
institution’s guidelines for experimental animals and with the guidelines of the 
American Physiological Society. The animal protection committee of the local 
authorities (Lower Saxony state department for food safety and animal welfare 
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LAVES) approved all experiments (approval: 33.9-42502-04-12/0846). Mice 
were housed under conventional conditions in individually ventilated cages 
produced by Techniplast Inc. (Italy) with a 12h light/dark cycle and had free 
access to food (Altromin 1324 standard mouse diet) and domestic quality 
drinking water ad libitum. 
LPS model 
C57BL/6 mice were i. p. challenged with 10 mg/kg bw LPS (n=6) or vehicle 
(n=6). After 24 h mice were anesthetized with isofluorane for blood sampling 
and organ retrieval. After perfusion with cold PBS lung, liver, kidney and heart 
tissue was collected. Tissue was immediately shock frozen in liquid nitrogen for 
later analysis and stored at -80°C till analysis.  
Cecal ligation puncture (CLP) 
CLP surgery was performed under isofluran anesthesia as described previously 
[28]. Briefly, after incision of the left upper quadrant of the peritoneal cavity the 
cecum was exposed and a tight ligature was placed around the cecum distal to 
the insertion of the small bowel. One puncture wound was made with a 
24-gauge needle into the cecum and small amounts of cecal contents were 
expressed through the wound, and 500 µL sterile normal saline solution was 
flushed into the abdomen. The cecum was placed back into the peritoneal 
cavity and the laparotomy site was closed in two layers. Finally, animals were 
returned to their cages with free access to food and water. 
6.2.3 Blood sampling and clinical chemistry 
Several days prior to sepsis induction and 24 h after blood was drawn from the 
retro orbital venus plexus using an EDTA coated capillary. After 10 min 
centrifugation at 4.000 g plasma was obtained and stored at -20°C to be used 
for clinical chemistry. Plasma urea, creatinine, aspartate transaminase (AST), 
alanine transaminase (ALT) and lactate dehydrogenase (LDH) levels were 
determined by using the fully automated Olympus AU 400 analyzer (Beckman 
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Coulter Inc.). Statistical differences between groups were determined by two-
way ANOVA followed by Bonferroni post-test. 
6.2.4 Oxylipin analysis 
Oxylipin analysis in plasma and tissue was carried out by solid phase extraction 
(SPE) followed by LC-MS as described with slight changes [29]. In brief, internal 
standards and 10 µL of an antioxidant/inhibitor solution (0.2 mg/mL EDTA, 0.2 
mg/mL buthylated hydroxytoluene, 100 µM indomethacin, 100 µM TUPS in 
MeOH/water (50/50 v/v)), 480 µL H2O (pH 6) and 120 µL MeOH were added to 
200 µL of plasma. Tissue samples were homogenized in 250 µL methyl formate 
in 1.5 mL tubes with a 3 mm metal bead using a ball mill (5 min, 25 Hz, Retsch, 
Haan, Germany) following addition of internal standards and 
antioxidant/inhibitor solution. After centrifugation, the supernatant was diluted 
with H2O (pH 6) to a total volume of 6 mL. Extraction was carried out on 
Chromabond C 18 ec cartridges (500 mg, Machery-Nagel, Düren, Germany) 
preconditioned with 2 column volumes of methyl formate, 1 column volume of 
MeOH and 3 column volumes of H2O (pH 6). Directly before plasma and tissue 
samples were loaded onto the SPE cartridge, samples were acidified with 80 µL 
HAc resulting in a pH of 3. After loading the sample, the cartridge was washed 
with 10 mL H2O (pH 6) and 6 mL n-hexane. The cartiged was dried for 20 min 
at -200 mbar. The analytes were then eluted with 8 mL methyl formate in glass 
tubes containing 6 µL of 30% glycerol in MeOH. Utilizing a Speedvac (Christ, 
Oserode, Germany), the extract was evaporated to dryness until only the 
glycerol plug was left. The residue was dissolved in 50 µL methanol. After 
centrifugation, 5 µL of the supernatant was injected to the LC-MS system. Mass 
spectrometric detection after electrospray ionization using an AB Sciex 6500 
QTRAP instrument (AB Sciex, Darmstadt, Germany) was performed as 
described [29, Chapter 5]. A list of all oxylipins covered by the method can be 
found in the appendix (Tab. 11.1). Multiquant (Sciex) was used for peak 
integration and determination of oxylipin concentration. 
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6.2.5 Data analysis 
Data analysis was performed using GraphPad Prism 5.0 (GraphPad Software, 
San Diego, USA). For the clinical chemistry parameters statistical differences 
between groups and both time points were determined by two-way ANOVA 
followed by Bonferroni post-test. Regarding oxylipin concentrations statistical 
differences between groups were determined by one-way ANOVA followed by 
Tukey post-test. 
6.3 Results 
6.3.1 Clinical chemistry 
The clinical chemistry parameters revealed that in both models sepsis with 
impairment of kidney and liver function was successfully induced. In comparison 
to the vehicle group with a bodyweight of 23.2 ± 0.5 g, the LPS group had a 
significantly reduced bodyweight of 21.8 ± 0.2 g 24 h after LPS treatment 
(p< 0.05). 24 hours after CLP the weight was also lower, however the difference 
between sham (24.1 ± 0.5 g) and the CLP (22.8 ± 0.5 g) group did not reach 
statistical significance. Plasma creatinine, urea, AST, ALT, urea and LDH levels 
at baseline and 24 h after treatment/surgery are shown in Fig.  6.1. 
Plasma creatinine levels of the LPS group significantly increased from 29 ± 1.3 
µmol/L to 54 ± 7.1 µmol/L 24 h after LPS treatment (p< 0.001). Additionally, an 
about five-fold increase of plasma urea concentration was observed (p< 0.001). 
Plasma activity of AST was significantly increased from 60 ± 7.2 U/L to 220 ± 20 
U/L (p< 0.05), while ALT activity showed no statistically significant changes 24 h 
after LPS treatment. Plasma LDH levels almost doubled in the LPS treated 
animals indicating substantial cell damage (p< 0.05). CLP resulted in increased 
plasma urea levels (baseline: 8.1 ± 0.36 mmol/L, 24 h: 17 ± 5.2 mmol/L, 
p< 0.05) but the effect was less pronounced as after LPS treatment (Fig.  6.1). 
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Fig.  6.1: Clinical chemistry of liver and renal function parameters prior to the experiment 
(baseline, gray bars) and 24 h after induction of sepsis by LPS or CLP (24 h, blue 
bars). Statistical differences were determined by two-way ANOVA followed by 
Bonferroni post-test test (*p<0.05, **p<0.01, ***p<0.001). 
 
Plasma creatinine levels were not affected by CLP. AST and ALT activities were 
elevated 24 h after CLP surgery: ALT activity was increased more than ten-fold 
(p< 0.001), whereas AST activity changed from 77 ± 6.5 U/L to 490 ± 89 U/L 
(p< 0.001, Fig.  6.1). As observed in a similar manner for LPS treatment, 
plasma LDH level raised from 740 ± 60 U/L to 1150 ± 260 U/L 24 h after CLP 
surgery (p< 0.05). 
6.3.2 Prostaglandins 
Plasma concentrations of all detected oxylipins (concentration > LOQ) are 
shown in Tab. 11.2. In the LPS treated group PGE2 and its analog derived from 
dihomo-γ-linoleic acid (DGLA 20:3, n-6), PGD2 and its analog from EPA, the 
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PGI2 metabolite 6-keto-PGF2α, PGF2α and its analog from DGLA as well as its 
metabolite 13,14-dihydro-PGF2α, the adrenic acid (22:4 n-6) derived 
1a,1b-dihomoPGF2α and 5-iPF2α were elevated in comparison to the vehicle. 
The increase was statistically significant (p< 0.05) for PGE2, PGE1, 
6-keto-PGF1α, 5-iPF2α, dihomo-PGF2α, 13,14-dihydro-15-keto-PGF2α, PGF1α and 
13,14-dihydro-15-keto-PGE1 (Fig.  6.2, Tab. 11.2). 
 
Fig.  6.2: PGE2 and PGE1 levels in plasma and different tissues 24 h after induction of sepsis 
by LPS i. p. injection or CLP surgery. Statistical differences were evaluated by one-
way ANOVA followed by Tukeys post-test and shown for LPS vs. vehicle and CLP 
vs. sham (*p<0.05, **p<0.01, ***p<0.001). 
 
For example, the PGE2 plasma level was found to be 3.9 ± 0.92 nM in the LPS 
group in comparison to 0.18 ± 0.048 nM in the vehicle group (p< 0.001), 
corresponding to an increase of 2100%. The effect of LPS treatment on PG 
tissue levels was less pronounced. In the liver most of the PG concentrations 
were unchanged between the LPS and vehicle group, only PGE2 and 5-iPF2α 
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were detected at statistically significant difference concentrations (Fig.  6.2, 
Tab. 11.3). In the kidney increased levels of PGD1, dihomo-PGF2α and PGF1a 
were observed in the LPS group (Tab. 11.4), while the concentrations of the 
other detected PGs were unchanged. 6-keto PGF1α, 13,14-dihdydro-15-keto-
PGE1 (p< 0.001) and 13,14-dihydro-15-keto-PGF2α (p< 0,05) were found to be 
elevated in the heart (Tab. 11.5). In lung tissue no changes in the detected PGs 
were observed (Tab. 11.6). 
24 h after inducing sepsis by CLP slightly elevated levels of PGE2 (CLP: 0.44 ± 
0.04 nM; sham: 0.22 ± 0.02 nM), 6-keto PGF1α (CLP: 3.1 ± 1.2 nM; sham: 0.81 
± 0.02 nM) and 13,14-dihydro-15-keto-PGE1 (CLP: 0.28 ± 0.066 nM; sham: 
< LOQ (0.036 nM)) were observed in the treatment group (Tab. 11.2). Except 
for PGD2, the concentrations of the other detected PGs were not different 
between CLP and sham control. Interestingly, PGD2 levels were decreased in 
the CLP group (0.75 ± 0.11 nM, p< 0.01) compared to the sham group (4.2 ± 
1.1 nM). PGD2 levels in the heart tissue showed the same trend: In the CLP 
group lower PGD2 concentrations (8.5 ± 1.0 fmol/mg) were detected compared 
to the sham group (20 ± 4.7 fmol/mg, p< 0.05, Tab. 11.5). For all other PGs no 
obvious changes in the tissue levels were observed (Tab. 11.3, Tab. 11.4, Tab. 
11.5, Tab. 11.6). 
6.3.3 Hydroxy-FAs 
LPS treatment showed different effects on the hydroxy-FAs. Plasma levels of 
8-, 12- and 20-HETE, 15-HETrE and 10-, 14- and 17-HDHA were increased 24 
h after LPS treatment in comparison to the vehicle group (p< 0.05, Tab. 11.2). A 
consistent trend towards higher concentrations in the LPS treated group were 
found for 8-HEPE, 12-HETE and 15-HEPE and 13-HDHA (Tab. 11.2, Fig.  
6.3 A,B). 5-HEPE and 9-HOTrE were detected at slightly lower levels after 
treatment, whereas the other detected hydroxy-FAs, such as 5- and 9-HETE, 
18-HEPE and 4-, 7-, 8- and 11-HDHA were found to be unaffected (Tab. 11.2). 
In the liver tissue the levels of 20-HETE, 10- and 20-HDHA were increased by 
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53-230% in the LPS group (p< 0.05, Tab. 11.3). 12-HETE, 12-HEPE and 
14-HDHA showed also trends towards higher levels in the LPS group. 
Interestingly the concentrations of 5- and 15-HEPE were decreased by about 
50% in the LPS treated animals (p< 0.05, Tab. 11.3). The concentrations of 
other hydroxy-FAs, such as 9- and 13-HOTrE, 5-, 8-, 9-, 11- and 15-HETE, 
18- and 20-HEPE and 4-, 7-, 8- and 11-HDHA were unchanged (Tab. 11.3). 
Similar observations were found in the kidney: 5-HEPE concentration was about 
20% lower in the LPS group (p< 0.001), whereas concentrations of other 
hydroxy-FAs, e.g. 20-HETE, 9- and 13-HODE and 7-, 10- and 11-HDHA were 
elevated (p< 0.05, Tab. 11.4). 12-HETE, 12-HEPE and 14-HDHA were found at 
140-310% higher concentrations in the LPS group (Tab. 11.4), most other 
hydroxy-FAs, such as 9- and 13-HOTrE, 5-, 8-, 9-, 11- and 15-HETE, 18- and 
20-HEPE and 4- and 8-HDHA, were unaffected. Only a minor modulation of the 
hydroxy-FAs concentrations in the lung tissue was observed in the sepsis 
models. Following LPS treatment, only 5-HEPE, 20-HETE and 7-HDHA were 
elevated in the LPS group (p< 0.05, Tab. 11.6) and for 5-HETE a trend towards 
higher levels was observed. 
Interestingly, the change in the hydroxy-FAs pattern in the heart revealed a 
different picture (Tab. 11.5): Most of the hydroxy-FAs, e. g. 13-HODE, 5-HETE 
and 4- and 11-HDHA showed a trend towards about 30% lower levels in the 
LPS group, reaching statistical significance (p< 0.05) for 5- and 12-HEPE, 
12-HETE and 10-, 14- and 17-HDHA. 
Similar to LPS treatment, CLP induced sepsis resulted in different changes in 
plasma hydroxy-FA concentrations. 9-HOTrE and 8-, 12- and 20-HETE were 
significantly elevated (83-300 %, p< 0.05). A similar trend of increased levels 
was observed for 8- and 12-HETE, 8-, 12- and 15-HEPE, 15-HETrE and 10-, 
13-, 14- and 17-HDHA (200-1200, Tab. 11.2, Fig.  6.3 A,B). The concentration 
of 9-HOTrE was decreased by 71% in the CLP group (p< 0.01). Levels of 5-, 
9- and 11-HETE, 18-HEPE and 9- and 13-HODE were not affected by CLP 
induced sepsis (Tab. 11.2). 
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Fig.  6.3: Plasma concentrations of selected metabolites of the LOX and CYP branch of the 
AA cascade 24 h after induction of sepsis by i. p. LPS injection or CLP surgery. 
Statistical differences were determined by one-way ANOVA followed by Tukeys 
post-test and shown for LPS vs. vehicle and CLP vs. sham (*p<0.05, **p<0.01, 
***p<0.001). 
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Consistent with the LPS model the concentration of 5-HEPE was decreased 
(p< 0.01) in the liver tissues of the CLP treated animals. Additionally, 9-HOTrE 
was also found at 47% lower levels while concentrations of 12-HETE, 12-HEPE 
and 10- and 12-HDHA were elevated by 99-580% during CLP induced sepsis 
(p< 0.05). The concentrations of the other hydroxy-FAs detected in the liver, 
e.g. 9- and 13-HODE, 5-, 8-, 9-, 11-, 15-HETE, 8-, 18- and 20-HEPE and 4-, 7-, 
and 8-HDHA were unchanged (Tab. 11.3). Similar to liver tissue, kidney 
5-HEPE level is decreased in CLP induced sepsis (18%, p< 0.01). Except for 
16-HDHA (increase by 48%, p< 0.05) and 14-HDHA (increase by 200%) which 
concentrations were elevated, other hydroxy-FAs detected were unaffected, 
e. g. 8-, 9-, 11-, 12-, 15-HETE and 4-, 7-, 8- and 11-HDHA (Tab. 11.4). In 
accordance to the LPS model, a trend towards lower hydroxy-FA levels in the 
heart was observed in CLP induced sepsis. The decrease was significant for 
9- and 13-HOTrE, 9- and 13-HODE, 5-HEPE, 5-, and 9-HETE and 11-HDHA 
(p< 0.05, Tab. 11.5). CLP surgery had no effect on the hydroxy-FA 
concentrations in the lung (Tab. 11.6).  
6.3.4 Epoxy-FAs 
The plasma epoxy-FA levels during LPS induced sepsis were either increased 
or unchanged. 9(10)- and 12(13)-EpODE, 9(10)- and 12(13)-EpOME and 
19(20)-EpDPE were found at 62-170% higher concentrations 24 h after LPS 
treatment (p< 0.05 Tab. 11.2). The levels of other detected epoxy-FAs, such as 
15(16)-EpODE, 5(6)-, 8(9)-, 11(12) and, 14(15)-EpETrE, 8(9)-, 14(15)-EpETE 
were unchanged (Fig.  6.3 C,D). In the kidney the effect of LPS on epoxy-FA 
levels was more pronounced: 14 out of 18 detected epoxy-FA concentrations 
were changed after LPS treatment (p< 0.5). Interestingly, the AA-derived 
epoxides 8(9)-, 11(12)- and 14(15) EpETrE were decreased by 13-25%, 
whereas most epoxy-FAs, e.g. 9(10)-, 12(13)- and 15(16)-EpODE, 9(10)- and 
12(13)-EpOME, 10(11)-EpDPE or 11(12)- and 14(15)-EpETE were found at 
11-87% higher concentrations (p< 0.05, Tab. 11.4). Only 17(18)-EpETE, 
5(6)-EpETrE, 8(9)-EpETE and 9(10)-epoxystearic acid kidney levels were not 
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affected by LPS treatment. Heart tissue epoxy-FA concentrations after LPS 
treatment were decreased by about 35% for the DHA derived epoxides 10(11)-, 
13(14)- and 16(17)-EpDPE (p< 0.05). The effects of LPS treatment on lung 
epoxy-FA levels were marginal, only 5(6)-EpETrE was found in an about two-
fold higher concentration (p< 0.05). In the liver no changes of epoxy-FA 
concentrations were detected. 
The CLP surgery showed only effects on a single plasma epoxy-FA level (Fig.  
6.3 C, D): Only 16(17)-EpDPE was increased in the treatment group (55%, 
p< 0.001). The other epoxy-FAs were unchanged and no obvious trend could 
be observed (Tab. 11.2). Similar to LPS induced sepsis, there was a trend 
towards decreased epoxy-FA levels in the heart 24 h after CLP. These 
differences were found to be statistically significant for the ALA derived epoxy 
metabolites 9(10), 12(13)- and 15(16)-EpODE (decrease about 60%, p< 0.05, 
Tab. 11.5). Regarding the epoxy-FA concentrations in liver, lung and kidney no 
changes by the CLP surgery were detected (Tab. 11.3, Tab. 11.4, Tab. 11.6). 
6.3.5 Dihydroxy-FAs 
LPS treatment resulted in increased plasma dihydroxy-FA levels. Out of 20 
detected dihydroxy-FAs 12 were significantly elevated by 57-170% (p< 0.05), 
e. g. 8(9)-, 11(12)- and 14,15-DiHETrE, 10,11-; 13,14- and 16,17-DiHDPE or 
14,15- and 17,18-DiHETE (Fig.  6.3 E,F, Tab. 11.2). In kidney all dihydroxy 
metabolites derived from LA and DHA were monitored at 49-101% higher 
concentrations in the LPS treated group (p< 0.05, Tab. 11.4). Dihydroxy-FAs 
derived from AA, ALA and DHA showed no significant change with a slight trend 
towards higher levels in LPS induced sepsis. Dihydroxy-FA levels in the lung 
were elevated in the LPS group, reaching statistically significance for 9,10- and 
12,13-DiHODE, 9,10-DiHOME, 4,5-; 7,8- and 10,11-DiHDPE and 5,6 and 
8,9-DiHETrE (Tab. 11.6). In contrast to the other oxylipins (see above) detected 
in the heart tissue, dihydroxy-FA levels of 4,5-, 10,11-, 13,14- and 
19,20-DiHDPE and 8,9- and 14,15-DiHETrE were increased by 22-78% in the 
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LPS treated group (p< 0.05, Tab. 11.5). The dihydroxy-FA metabolites in the 
liver were not affected by LPS treatment (Tab. 11.3). 
Dihydroxy-FA levels in plasma showed a trend towards higher concentrations in 
CLP induced sepsis. 8 out of 20 detected plasma dihydroxy-FA levels were 
significantly elevated by 72-170% after CLP surgery (9,10- and 12, 13-DiHOME, 
11,12- and 14,15-DiHETrE, 10,11-; 13,14-; 16,17- and 19,20-DiHDPE, p< 0.05, 
Fig.  6.3 E, F, Tab. 11.2). In the kidney 14,15-DiHETE, 9,10-DiHOME and 4,5-; 
10,11-; 13,14-; 16,17- and 19,20 DiHDPE were increased by 43-71% after CLP 
surgery (p< 0.05, Tab. 11.4). Interestingly, for 15,16-DiHODE a 46% lower 
concentration after CLP was observed (p< 0.05). The other dihydroxy-FA levels 
in kidney, such as 9,10-DiHODE, 12,13-DiHOME, 8,9-; 11,12- and 
14,15-DiHETrE and 7,8-DiHDPE were unaffected. In the heart tissue 
inconsistent effects of LPS induced sepsis on dihydroxy-FA levels were 
observed: 15,16-DiHODE and 9,10-dihydroxystearic acid concentration were 
decreased by 69 and 32%, respectively (p< 0.01). Levels of 17,18-DiHETE, 
10,11- and 19,20-DiHDPE and 14,15-DiHETrE were elevated by 27-75% 
(p< 0.05, Tab. 11.5). In the liver 12,13- and 15,16-DiHODE, 17,18-DiHETE and 
12,13-DiHOME were significantly decreased by 30-62% after CLP surgery 
(p< 0.05). Except for the 15-LOX metabolite 8,15-DiHETE, which was 
decreased by 56% (p< 0.05) in the treatment group, no changes were observed 
for the CYP/sEHi formed dihydroxy-FAs detected in the lung tissue. 
6.4 Discussion 
Sepsis is a severe medical condition characterized by the release of pro-
inflammatory mediators resulting in centralization and multi organ failure. Aside 
from interleukins, induction of COX-2 leads to an increase of PGE2 in sepsis [5]. 
This study aims to comprehensively investigate if and how other lipid mediators 
derived from AA or other n-3 FAs and PGs are involved in the inflammatory 
processes of sepsis by comparing two commonly used sepsis models, the LPS 
and CLP model. 
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Both models successfully induced sepsis as characterized by clinical chemistry. 
The increased plasma creatinine and urea levels in the LPS group indicate an 
acute kidney injury (AKI), a common condition in human sepsis [30]. Liver injury 
was moderate in the LPS group, with only a slight increase in AST levels. CLP 
surgery resulted in a dramatic increase of AST and ALT, indicating a more 
pronounced liver damage. No change in plasma creatinine and only ~50% 
increase in serum urea compared to the LPS model was observed in the CLP 
induced sepsis model. Elevation of urea without s-creatinine elevation points 
towards increased catabolism [31] but subclinical AKI cannot be excluded. 
Comparing both models the LPS induced sepsis resulted in AKI, whereas after 
CLP surgery the liver failure was more pronounced. 
The induction of sepsis is characterized by increased COX-2 expression, e. g. 
in activated macrophages, and as a consequence by increased levels of PGs 
[5]. Utilizing targeted metabolomics we simultaneously monitored the increase 
of a large number of PGs, such as PGE2, the prostacyclin metabolite 6-keto-
PGF1α and the PGF2α metabolite 13,14-dihydro-15-keto-PGF2α. Moreover, 
metabolites derived from other FAs, e. g. 13,14-dihydro-15-keto-PGE1 were 
observed for the first time in LPS-induced sepsis. The massive increase of 
PGE2 and 6-keto-PGF1α after LPS treatment is consistent the results of previous 
studies [8]. CLP surgery led to a comparable moderate increase in PG levels, 
indicating a significant difference between both models. Similar observations 
have been made regarding cytokine production, which were about 100-fold 
higher in the LPS model in comparison to the CLP model [4, 32]. Moreover, it 
has been reported that LPS injection is followed by fast and transient increase 
of systemic cytokine levels, whereas after CLP surgery the increase is more 
continuous and sustained [4, 26]. Since both models were only analyzed after 
24 hours it can only be assumed that the increase of PGs may follow a similar 
kinetics. In other studies a rapid increased of PGE2 levels in serum or peritoneal 
lavage fluid was observed after 5 h, 12 h or 18 h after surgery [9, 33, 34]. 
Overall, it is difficult to compare different CLP studies because different 
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numbers of cecal punctures and needle puncture size influence the release of 
intestinal bacteria which affects the onset and progression of sepsis [4]. 
Regarding lipid mediators formed in the LOX and CYP pathway of the AA 
cascade a large number of oxylipins is elevated in the LPS and CLP induced 
sepsis. Only a slight to moderate increase of the non-enzymatically formed 
autoxidation markers 9- and 11-HETE was observed indicating a specific effect 
rather than an unspecific formation in response to elevated activity of PLA2 or 
other lipases, as observed in inflammatory in vivo models [35, Chapter 5]. 
Remarkably, there is a trend towards increased 12-LOX products (12-HETE, 
12-HEPE) in plasma, liver and kidney, indicating an elevated 12-LOX and 
12-lipoxygenating ALOX-15 activity during sepsis. The massive plasma 
increase of the neutrophil chemoattractant 12-HETE [36, 37] suggests an 
involvement of this lipid mediator in the development of sepsis. A 
pharmacological decrease of this pro-inflammatory mediator may help to reduce 
neutrophil recruitment, as already shown in mouse models of acute lung injury 
[38], and therefore might allow attenuating multi organ failure during sepsis. 
However, it has to be considered that a reduced neutrophil recruitment is 
controversial in early stage of sepsis [39]. Interestingly, plasma, liver, kidney 
and lung levels of the vasoconstrictor 20-HETE [40] are increased after LPS 
treatment or CLP surgery, although one would expect based on the reduced 
blood pressure during acute septic shock a low level of this oxylipin. 
It is remarkable that sepsis leads to a general elevation of dihydroxy-FA plasma 
levels, which is consistent with earlier studies [8, 23, 41]. The CLP model elicits 
the same effect, albeit less pronounced. Regarding epoxy-FAs as precursors of 
dihydroxy FAs, only few were elevated during sepsis. This suggests that sepsis 
increases CYP formation of highly biological active epoxy FAs [42] which are 
rapidly hydrolyzed to less active dihydroxy-FA by soluble epoxide hydrolase 
(sEH). This assumption is substantiated by the observation that the most 
abundant epoxides, e. g. 9(10)- and 12(13)-EpOME, are increased in sepsis. 
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These might be formed at such high concentrations that the capacity of sEH is 
too low to abolish the massive increase in epoxy-FAs completely. 
Although clinical chemistry revealed a severe kidney injury in the LPS group, no 
effect on AA derived PGs was observed. Only levels of PGD1 and PGF1α 
derived from DGLA and dihomo PGF2α derived from adrenic acid - known to be 
produced in renal medulla - were elevated [43]. Interestingly, most of the 
changes in oxylipin levels in the kidney were detected in the CYP branch, 
especially for the epoxy-FAs resulting in increased epoxy to dihydroxy ratios of 
LA and ALA. The vasodilatory properties of the epoxides [42] may contribute to 
the development of hypotension during sepsis. However, the best investigated 
EpETrEs derived from AA were found at decreased concentrations.  
Consistent with clinical chemistry which revealed no acute kidney injury in the 
CLP group, no effect on kidney PGs, hydroxy- and epoxy-FA levels was found, 
showing again differences in LPS and CLP induced sepsis. The liver injury in 
the CLP group was not accompanied by increased PG levels and only a small 
number of hydroxy-FAs were elevated. Because LPS treatment resulted in 
changes of few oxylipins as well, it is concluded that oxylipins are not a suitable 
marker for liver damage in LPS and CLP sepsis models. 
6.5 Conclusions 
Overall, the present study shows that both in vivo models of sepsis are 
characterized by massive changes in plasma oxylipin derived from all enzymatic 
branches of the AA cascade. Comparing both models 24 h after induction of 
sepsis the LPS model caused a more pronounced increase in oxylipins. Thus, 
this model seems to be better suited to investigate effects on the AA cascade 
than CLP. 
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7 Chapter 7 
Determining COX-2 Activity in Three Different Test 
Systems Utilizing online-SPE-LC-MS for Parallel 
Quantification of Prostaglandin E2, D2 and 
Thromboxane B2 * 
Cyclooxygenase-2 (COX-2) catalyzes the formation of PGH2 from arachidonic acid. 
PGH2 is further converted to different prostaglandins (PG), such as PGE2, PGD2 and 
TxB2. In this study a rapid online-SPE-LC-MS method for the simultaneous 
quantification of PGE2, PGD2 and TxB2 streamlined for COX-2 enzyme assays is 
presented. Baseline separation of all analytes was achieved in only 7.1 min per 
sample, including sample preparation by online SPE. The method showed high 
sensitivity (LODs of 0.65-1.25 fmol on column) and accuracy (89-113%) in protein 
containing media. Because of online-SPE, no manual sample preparation was 
required, except for addition of IS solution, allowing to use the approach as rapid 
read-out in COX-2 activity assays. This was demonstrated by applying the method 
on three in vitro test systems: a cell-free enzyme assay, an assay using HCA-7 cells 
constitutively expressing COX-2 and primary human monocytes. In these assays, the 
potency of three popular drugs celecoxib, indomethacin and dexamethasone was 
successfully characterized with the new online-SPE-LC-MS method. The comparison 
of the results showed that the inhibitory effects of PG formation strongly depend on 
the test system. Thus we suggest that the modulation of COX-2 activity of a test 
compound should be at least characterized in two assay systems. With the online-
SPE-LC-MS method described in here we present a versatile tool as read-out for 
these types of assays. 
* Reprinted from Journal of Chromatography A, vol. 1391, Willenberg I., Meschede A. 
K., Schebb N. H., Determining COX-2 Activity in Three Different Test Systems Utilizing 
online-SPE-LC-MS for Parallel Quantification of Prostaglandin E2, D2 and 
Thromboxane B2, pp. 40-48, Copyright (2015), with permission from Elsevier. 
Author contributions: IW: Designed research, performed experiments, and wrote manuscript; 
AKM: Performed Western Blots as part of her master thesis under the supervision of IW; NHS: 
Designed research and wrote the manuscript.
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7.1 Introduction 
Cyclooxygenases (COX) are enzymes of the arachidonic acid (AA) cascade 
catalyzing the conversion of AA to prostaglandin (PG) H2 (Fig.  7.1) [1]. This 
reaction comprises two steps: In the first step PGG2 is formed by addition of two 
molecules of oxygen to the fatty acid. In the second step the peroxidase activity 
of COX reduces the hydroperoxide leading to PGH2 which is further 
metabolized via various downstream enzymes (Fig.  7.1) [1]. 
 
 
Fig.  7.1: Prostaglandin formation: Arachidonic acid is released from membrane phospholipids 
by phospholipases. Cyclooxygenases (COX) convert AA via PGG2 to the 
endoperoxid PGH2. Subsequent formation of PGE2 and PGD2 is catalysed by 
prostaglandin-E/D-synthase (PGE/DS). TxA2 is formed by thromboxane-A-synthase 
(TxAS) and under aqueous conditions rapidly hydrolysed to the biologically inactive 
TXB2 [1].  
 
COXs exist in different isoforms [2]. Simplified, COX-1 is constitutively 
expressed regulating homeostasis, e. g. stomach acidity or renal function [1]. By 
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contrast, COX-2 is induced by several growth factors such as cytokines and 
mechanical stress e. g. during inflammatory processes [3]. Moreover a third 
isoform, COX-3, of unclear biological relevance has been described.  
Downstream processing of PGH2 leads to several potent lipid mediators such 
as TxA2 which is formed by thromboxane-A-synthase. TxA2 is under aqueous 
conditions unstable and rapidly hydrolyzed to the biologically inactive TxB2 [1]. 
Prostaglandin-E-synthase yields PGE2 which mediates pain, fever and 
inflammation among several other biological functions [4]. Prostaglandin-D-
synthase catalyzes the conversion from PGH2 to PGD2 [1], a 
bronchoconstrictory lipid mediator [5] (Fig.  7.1). Which metabolite is formed 
depends on the specific cell or tissue where the precursor PGH2 is formed: 
thromoboxane-A-synthase is for example located in platelets, while 
prostaglandin-D-synthase is expressed in mast cells and in the brain [4]. 
Prostaglandin-E-synthase can be found in most cells and tissues [4, 6]. 
The biological role of PGE2 in regulation of pain, fever and inflammation makes 
COX, especially COX-2, a prominent drug target. Non-steroidal anti-
inflammatory drugs (NSAIDs), which are one of the most used classes of 
pharmaceuticals, act by inhibiting COX resulting in reduced prostaglandin levels 
[7]. In order to overcome side effects of NSAIDs caused by inhibition of both 
COX isoforms, many efforts were made to develop COX-2 selective inhibitors 
(e. g. celecoxib, valdecoxib) [8, 9]. To characterize compounds for their ability to 
inhibit COX, in vitro screening assays are performed. For this purpose several 
assays have been developed, for example cell-free enzyme inhibition assays 
with recombinant COX-1 or COX-2 in the presence of cofactors and the 
endogenous substrate AA [10]. Other approaches use cell lines which 
constitutively express COX-2 [11] or which express COX-2 upon inflammatory 
stimulus [12, 13]. All test systems have in common that they determine enzyme 
activity and inhibition based on substrate consumption or product formation. 
One possible read-out is to measure the oxygen (substrate) consumption [8] or 
to apply spectrophotometric assays with a dye which is oxidized during the 
reduction of PGG2 to PGH2 [14]. However, methods which directly quantify the 
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formed PGs are more reliable [15]. Analysis of the direct COX products PGG2 
and PGH2 is not suitable because of their short half-lifes in aqueous solution 
[16]. If no further downstream processing enzyme is present, the amount of 
PGE2 can be monitored because PGH2 spontaneously reacts to PGE2, PGD2 
and PGF2α in aqueous solution with PGE2 as main product [16]. Thus, most 
commonly formation of PGE2 is used for the determination of COX activity and 
inhibitory potency (expressed as IC50 value) of test compounds. However, the 
fate of initially formed PGH2 depends on the test system, and the TxB2 
concentration is also commonly used as read-out. Quantification of PGs and 
TxB2 can be achieved either by applying ELISA [17], the use of radiolabeled AA 
followed by a separation technique and scintillation counting [18] or liquid 
chromatography (LC) coupled to mass spectrometry [10, 19]. The disadvantage 
of ELISAs is the potential risk of insufficient selectivity due to cross-reactivities 
of the antibodies. For the radioisotope assay the labeled substrate has to be 
available and it requires permissions, specialized handling and disposal of 
waste. Therefore LC-MS analysis seems - if instrumentation is available - to be 
the most straightforward read-out. Several comprehensive LC-MS methods for 
the quantification of PGs and other oxidative metabolites of AA and other 
polyunsaturated fatty acids have been developed [20]. Additionally, methods 
covering only some metabolites of the COX branch of the AA cascade, are 
described [10, 16, 21-23] and used in COX inhibition assays. However, all of 
these methods require a time consuming and laborious sample preparation by 
liquid/liquid extraction or solid phase extraction (SPE) impeding sample 
throughput. COX activity assays, e.g. for the characterization of the inhibitory 
potency of drugs, result in a large number of samples. The present study 
describes the development of a rapid online-SPE-LC-MS method streamlined 
for these kinds of analyses. PGE2, PGD2 and TxB2 are simultaneously 
quantified in biological samples with minimal manual sample preparation. The 
applicability of the approach is demonstrated for three COX-2 inhibitory in vitro 
test systems: (I) a cell-free system utilizing recombinant COX-2, (II) the human 
colon carcinoma cell line HCA-7 constitutively expressing COX-2 and (III) 
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primary human monocytes which express COX-2 upon lipopolysaccharide 
(LPS) stimulus. 
7.2 Experimental 
7.2.1 Chemicals and biological materials 
Oxylipin standards and internal standards (IS), human recombinant COX-2 and 
arachidonic acid were from Cayman Chemicals (local distributor: Biomol, 
Hamburg, Germany). Methanol (MeOH), LC-MS grade acetonitrile (ACN) and 
acetic acid were purchased from Fisher Scientific (Schwerte, Germany). TRIS 
and DMSO were obtained from Roth (Karlsruhe, Germany) and hydrochloric 
acid from Merck (Darmstadt, Germany). LPS from Escherichia coli 0111:B4 and 
other chemicals were purchased from Sigma-Aldrich (Schnelldorf, Germany). 
Dulbecco’s modified Eagle’s medium (DMEM), RPMI 1640 buffered with 20 mM 
HEPES, fetal calf serum (FCS) and all other cell culture reagents, except 
DME/High modified (Sigma-Aldrich Cat. No. 56436C) were purchased from 
Biochrom (Berlin, Germany). HCA-7 cells were obtained from the European 
Collection of Cell Cultures (ECACC, Salisbury, United Kingdom). 
7.2.2 Online-SPE-LC-MS method 
Quantification of TxB2, PGE2 and PGD2 was carried out by LC-MS with online-
SPE in backflush mode (Fig.  7.2) [24]. Samples were kept at 4 °C in a xt-PAL 
autosampler (CTC Analytics, Zwingen, Switzerland) equipped with a 100 µL 
syringe. Wash solution 1 was 0.1% acetic acid in water and wash solution 2 
was ACN. The LC system consisted of an Agilent 1290 column oven (Agilent, 
Waldbronn, Germany) operated at 40 °C with a high pressure two-way six port 
valve (valve 1, Fig.  7.2) and two Agilent 1290 binary pumps (Agilent). An 
Agilent Inline Filter (Part No. 50674638) was connected to the outlet of the 
autosampler. Detection was carried out on a QTRAP 6500 triple quadrupol 
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mass spectrometer (ABSciex, Darmstadt, Germany) equipped with a high 
pressure two-way six port valve (valve 2, Fig.  7.2). 
 
Fig.  7.2: Setup of the online-SPE-LC-ESI-MS/MS system [24]. The samples are loaded on 
the SPE column by the flow of pump 1 (I). After 0.5 min the six port valve 1 (V1) is 
switched and the analytes are backflushed toward the separation column by the flow 
of pump 2 (II). After 2.5 min V1 is switched back to position A and the eicosanoids 
are separated by the gradient delivered by pump 2. Meanwhile the SPE column is 
cleaned and re-equlibrated (IV). The second six port valve (V2) reduces 
contamination of the ESI source by directing polar matrix compounds eluting close to 
the void volume to waste. Moreover, it enables separation of aqueous and organic 
waste and therefore reduces environmental impact. 
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The samples were injected into the loading flow delivered by pump 1((eluent A: 
0.1% acetic acid; eluent B: 95/5 (v/v) ACN/water acidified with 0.1% acetic 
acid). During this step of analysis the analytes were retained by the SPE 
material while proteins and salts were washed to waste. After switching valve 1 
to position B (Fig.  7.2) the analytes were backflushed toward the separation 
column by the flow of pump 2 (eluent A: 95/5 (v/v) water/eluent B, acidified with 
0.1% acetic acid, eluent B: 800/150/1 (v/v/v) ACN/MeOH/acetic acid). After 
analyte transfer from the SPE column to the analytical column, valve 1 was 
switched back to position A. Polar matrix compounds eluting close to the void 
volume of the analytical column were directed to waste. Thereafter valve 2 was 
switched directing the eluent of the separation column to the MS and enabling 
detection of the analytes. During chromatographic separation, the SPE column 
was cleaned with solvent B. Shortly after elution of all analytes valve 2 was 
switched back to position A and the SPE column was equilibrated for the next 
run while the separation column was washed and reconditioned. The final 
switching times of both valves are shown in Tab. 7.1. 
Tab. 7.1: Valve positions during the different steps of analysis (Fig.  7.2). 
 
Step 
Time 
(min) 
V1 V2 SPE column 
Separation 
column 
I 0-0.5 A A loading equilibrating 
II 0-2.5 B A eluting loading 
III 2.5-3.2 A A - eluting 
IV 3.2-5.8 A B cleaning eluting 
V 5.8-7.1 A A equilibrating cleaning 
 
Three SPE columns were tested for their performance extracting PGE2, PGD2 
and TxB2: (I) Waters HLB direct connect HP (2.1 × 30 mm, 20 µm particle; 
Waters, Eschborn, Germany), (II) Cyclone (0.5 × 50 mm, 50 µm particle; 
Thermo Fisher Scientific, Schwerte, Germany) and (III) a Kinetex C-18 pre-
column (2 × 4 mm, 1-5 µm particle; Phenomenex, Aschaffenburg, Germany). 
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The chromatographic separation was optimized on a Kinetex C-18 column (50 × 
2.1 mm, 1.3 µm fused core particles, pore size 100 Å) (Phenomenex) equipped 
with a KrudKatcher inlet filter (Phenomenex). The optimized solvent gradients 
and flow rates are shown in Fig.  7.3. 
 
Fig.  7.3: Solvent gradients (black line) and the flow rate (gray line) of (A) pump 1 and (B) 
punp 2. The background color (gray and white) indicates the switching of the valve 
positions. 
 
Mass spectrometric detection following electrospray ionization (ESI) in the 
negative mode was carried out in selected reaction monitoring (SRM) mode 
using the following parameters optimized for PGE2 detection: ion spray voltage -
4.5 kV, entrance potential -10 V, curtain gas 35 psi, gas 1 and gas 2 both 
60 psi, temperature 450°C, collision-activated dissociation (CAD) gas was set to 
high value (12 psi). For the transition of each analyte declustering potential 
(DP), collision energy (CE) and collision cell exit potential (CXP) were optimized 
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(Tab. 7.3). Nitrogen was used as nebulizer, desolvation and collision gas. The 
instrument was operated in scheduled SRM mode with a detection window of 
± 22.5 s around the expected retention time. Quantification was performed by 
an external calibration and 2H4-PGE2, 
2H4-PGD2 and 
2H4-TxB2  (20 nM) as IS. 
For calibration, the analyte to IS area ratios were linearly fitted reciprocally 
weighted by concentration. Instrument controlling was performed with Analyst 
1.6.1 and data analysis was carried out with Multiquant 2.2 (AB Sciex). 
In order to test the extraction efficacy of the different SPE columns the eluent of 
the SPE column was connected to the MS (split 1:10). 
Accuracy and precision of the method was tested in spiked cell culture medium 
(RPMI 1640, 20 mM HEPES, 10% FBS, 2 mM glutamine, penicillin (100 U/mL) 
and streptomycin (10 µg/mL)). For this purpose 990 µL medium was mixed with 
10 µL standard solution in MeOH yielding concentrations of 10, 100 and 250 nM 
PGE2, PGD2 and TxB2, respectively. The spiked solutions were prepared in 
triplicate in order to determine intersample variation. The intrasample variation 
was determined by non-consecutively injecting the same spiked sample three 
times. Accuracy was calculated as recovery rate by dividing the measured 
concentration to the spiked amount. For calculation of the interday variation a 
QS sample standard (20 nM) was analyzed seven times over a period of 
6 weeks.  
7.2.3 Sample preparation 
The only sample preparation carried out was mixing the sample with IS solution 
prior to the injection of 5 µL supernatant into the online-SPE-LC-MS system. 
50 µL cell culture supernatant derived from incubations of HCA-7 cells was 
spiked with 10 µL IS solution in MeOH. For the monocyte and cell-free assays 
volumes of supernatant (30 µL) or buffer (75 µL) were mixed with equal 
volumes of IS in MeOH. Samples from cell based assays were centrifuged 
(20 000 x g, 5 min, 4°C) prior to injection. 
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7.2.4 Cell-free COX-2 activity assay 
The cell-free COX-2 assay was performed as described [10] and adapted to a 
96-well plate format. In brief, different concentrations of the test compound (final 
DMSO concentration 0.8%) were incubated in 100 mM TRIS buffer (pH 8) 
containing 50 ng COX-2 protein/mL (0.5 U/mL), 1 µM hematin and 2 mM 
L-epinephrin. After 10 min preincubation at 37°C the reaction was started by the 
addition of AA (final 5 µM). After 10 min HCl (final 0.2 N) was added to 
terminate the enzyme reaction. 
7.2.5 HCA-7 cell based assay 
HCA-7 cells were cultured in DMEM with 10% FCS, 2 mM glutamine, penicillin 
(100 U/mL) and streptomycin (10 µg/mL) in a humidified 37°C incubator with 
5% carbon dioxide. Stock cultures were split at a confluence of 70-80% by 
using trypsin/EDTA and seeded at a density of 270.000 cells/cm2. For the COX-
2 inhibition assay the cells were seeded at a density of 750.000 cells/well in 
6 plate dishes. After 24 h the about 70-80% confluent cells were washed with 
PBS and treated with the test compound solved in assay medium (DME/High 
modified without FCS and phenol red adjusted to pH 7.4 with 50 mM TRIS and 
supplemented with 5 µg/mL AA, 0.1% DMSO). Celecoxib and dexamethasone 
were tested in a concentration range between 1 nM and 10 µM, the 
concentrations used for indomethacin ranged between 1 nM and 25 µM. After 
24 h of incubation with the test compound the cell culture supernatant was 
collected and stored at -20 °C until online-SPE-LC-MS analysis. The cells were 
detached with trypsin/EDTA. After washing the pellet with PBS, it was stored at 
-80°C till Western Blot analysis. The cytotoxicity of the test compounds in 
HCA-7 cells was evaluated by a lactate dehydrogenase leakage test (Cyto-Tox-
ONE, Promega Mannheim, Germany). Indomethacin showed no cytotoxicity up 
to a concentration of 25 µM, celecoxib and dexamethasone showed no 
cytotoxicity up to 10 µM within 24 h of incubation (data not shown). 
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7.2.6 Primary monocyte based assay 
Freshly collected whole EDTA-blood from healthy human subjects was layered 
over the same volume of Polymorphprep (Axis-Shield, Oslo, Norway) in a 
50 mL centrifugation tube. The tubes were centrifuged for 30 min at 555 x g at 
22 °C in a swing-out rotor without brake. After centrifugation, the upper band 
containing the mononuclear cells was collected utilizing a pasteur pipette. After 
centrifugation for 5 min at 500 x g the pellet of the mononuclear cells was 
washed two times with PBS-EDTA buffer (0.5% BSA in PBS with 2 mM EDTA). 
Finally, the pellet was resuspended in RPMI 1640, buffered with 20 mM HEPES 
and supplemented with 10% FCS, 2 mM glutamine, penicillin (100 U/mL) and 
streptomycin (10 µg/mL). The cells were seeded at a density of 6-8 x 106 cells 
per well in 6-well plates in 2 mL medium. After 3 h, non-adherent cells were 
removed by washing the cells two times with PBS. Test compound dissolved in 
DMSO was added to freshly prepared medium containing LPS (10 µg/mL). This 
medium (final DMSO 0.1%) was added to the cells. Indomethacin and celecoxib 
were tested in a concentration range from 0.1 nM to 10 µM and dexamethasone 
from 0.01 nM to 1 µM. After 24 h of incubation cell culture supernatant was 
collected for LC-MS analysis and the cells were harvested for Western Blot (see 
above). Cell viability was determined by counting the cells in the supernatant 
and the pellet after mixing with trypan blue solution (0.5%, Biochrom, Berlin, 
Germany) in a Neubauer chamber. No effects of the compounds in the tested 
concentrations were observed (data not shown). 
7.2.7 COX-2 specific Western Blot 
Cells were lysed in ice cold RIPA-buffer (50 mM TRIS, 150 mM NaCl, 1 mM 
EDTA, 1% (v/v) Triton X-100, 1% (w/v) sodium desoxycholat, 0.1 % (w/v) SDS, 
pH 7.4, protease inhibitors (Complete Mini Protease-Inhibitor Cocktail tablet, 
Hoffmann-La Roche Ltd, Switzerland). After centrifugation (16000 x g, 5 min, 
4 °C) protein concentration was determined with the bicinchoninic acid (BCA) 
method (BCA assay kid, Sigma, Schnelldorf, Germany) and BSA as standard 
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for quantification. Aliquots (20 µg protein) and a prestained protein marker 
(Thermo Scientific, Schwerte, Germany) were separated by SDS-PAGE under 
reducing conditions on a 10% polyacrylamide gel with a 4% stacking gel and 
then blotted onto a nitrocellulose membrane (GE, Amersham, UK). Membranes 
were blocked for 1 h at room temperature with 5% (w/v) non-fat dry milk powder 
(Fluka, Switzerland, Buchs) in TRIS-buffered saline with tween (TBST: 3.5 mM 
TRIS, 16.5 mM TRIS hydrochloride, 150 mM NaCl, 0.1% (v/v) Tween 20, pH 
7.5). After cutting the membrane at the 55 kDa marker, the upper part of the 
membrane containing the COX-2 protein was incubated overnight at 4 °C with 
mouse monoclonal anti-COX-2 antibody (Cayman, product no. 160112) diluted 
1:1000 in TBST. The lower part of the membrane was incubated the same way 
with a mouse monoclonal anti-β-actin antibody (Biovision, local distributor 
BioCat, Heidelberg, Germany) diluted 1:4000 in TBST. After three times 
washing for 10 min in TBST, the membranes were incubated with a horseradish 
peroxidase labeled goat anti-mouse IgG antibody (Santa Cruz Biotechnology, 
Heidelberg, Germany) diluted 1:4000 in TBST for 1 h at room temperature. 
COX-2 and β-actin were detected by enhanced chemiluminescence (Super 
Signal West Pico Chemiluminescent Substrate, Thermo) by a Chemocam 
Imager (INTAS, Göttingen, Germany). 
7.2.8 Data processing 
Inhibitory effects were calculated based on the PGE2 formation. GraphPad 
Prism 5.0 (GraphPad Software, San Diego, USA) was used for the fitting of the 
resulting dose response curve and calculation of the IC50 values. 
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7.3 Results and discussion 
7.3.1 Online SPE-LC-MS method development 
Central aim of this study was the development of a LC-MS method for the 
quantification of TxB2, PGE2 and PGD2 as rapid read-out for determining COX-2 
activity in different in vitro test systems. The most promising strategy to reduce 
manual sample preparation in LC-MS methods to a minimum is the use of 
online-SPE as already successfully demonstrated in the field of oxylipin analysis 
for the quantification of hydroxy-FAs [25] or epoxy-FAs and dihydroxy-FAs [26]. 
Using an online-SPE setup with two valves enables also the separation of 
organic and aqueous waste and thus reduces environmental impact and 
contamination of the MS source (Fig.  7.2) [24]. 
For the development of the online-SPE, the choice of an appropriate SPE 
column is crucial: On the one hand the column has to ensure complete 
extraction of the analytes from the matrix in the loading flow and on the other 
hand a rapid transfer from the SPE column to the separation column. In order to 
identify a suitable SPE column both criteria were evaluated for three different 
SPE columns. At an injection volume of 20 µL (10 nM solution in 50/50 (v/v) 
MeOH/water) the Thermo Fisher cyclone column showed a significant 
breakthrough for TxB2 (13%), PGE2 (6%) and PGD2 (5%). Utilizing the Waters 
HLB direct connect column and the Kinetex RP-18-pre-column, the 
breakthrough was for all analytes <1%. Based on the breakthrough of all 
analytes, the Thermo Fisher cyclone does not seem to be suitable as online-
SPE column for extraction of TxB2, PGE2 and PGD2. This may be explained by 
the properties of the polymeric styrol-divinylbenzene phase of the Thermo 
Fisher cyclone allowing only non-polar and π-π interactions. In contrast, the 
HLB column consists of a mixed mode phase which enables both hydrophilic 
and lipophilic interactions and therefore may better retain the moderate polar 
TxB2 and PGs. The (non-polar) C-18 material (Phenomenex C-18 pre-column) 
led with higher injection volumes (25, 50 and 90 µL) to breakthrough (Tab. 7.2). 
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Tab. 7.2: Comparison of the breakthrough test of the Waters Oasis direct connect  HP (2.1 x 
30 mm, 20 µm particle) and a phenomenex RP-18 pre-column (2 x 4 mm, particle 1-
5 µm). Different volumes (25, 50 and 90 µL) of a 10 nM multi-standard solution 
(50/50 water/ACN) were injected in the loading flow (3500 µL min
-1
, 0.1% acetic 
acid). The eluent of the SPE was monitored by MS/MS (split 1:10). After 1.5 minutes 
the eluent was changed to 100 % B (95/5 ACN/water, 0.1% acetic acid) in order to 
elute the loaded analytes. The breakthrough (%) of each analyte was calculated by 
the peak areas at a mobile phase composition of 100% aquaous acetic acid in 
comparison to that of 100% B 
 
Injection 
volume 
Breakthrough (%) 
Waters direct connect 
Phenomenex 
RP-18 pre-column 
TxB
2
 PGE
2
 PGD
2
 TxB
2
 PGE
2
 PGD
2
 
25 µL 0.1 0.2 0.1 3.3 0.3 0.3 
50 µL 0.1 0.1 0.1 60 43 44 
90 µL 0.1 0.1 0.1 100 100 100 
 
While the most polar analyte TxB2 already showed a slight breakthrough (3%) at 
an injection volume of 25 µL, an injection of 50 µL let to a breakthrough of all 
analytes (43-60%). The injection of 50 µL of the same amount of multi-standard 
solution solved in 10/90 (v/v) ACN/water resulted for all analytes in a 
breakthrough of below 0.1% indicating sufficient extraction capacity of the 
material to retain the injected 0.5 pmol of analytes. However, the elution power 
for 50/50 (v/v) ACN/water causes a poor extraction efficacy on this material 
already at 50 µL injection volume despite high flow rate of 3.5 mL/min water. By 
contrast, no (<0.2%) breakthrough was observed for the Waters HLB direct 
connect column up to an injection volume of 90 µL in 50/50 ACN/water (v/v), 
thus showing clearly the best extraction efficacy and was selected for further 
analysis. 
As a next step the elution profile - in backflush mode - of the analytes from 
Waters SPE column was investigated with different concentrations of solvent B 
(15, 20 and 30%). 15% B resulted in a broad signal, and transfer was 
ONLINE-SPE-LC-MS METHOD FOR THE QUANTIFICATION OF COX METABOLITES 
 
127 
 
completed in 3.0 min while elution at 20 and 30% B yielded only moderately 
tailing peaks of the analytes and a transfer time of 1.5 min (Fig.  7.4). 
 
Fig.  7.4: Elution profile from Waters Oasis direct connect  HP (2.1 x 30 mm, 20 µm particle). 
The separation column was removed from the online-SPE-LC-MS setup and the 
eluent of the SPE at (A) 15%, (B) 20% and (C) 30 % eluent B was directly monitored 
by ESI-MS/MS. The SRM signals of the analytes of an injection (5 µL) of a 10 nM 
multi-standard solution are shown. 
 
In order to ensure rapid analysis and sharp chromatographic peaks, elution 
from the SPE column towards the separation column has therefore to be carried 
out with at least 20% B. The injection volume also influenced the elution profile 
probably causing a deeper penetration of the analytes into the SPE column 
requiring a longer elution. For the injection of 20 µL (50/50 (v/v) ACN/water) and 
elution with 20% B the transfer time of was 2.5 min. Higher injection volumes 
(25 µL and more) in this solvent led to massive tailing. Based on these results 
SPE of TxB2, PGE2 and PGD2 was carried out on the Waters HLB direct 
connect with a maximal injection volume of 20 µL (50/50 (v/v) water/ACN), 
elution at 20% B and a minimum switching time of valve 1 back to position A of 
2.5 min (Fig.  7.2, Tab. 7.1). 
The chromatographic separation was carried out on a Kinetex C-18 column 
(50 × 2.1 mm, 1.3 µm) in standard LC mode. This represents the latest 
development in RP high performance liquid chromatography combining the 
advantages of sub-2-µm particles with the improved mass transfer of solid 
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(fused) core particles. Baseline separation of the analytes was achieved with an 
isocratic flow of 31% B in less than 3 min. Retention times: TxB2 (1.4 min), 
PGE2 (2.3 min), PGD2 (2.7 min). Due to similar MS spectra of both PGs the 
same SRM transitions were used for the regioisomers PGE2 and PGD2.The use 
of a more selective transition for PGD2 (m/z 351/233) dramatically decreased 
sensitivity, while not being fully selective for this isomer [27]. Therefore the 
chromatographically separation is crucial to quantify both PGs independently 
from each other with high sensitivity.  
When combining the online-SPE setup with the analytical column using 31% B 
for both, the transfer and the separation, broad peaks and insufficient 
separation of PGE2 and PGD2 resulted (Fig.  7.5). 
 
Fig.  7.5: Insufficient separation of PGE2 and PGD2 utilizing the online-SPE-LC-MS setup with 
an isocratic flow of 30% B of pump 2. Shown are the SRM transitions of the injection 
of 20 µL of a 40 nM standard solution. 
 
By including a focusing step of the analytes on the analytical column at organic 
solvent concentration <30% the separation improved dramatically. Transfer 
from SPE to analytical column with 20% B followed by isocratic elution at 31% B 
led to baseline separation of TxB2, PGE2 and PGD2 (Fig.  7.6). 
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Fig.  7.6: SRM chromatogram (m/z 369  169: blue; m/z 351  271: green) of the online-
SPE-LC-MS system utilizing a Waters Oasis direct connect  HP (2.1 × 30 mm, 
20 µm particle) and a Phenomenex Kinetex C18 separation column (2.1 × 50 mm, 
1.3 µm). Shown is the chromatogram of an injection of 5 µL standard solution (4 nM). 
 
The total analysis time of 7.1 min per sample is much longer than those of other 
online-SPE-LC-MS methods for oxylipins [26]. However, separation of the PGs 
by RP chromatography is challenging, and even the use of a state of the art 
1.3 µm solid core particle filled column does not allow a shorter analysis time. 
Nevertheless, in comparison to other online-SPE methods including PGs the 
presented method is faster. For example, the online-SPE-LC-MS method for 
quantification of PGs described by Rinne et al. required an analysis time of 14 
min [19], other online-SPE methods had total runtimes of 13 min [28] and 
27 min [29]. An earlier described online-SPE-LC-UV method for PGE2 had a run 
time of 28 min per sample [30]. Moreover, it is not clear if the latter one is able 
to distinguish between PGE2 and PGD2 which is mandatory for precise 
measurement of COX activity because both PGs are formed in the cell-free and 
cell based test systems. 
With the online-SPE-LC-MS method a limit of detection (LOD; signal to noise 
ratio ≥ 3) of 0.13 nM (0.65 fmol on column) was determined for TxB2, both PGs 
showed a LOD of 0.25 nM (1.25 fmol on column) (Tab. 7.3). 
CHAPTER 7 
 
130 
 
Tab. 7.3: Method characteristics of the online-SPE-LC-MS/MS method. Shown are MS 
parameters, retention time (tR), LOD, dynamic range (dyn. range) of the linear 
regression. The coefficient of determination (r
2
) was < 0.999 for all analytes. 
 
Analyte 
Parent 
ion 
m/z 
Frag. 
ion 
m/z 
DP 
(V) 
CE 
(V) 
CXP 
(V) 
tR
a 
(min) 
LODb 
(nM) 
LODb 
on 
column 
(fmol) 
Dyn. 
range
c 
(nM) 
TxB2 369 169 -50 -28 -20 
4.02 
± 0.03 
0.13 0.65 
0.25 
- 500 
PGE2 351 271 -50 -28 -10 
4.69 
± 0.04 
0.25 1.25 
0.5 
- 500 
PGD2 352 271 -40 -30 -15 
4.96 
± 0.04 
0.25 1.25 
0.5 
- 500 
2H4-TxB2 373 173 -50 -28 -20 
4.02 
± 0.02 
- - - 
2H4-PGD2 355 275 -50 -28 -10 
4.67 
± 0.03 
- - - 
2H4-PGD2 355 275 -40 -30 -15 
4.93 
± 0.04 
- - - 
a Shown is the mean over a period of 6 month (n=6) 
b Limit of detection (LOD) is defined as s/n = 3 
c Lower limit of dynamic range match with the limit of quantification (LOQ, definded as 
s/n = 9); 500 nM is highest concentration tested, upper limit of dynamic range might be 
higher as 500 nM; accuracy ± 15% 
d Coefficient of determination 
This high sensitivity was due to the narrow peaks and the high ion transmission 
efficacy of the used MS instrument. In comparison with the sensitivity of other 
methods applied for the measurement of COX metabolites in cell culture 
samples the developed method shows a comparable sensitivity. Cao et al. 
reported LODs for PGs of 0.55 fmol on column [10, 31], other studies described 
LODs of 23 fmol (PGE2) and 28 fmol on column (PGD2) [22], or a lower limit of 
quantification (LLOQ) at 2.8 fmol on column [21] and at 28 fmol on column [23]. 
All earlier reported online-SPE-LC-MS methods for PGs found higher LODs of 
28 fmol (PGE2) and 51 fmol (PGD2) on column [19] or 116 fmol (PGE2) and 
159 fmol (PGD2) on column [29] and 28 fmol on column for PGE2 and PGD2 
and 27 fmol on column for TxB2 [28]. Even the sensitivity (LOD 1-5 fmol on 
column) of state-of-the-art targeted metabolomics approaches which 
simultaneously monitor a large number of 80 oxidative metabolites of AA and 
other LC-PUFA after offline SPE [32-34] are comparable to the developed 
method. 
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The linear range covers for all analytes at least four orders of magnitude. The 
LLOQ (signal to noise ratio ≥ 9 and accuracy of <±15%) was 0.25 nM for TxB2 
and 0.5 nM for PGE2 and PGD2. The upper limit of quantification (ULOQ) was 
set to the highest injected standard (500 nM). The calibration fulfills common 
validation criteria e.g. EMA Guideline on Bioanalytical Method Validation [35] 
with respect to accuracy of each calibration standards below ±15% and the 
LLOQ is at least five times the signal of a blank. Moreover, calibration was 
stable for at least six weeks resulting in consistent concentrations (± 5%). Thus, 
it is not necessary to analyze a new calibration curve each working day. These 
results clearly demonstrate that the analytical performance is not adversely 
affected using online-SPE. 
Accuracy and precision of the method were determined in DMEM supplemented 
with 10% FBS for three concentration levels (Tab. 7.4).  
Tab. 7.4: Accuracy and precision of quantification in spiked cell culture media (DMEM) with 
10% FBS. Shown are the recovery rates, intersample variation of independent 
prepared samples (n=3) and intrasample variation based on non-consecutive 
repeated injection of the same samples (n=3). Interday variation was below 6% (n=7, 
analysed in a period of 1.5 month). 
 
Analyte 
Spiked 
concentration 
(nM) 
Recovery 
(%) 
Intersample 
variation 
(%) 
Intrasample 
variation 
(%) 
TxB2 
10 
100 
250 
105 
95.5 
104 
8.9 
8.2 
3.3 
3.7 
1.3 
0.8 
PGE2 
10 
100 
250 
104 
88.6 
100 
7.1 
8.5 
4.2 
1.3 
1.0 
1.1 
PGD2 
10 
100 
250 
112 
101 
113 
8.4 
7.0 
3.5 
0.9 
0.4 
0.4 
 
For TxB2 the accuracy expressed as recovery rate was 95.5 - 105%. The 
accuracy for PGE2 was found to be 88.6 to 104% and 101 to 113% for PGD2. 
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Precision was high, with an intrasample variation of <1.4% except for TxB2 
(10 nM) at 3.7%. For all analytes interday and intersample variation were below 
9%. Performing the spiking experiments with other media used in the assays 
resulted in similar recoveries. The good accuracy and precision fulfill common 
validation criteria [35] and demonstrate that the developed method is suited for 
the quantification of TxB2, PGE2 and PGD2 in protein containing biological 
matrices. The most striking advantage of the presented method in comparison 
to other methods quantifying PGs is the minimized sample preparation and the 
analysis time of 7.1 min per sample including the online SPE. The only step to 
be carried out before the injection to the online-SPE-LC-MS system is the 
addition of IS. Most other methods for the quantification of PGs in biological 
matrices such as cell culture supernatant require a laborious and time-
consuming sample preparation either via liquid/liquid extraction or offline SPE 
[10, 16, 21-23, 31]. Even in comparison to earlier attempts to apply online-SPE-
LC-MS for the quantification of PGs the analysis time of the presented method 
is reduced and additionally more sensitive [19, 29]. Therefore the developed 
method is a fast and powerful tool for enzyme activity studies, requiring specific 
and sensitive detection of PGE2, PGD2 and TXB2 in large sets of samples.  
7.3.2 Application of the online-SPE-LC-MS method on three different COX-2 
inhibition assays 
The applicability of the presented online-SPE-LC-MS method was tested by 
analyzing the PGE2 formation in different COX-2 inhibitory assays. Three 
different in vitro test systems were compared regarding observed effects of the 
major drugs celecoxib, indomethacin and dexamethasone on the modulation of 
COX-2 activity. In the cell-free system AA was incubated with recombinant 
COX-2 and the inhibitory effects of the pharmaceuticals on COX-2 were 
evaluated by monitoring the PGE2 formation at different inhibitor concentrations. 
Fig.  7.7 A shows the formation of PGE2 when incubating the system with 
vehicle (DMSO) only. 
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Fig.  7.7: PGE2 formation in different in vitro test systems. (A) PGE2 formation in the cell free 
assay utilizing recombinant human COX-2 (0.05 µg/mL). (B) HCA-7 cells were 
incubated with 10 µM AA and PGE2 formation in cell culture media was measured at 
different time points. (C) Time dependant PGE2 formation in LPS (10 µg/mL) treated 
primary monocytes. (D) COX-2 specific Western Blot in primary monocytes after 2 h 
and 24 h incubation either with or without LPS. 
 
Under the applied conditions the PGE2 formation is linear up to 12.5 min. 
Therefore, an incubation time of 10 min was used for the determination of the 
inhibitory potential. As expected the glucocorticoid dexamethasone, which acts 
by reducing COX-2 expression [3, 36] showed no COX-2 inhibitory effect in this 
assay. The COX-2 selective inhibitor celecoxib inhibited the enzyme with a 
potency of an IC50 of 242 nM (Fig.  7.8 A) and for the non-selective COX 
inhibitor indomethacin an IC50 of 362 nM was calculated (Tab. 7.5). Cao et al. 
reported IC50 values of 50 nM and 2590 nM for celecoxib and indomethacin 
respectively using a similar in vitro assay with recombinant COX-2 and 
quantification of PGE2 by LC-MS [10]. Further studies using other cell-free in 
vitro assays, e.g. enzyme immune assays (EIA), spectrophotometric assays or 
scintillation analysis after LC, reported IC50 values between 40 nM and 440 nM 
for celecoxib [8, 37, 38] and IC50 values of 340-1000 nM for indomethacin [8, 17, 
18, 38, 39].  
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Fig.  7.8: Exemplary dose-response curves of celecoxib in the different assay systems: (A) 
cell-free assay, (B) HCA-7 and (C) primary human monocytes COX-2 inhibition 
(mean ± SD, n=3) is calculated based on the PGE2 formation. 
 
These data suggest that even for cell-free assays the IC50 value strongly 
depends on the assay conditions and the applied read-out. Studies which aim to 
investigate the COX-2 inhibitory potential of new compounds should therefore 
include a suitable reference compound in order to classify the effects on COX-2 
in comparison to already known pharmaceuticals. 
Tab. 7.5: Effects of celecoxib, indomethacin and dexamethasone on COX-2 activity in different 
test systems. IC50 values are calculated based on PGE2 formation determined by 
online-SPE-LC-MS. Results are presented as mean with the 95% confidence interval 
(CI) of the fitting of the dose response curve (n=3). In addition the effects of the 
compounds on COX-2 expression in the cell assays is described half quantitatively 
based on the results from western blot analysis. 
 
 
cell-free HCA-7 primary monocytes 
 IC50 (nM) 
(95% CI) 
IC50 (nM) 
(95% CI) 
COX-2 
expression 
IC50 (nM) 
(95% CI) 
COX-2 
expression 
Celecoxib 
242 
(102-578) 
292 
(179-477) 
no effect 
(up to 10 µM) 
14 
(8.0-24) 
no effect 
(up to 1 µM) 
Indo-
methacin 
362 
(195-671) 
583 
(254-1360) 
no effect 
(up to 25 µM) 
10 
(6.7-16) 
no effect 
(up to 100 µM) 
Dexa-
methasone 
no effect 
(up to 100 µM) 
no effect 
(up to 10 µM) 
no effect 
(up to 100 µM) 
1.6 
(1.4-1.9) 
1 µM - 3 nM: 
COX-2 ↓ 
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The second system in which the newly developed online-SPE-LC-MS method 
was applied was a cell based assay with the human colon carcinoma derived 
cell line HCA-7 which constitutively expresses COX-2 [40]. Incubation of the 
cells with vehicle (DMSO) resulted in a time-dependent increase of PGE2 levels 
in the cell culture supernatant for the first 4 h of incubation. After 4 h the PGE2 
concentration in the media remained constant up to an incubation time of 32 h 
(Fig.  7.7 B). Based on these results and to enable analysis of COX-2 
expression, cells were incubated for 24 h with the test compounds. Here, IC50 
values of 292 nM and 583 nM resulted for celecoxib (Fig.  7.8 B) and 
indomethacin, respectively. Both competitive active side inhibitors [41, 42] 
showed no effects on COX-2 expression in HCA-7 (Fig.  7.9 A, B). 
 
Fig.  7.9: Western Blot analysis of (A-C) HCA-7 cells and monocytes (D-E) after 24 h 
incubation with different concentrations of celecoxib (A, D), indomethacine (B, E) 
and dexamethasone (C, F). Shown are the signals for COX-2 and the loading control 
β-Actin. 
 
Interestingly, dexamethasone showed no effect on PGE2 formation (Tab. 7.5) 
and COX-2 expression in HCA-7 cells (Fig.  7.9 C). This may indicate that 
COX-2 overexpression in tumor cells cannot be modulated by glucocorticoids. 
The third assay utilizes primary monocytes in which the expression of COX-2 
was elicited by LPS [43] (Fig.  7.7 D). Following LPS treatment, PGE2 formation 
in these cells increased in a time-dependent manner (Fig.  7.7 C). In order to 
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test the ability of the drugs to modulate COX-2 expression and activity in 
primary monocytes the cells were incubated with LPS and the test substance 
for 24 h. All three pharmaceuticals significantly reduced LPS elicited PGE2 
formation resulting in IC50 values of 14 nM, 10 nM and 1.6 nM for celecoxib (Fig.  
7.8), indomethacin and dexamethasone (Tab. 7.5). Regarding the effects on 
COX-2 expression Western Blot analysis showed that incubation with 3 nM to 
1000 nM dexamethasone resulted in a decreased COX-2 expression while the 
expression was not affected by celecoxib and indomethacin (Fig.  7.9 D-F). In 
comparison to the cell-free assay and HCA-7 cell assay the effects on COX-2 
activity were for all compounds more pronounced in LPS triggered monocytes.  
One explanation could be a higher uptake of the inhibitors in the monocytes 
compared to the HCA-7 cells. The large deviation in IC50 values obtained with 
different test systems clearly demonstrates that the selection of an appropriate 
in vitro test system is crucial to get meaningful results for biological questions 
regarding COX-2 inhibition. For a comprehensive analysis of the potency of 
COX inhibitors, the compound should be at least tested in two different assay 
systems and results should be compared with common compounds. The 
presented online-SPE-LC-MS method with its sensitivity and short analysis time 
per sample is ideally suited as read-out for these types of COX-2 inhibitory 
studies resulting in large sets of samples. 
7.4 Conclusions 
In the present study an online-SPE-LC-MS method for the quantification of 
PGE2, PGD2 and TxB2 in biological matrices was developed. Regarding the 
sensitivity the method is comparable or even better than other LC-MS methods. 
The accuracy and precision for direct analysis of protein containing cell culture 
media was high (102 ± 7.60%, variation < 9%). 
Sample preparation only includes mixing the sample with IS and if necessary 
centrifugation. Time consuming manual sample preparation such as laborious 
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offline SPE or liquid/liquid extraction can be omitted. With an analysis time of 
7.1 min it can compete with the fasted LC-MS method for the simultaneous 
analysis of TXB2, PGE2 and PGD2, while including online sample preparation. 
Therefore the new method is ideally suited as read-out for enzyme activity and 
inhibition assays with large sample sets. 
As demonstrated for the drugs celecoxib, indomethacin and dexamethasone the 
method can be applied to both pure enzyme as well as cell assays. 
Interestingly, our results show that the observed potencies strongly depend on 
the test system. For example celecoxib and indomethacin showed similar 
inhibitory effects in the cell-free assay and in the HCA-7 cells. However, 
comparing the cell based assays both drugs showed more potent COX-2 
inhibitory effects in primary monocytes compared to the colon carcinoma 
derived cell line HCA-7. Thus, it is crucial to choose an appropriate in vitro test 
system to study effects on COX-2 to answer biological questions. The online-
SPE-LC-MS method described here is a versatile tool for all different in vitro 
assays.   
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8 Chapter 8 
Food Polyphenols Fail to Cause a Biologically Relevant 
Reduction of COX-2 Activity * 
Epidemiologic studies show a correlation between the dietary intake of food 
polyphenols and beneficial health effects. Several in vitro studies indicate that 
the anti-inflammatory potential of polyphenols is, at least in part, mediated by a 
modulation of the enzymes of the arachidonic acid cascade, such as the 
prostaglandin forming cyclooxygenases (COX). Evidence that this mode of 
action can be transferred to the situation in vivo is scarce. This study 
characterized the effects of a small library of polyphenols on COX-2 expression 
and activity in vitro and compared the potency with known drugs. In the next 
step, the in vivo relevance of the observed in vitro effects was tested. Enzyme 
assays and incubations of polyphenols with the cancer cell line HCA-7 and 
lipopolysaccharide (LPS) stimulated primary monocytes support the hypothesis 
that polyphenols can affect COX-2 expression and activity in vitro. The effects 
were most pronounced in the monocyte assay for wogonin, apigenin, resveratrol 
and genistein with IC50 values of 1.5 µM, 2.6 µM, 2.8 µM and 7.4 µM. However, 
these values are 100 to 1000-fold higher in comparison to those of the known 
pharmaceuticals celecoxib, indomethacin and dexamethasone. In an animal 
model of LPS induced sepsis, pretreatment with polyphenols (i. p. 100 mg/kg bw) 
did not result in decreased plasma or tissue prostaglandin levels, whereas the 
positive control celecoxib effectively attenuated LPS induced prostaglandin 
formation. These data suggest that despite the moderate potency in vitro, an 
effect of polyphenols on COX-2 during acute inflammation is unlikely, even if a 
high dose of polyphenols is ingested. 
* Willenberg I., Meschede A. K., Gueler F., Jang M. S., Shushakova N., Schebb 
N. H. (2015) in preparation 
Author contributions: IW: Designed research, performed experiments and wrote manuscript; 
AKM: Performed Western Blots as part of her master thesis under the supervision of IW, MSJ: 
Performed PCR experiments, NS: Performed in vivo experiment; FG: Designed research, 
helped writing the manuscript. NHS: Designed research and wrote the manuscript. 
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8.1 Introduction 
The dietary intake of fruits and vegetables is correlated with a longer healthier 
life. Health promoting effects are discussed for secondary plant metabolites in 
particular for polyphenols: Epidemiological studies suggest beneficial effects of 
polyphenols on cardiovascular diseases and the risk for the development of 
cancer [1, 2]. Chronic inflammation plays an important role in the development 
of these diseases and a large number of studies report anti-inflammatory effects 
for polyphenols [3, 4]. Aside from their antioxidative and radical scavenging 
properties, a modulation of pro-inflammatory mediators formed in the 
arachidonic acid (AA) cascade, such as cyclooxygenase-2 (COX-2) products, 
are suggested as modes of action underlying the anti-inflammatory effects [3]. 
COX-2 is expressed during inflammatory processes, giving rise to a large 
number of biologically active prostaglandins (PGs), for example the pain, fever 
and inflammation mediating PGE2 [5]. Based on this central role COX-2 is a 
major target of selective COX-2 inhibitors (COX-2i) and non-steroidal anti-
inflammatory drugs (NSAIDs), which also inhibit the constitutively expressed 
COX-1. Effects of polyphenols on COX-2 activity have been demonstrated in a 
vast number of in vitro studies [6-11]. However, different test systems were 
used and the lack of a correlation with the efficacy of known COX-2i or NSAIDs 
makes it impossible to compare and evaluate the potency of polyphenols. 
Moreover, a highly potent inhibition of COX-2 in vitro does not directly translate 
into an anti-inflammatory potential in vivo. The aim of the present study was to 
evaluate if food polyphenols could elicit a pharmacological relevant inhibition of 
COX-2. Therefore, polyphenols, which are known to inhibit COX-2 in vitro, i.e. 
nobiletin [9, 12], naringenin [7, 13], apigenin [6, 10, 13], wogonin [8, 14], 
genistein [10], epigallocatechingallate (EGCG) [10, 15] and resveratrol [11, 16, 
17], as well as the resveratrol oligomers ε-viniferin and hopeaphenol, were 
comprehensively analyzed regarding their effects on COX-2. In a tiered 
approach the effect on COX-2 was tested in a cell-free enzyme assay, in a 
cancer cell line and in lipopolysaccharide (LPS) stimulated primary human 
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monocytes. Finally, the most potent COX-2 inhibitors were tested for their ability 
to modulate COX-2 activity during acute inflammation in the LPS induced sepsis 
model with multi organ failure. In this model a modulation of all branches of the 
AA cascade by polyphenols was analyzed by means of targeted metabolomics 
in plasma and different organs. 
8.2 Experimental 
8.2.1 Chemicals 
Trans-resveratrol (≥ 99%), apigenin (≥ 97%), genistein (≥ 98%), naringenin 
(≥ 95%), EGCG (≥ 95%) and wogonin (≥ 98%) were purchased from Sigma 
(Schnelldorf, Germany). Hopeaphenol (≥ 90%) and ε-viniferin (≥ 90%) were 
obtained from Actichem (Montauban, France). Celecoxib was purchased from 
Santa Cruz Biotechnology (Dallas, USA).  
8.2.2 In vitro assays 
The in vitro assays were performed as described [6, 16, 18] and COX 
metabolites were quantified by LC-MS [18]. 
In the cell-free assay polyphenols were incubated with ovine recombinant 
COX-1 (70 ng/mL, Cayman Chemicals/ Biomol, Hamburg, Germany) or human 
recombinant COX-2 (50 ng/mL, Cayman Chemicals). 
HCA-7 cells were incubated with sub-cytotoxic concentrations of the 
polyphenols dissolved in TRIS-buffered DMEM medium. Cytotoxicity of the 
polyphenols was evaluated by the lactate dehydrogenase leakage test (Cyto-
Tox-ONE, Promega Mannheim, Germany). After 24 h the supernatant was 
collected for LC-MS analysis and the cells were harvested to analyze the 
COX-2 expression by Western Blotting. 
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Freshly isolated primary human monocytes were incubated with media 
containing 10 µg/mL LPS from Escherichia coli 0111:B4 (Sigma, Schnelldorf, 
Germany, L2630) and sub-cytotoxic concentrations of the polyphenols. After 
24 h, the supernatant was sampled for LC-MS and cells were collected for the 
COX-2 expression analysis by Western Blotting. In all assays, the 
concentrations of the polyphenols were stable (recovery > 80%) for up to 24 h, 
as determined by LC. Inhibitory effects were calculated based on the PGE2 
formation determined by LC-MS. 
8.2.3 Animals 
Twelve week old male C57BL/6N mice (Charles River, Sulzfeld, Germany) were 
used for all experiments. C57BL/6 male mice (H2b, 11-13 weeks of age) were 
obtained from Charles River (Sulzfeld, Germany). Animals were cared for in 
accordance with the institution’s guidelines for experimental animals and with 
the guidelines of the American Physiological Society. The animal protection 
committee of the local authorities (Lower Saxony state department for food 
safety and animal welfare LAVES) approved all experiments (approval: 
33.9-42502-04-12/0846). Mice were housed under conventional conditions in 
individually ventilated cages produced by Techniplast Inc. (Italy) with a 12 h 
light/dark cycle and had free access to food (Altromin 1324 standard mouse 
diet) and domestic quality drinking water ad libitum. Mice were monitored 
closely and if they appeared compromised (i.e. inactivity, no intake of food or 
water) after compound or LPS injection the experiment was terminated.  
8.2.4 In vivo model 
C57BL/6N mice were pretreated with the polyphenols (i. p., 100 mg/kg bw) or 
vehicle (80/20 (v/v) PEG 400/DMSO, 5µL/g bw). After 2 h mice were i. p. 
challenged with 10 mg/kg bw LPS (from E.coli 0111:B4, Sigma, L2630) or 
vehicle (10 µL/g bw). The control group, received COXi vehicle and LPS vehicle 
(n=8), the LPS control group received the COXi vehicle and LPS (n=7). 24 h 
EFFECTS OF POLYPHENOLS ON CYCLOOXYGENASE-2 
 
147 
 
after LPS treatment animals were sacrificed in general isofluran anesthesia by 
whole body perfusion with ice cold PBS. Thereafter, organ retrieval of liver, 
kidney samples was done and tissues were shock frozen and fixed in RNA 
later. Samples were stored at -80°C till further analysis. Blood drawing form the 
retro orbital venus plexus with an EDTA coated capillary was done at baseline 
(i.e. 4 days prior to study start) and 24 h thereafter. Plasma was generated by 
centrifugation at 4000 g at 4°C and stored at -80°C till further analysis. 
8.2.5 Oxylipin analysis 
Oxylipin levels were analyzed in plasma and tissues by LC-MS following SPE 
extraction of 200 µL plasma or tissue homogenate (50 mg) on Chromabond C18 
ec cartridges (Machery-Nagel, Düren, Germany) [19, Chapter 6]. A list of the 
covered analytes can be found in the appendix (Tab. 11.1). 
8.2.6 Clinical chemistry 
Clinical chemistry parameters (urea, creatinine, aspartate transaminase (AST), 
alanine transaminase (ALT), lactate dehydrogenase (LDH)) in plasma were 
analyzed at baseline (4 days prior the experiment) and 24 h after LPS injection. 
Parameters were determined by using the fully automated Olympus AU 400 
analyzer (Beckman Coulter Inc.). Only healthy mice (AST below 80 U/mL and a 
LDH below 1000 U/mL) were included in the experiment. 
8.2.7 RNA extraction and real time quantitative PCR 
Tissue sections were stored in RNA-later immediately after organ retrieval. 
Total RNA was extracted using the RNeasy mini kit system (Qiagen, Hilden, 
Germany) and transcribed using Superscript II Reverse transcriptase 
(Invitrogen). Quantitative (q) PCR was performed on Lightcycler 420 II (Roche 
Diagnostics, Penzberg, Germany) using FastStart Sybr-Green chemistry. Gene-
specific primers for IL-6 (Quantitec QT00098875, Qiagen) and MCP-1 
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(Quantitec QT00167832, Qiagen) were used for the gene of interest and HPRT 
served as house keeping gene for normalization (Quantitec QT00166768, 
Qigaen). Quantification was carried out using qgene software. 
8.2.8 Data analysis 
GraphPad Prism 5.0 (GraphPad Software, San Diego, USA) was used for data 
analysis, the fitting of dose response curves and calculation of the IC50 values. 
Statistical differences were determined by Dunnetts test (LPS vs. other groups). 
8.3 Results 
8.3.1 Enzyme assay 
In the cell-free enzyme assay nobiletin, naringenin, wogonin and genistein 
showed no effect on COX-1 or COX-2 dependent PGE2 formation (Tab. 8.1). 
Incubation of COX-1 with 100 µM apigenin resulted in a 31% decreased PGE2 
formation in comparison to the control, while the COX-2 activity remained 
unaffected. EGCG, resveratrol, ε-viniferin and hopeaphenol dose-dependently 
decreased the product formation of both isoforms (Tab. 8.1, Fig.  8.1). 
Resveratrol was the most potent compound tested and the IC50 values of 0.49 
µM (COX-1) and 0.43 µM (COX-2) were comparable for both isoforms. For 
EGCG, ε-viniferin and hopeaphenol the IC50 values to inhibit the COX-2 isoform 
were higher in comparison to those required to inhibit COX-1, e.g. 1.6 µM 
(COX-1) and 11 µM (COX-2) for ε-viniferin (Tab. 8.1). 
8.3.2 Modulation of COX-2 activity in cells  
Incubation of HCA-7 cells with non-cytotoxic concentrations of the polyphenols 
nobiletin, EGCG, wogonin, ε-viniferin and hopeaphenol resulted in no or only 
slight (inhibition < 50%) changes of PGE2 formation (Tab. 8.1).   
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Tab. 8.1: Effect of polyphenols on COX activity in the different in vitro test systems. 
 
  
 
c
e
ll
-f
re
e
 
C
O
X
-1
 
c
e
ll
-f
re
e
 
C
O
X
-2
 
H
C
A
-7
 
p
ri
m
a
ry
 m
o
n
o
c
y
te
s
 
 
IC
5
0
 (
n
M
) 
(9
5
%
 C
I)
 
IC
5
0
 (
n
M
) 
(9
5
%
 C
I)
 
IC
5
0
 (
n
M
) 
(9
5
%
 C
I)
 
C
O
X
-2
 
e
x
p
re
s
s
io
n
 
IC
5
0
 (
n
M
) 
(9
5
%
 C
I)
 
C
O
X
-2
 
e
x
p
re
s
s
io
n
 
N
o
b
ile
ti
n
 
n
o
 e
ff
e
c
t 
(u
p
 t
o
 1
0
0
 µ
M
) 
n
o
 e
ff
e
c
t 
(u
p
 t
o
 1
0
0
 µ
M
) 
in
h
ib
it
io
n
 <
 5
0
%
 
(u
p
 t
o
 1
0
0
 µ
M
) 
1
0
0
 µ
M
: 
C
O
X
-2
 ↓
 
2
4
 
(1
8
-3
4
) 
n
o
 e
ff
e
c
t 
(u
p
 t
o
 1
0
0
 µ
M
) 
N
a
ri
n
g
e
n
in
 
n
o
 e
ff
e
c
t 
(u
p
 t
o
 1
0
0
 µ
M
) 
n
o
 e
ff
e
c
t 
(u
p
 t
o
 1
0
0
 µ
M
) 
1
0
0
 µ
M
: 
5
3
%
 i
n
h
ib
it
io
n
 
1
0
0
 µ
M
: 
C
O
X
-2
 ↓
 
2
9
 
(2
7
-3
0
) 
1
0
0
, 
3
0
 µ
M
: 
C
O
X
-2
 ↓
 
G
e
n
is
te
in
 
n
o
 e
ff
e
c
t 
(u
p
 t
o
 3
0
 µ
M
) 
n
o
 e
ff
e
c
t 
(u
p
 t
o
 3
0
 µ
M
) 
1
0
0
 µ
M
: 
5
4
%
 i
n
h
ib
it
io
n
 
1
0
0
 µ
M
: 
C
O
X
-2
 ↓
 
7
.4
 
(4
.4
-1
3
) 
n
.d
. 
A
p
ig
e
n
in
 
in
h
ib
it
io
n
 
<
5
0
%
 
(u
p
 t
o
 1
0
0
 µ
M
) 
n
o
 e
ff
e
c
t 
(u
p
 t
o
 1
0
0
 µ
M
) 
1
0
 µ
M
: 
5
9
%
 i
n
h
ib
it
io
n
 
n
o
 e
ff
e
c
t 
(u
p
 t
o
 1
0
 µ
M
) 
2
.6
 
(2
.4
-3
.0
) 
1
0
, 
3
 µ
M
: 
C
O
X
-2
 ↓
 
E
G
C
G
 
1
7
 
(2
.6
-1
0
8
) 
3
2
 
(1
6
-6
4
) 
n
o
 e
ff
e
c
t 
(u
p
 t
o
 1
0
 µ
M
) 
n
o
 e
ff
e
c
t 
(u
p
 t
o
 1
0
 µ
M
) 
n
o
 e
ff
e
c
t 
(u
p
 t
o
 1
0
 µ
M
) 
1
0
 µ
M
: 
C
O
X
-2
 ↓
 
W
o
g
o
n
in
 
n
o
 e
ff
e
c
t 
(u
p
 t
o
 1
0
0
 µ
M
) 
n
o
 e
ff
e
c
t 
(u
p
 t
o
 1
0
0
 µ
M
) 
in
h
ib
it
io
n
 <
 5
0
%
 
(u
p
 t
o
 1
0
 µ
M
) 
n
o
 e
ff
e
c
t 
(u
p
 t
o
 1
0
 µ
M
) 
1
.5
 
(0
.8
9
-2
.5
) 
n
.d
. 
R
e
s
v
e
ra
tr
o
l 
0
.4
9
 
(0
.3
4
-0
.7
1
) 
0
.4
3
 
(0
.2
7
-0
.6
7
) 
4
.7
 
(2
.9
-7
.7
) 
n
o
 e
ff
e
c
t 
(u
p
 t
o
 5
0
 µ
M
) 
2
.8
 
(2
.2
-3
.5
) 
5
0
, 
1
0
 µ
M
: 
C
O
X
-2
 ↓
 
ε-
v
in
if
e
ri
n
 
1
.6
 
(0
.9
7
-2
.6
) 
1
1
 
(2
.5
-4
4
) 
n
o
 e
ff
e
c
t 
(u
p
 t
o
 1
 µ
M
) 
n
o
 e
ff
e
c
t 
(u
p
 t
o
 1
 µ
M
) 
in
h
ib
it
io
n
 <
 5
0
%
 
(u
p
 t
o
 1
 µ
M
) 
n
o
 e
ff
e
c
t 
(u
p
 t
o
 1
 µ
M
) 
H
o
p
e
a
p
h
e
n
o
l 
4
.0
 
(2
.4
-6
.7
) 
2
2
 
(6
.9
-6
8
) 
n
o
 e
ff
e
c
t 
(u
p
 t
o
 1
 µ
M
) 
n
o
 e
ff
e
c
t 
(u
p
 t
o
 1
 µ
M
) 
in
h
ib
it
io
n
 <
 5
0
%
 
(u
p
 t
o
 1
 µ
M
) 
1
 µ
M
: 
C
O
X
-2
 ↓
 
a
 I
C
5
0
 v
a
lu
e
s
 w
e
re
 c
a
lc
u
la
te
d
 b
a
s
e
d
 o
n
 t
h
e
 P
G
E
2
 f
o
rm
a
ti
o
n
 (
n
=
3
).
 
b
 C
O
X
-2
 p
ro
te
in
 l
e
v
e
ls
 w
e
re
 a
n
a
ly
z
e
d
 b
y
 C
O
X
-2
 s
p
e
c
if
ic
 W
e
s
te
rn
 B
lo
t;
 d
e
c
re
a
s
e
d
 C
O
X
-2
 p
ro
te
in
 i
n
 c
o
m
p
a
ri
s
o
n
 t
o
 
th
e
 c
o
n
tr
o
l 
is
 i
n
d
ic
a
te
d
 b
y
 ↓
. 
n
. 
d
. 
n
o
 d
a
ta
 
F
o
r 
c
o
m
p
a
ri
s
o
n
 t
o
 p
h
a
rm
a
c
e
u
ti
c
a
ls
 r
e
fe
r 
to
 
T
a
b
. 
7
.5
; 
IC
5
0
 v
a
lu
e
s
 i
n
 
in
 t
h
e
 c
e
ll 
fr
e
e
 C
O
X
-1
 a
s
s
a
y
: 
c
e
le
c
o
x
ib
: 
2
1
5
0
0
 n
M
, 
in
d
o
m
e
th
a
c
in
 1
7
 n
M
, 
d
e
x
a
m
e
th
a
s
o
n
e
 n
o
 e
ff
e
c
t 
(u
p
 t
o
 1
0
0
 µ
M
).
 
CHAPTER 8 
 
150 
 
Naringenin (100 µM), genistein (100 µM) and apigenin (10 µM) inhibited the 
formation of PGE2, and the IC50 values were estimated to be about 100 µM. In 
contrast, resveratrol potently reduced PGE2 formation in HCA-7 cells at an IC50 
of 4.7 µM (Tab. 8.1, Fig.  8.1). 
 
Fig.  8.1: Effects of resveratrol (A) and apigenin (B) on PGE2 formation and COX-2 expression 
in the COX-2 enzyme assay (I), in HCA-7 cells (ii) and in LPS-stimulated primary 
human monocytes (III). The inhibition (% of control) was calculated based on the 
PGE2 formation. 
 
A COX-2-specific Western Blot analysis of the cells treated with the polyphenols 
indicated for nobiletin, naringenin and genistein a decreased COX-2 expression, 
while all other compounds did not affect the COX-2 protein levels (Tab. 8.1). 
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COX-2 activity in LPS stimulated primary human monocytes was slightly 
reduced by ε-viniferin and hopeaphenol (inhibition < 50%, Tab. 8.1). The other 
active polyphenols inhibited PGE2 formation with IC50 values between 1.5 and 
29 µM (Tab. 8.1). The most potent polyphenols tested were wogonin (1.5 µM), 
apigenin (2.6 µM), resveratrol (2.8 µM) and genistein (7.4 µM). Decreased 
COX-2 protein levels were found in incubations with naringenin, apigenin, 
EGCG, resveratrol and hopeaphenol (Tab. 8.1, Fig.  8.1).  
8.3.3 In vivo model 
In acute systemic inflammation caused by LPS (i. p. 10 mg/kg, no COX-i) 
plasma PG levels were massively elevated compared to the control (Fig.  8.2). 
 
Fig.  8.2: Plasma PG levels in acute (24 h) LPS induced sepsis in mice. The test compounds 
were administered 2 h prior to the  induction of sepsis by LPS (100 mg/kg bw, i. p.). 
PG concentration is below the limit of quantification (LOQ, dotted line) if no bar is 
displayed. Shown are mean ± SE. (n= 4-8, ANOVA followed by Dunnett‘s test 
*p<0.05, **p<0.01, ***p<0.001). 
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The plasma concentration of the non-enzymatically formed 8-iPF2α was not 
significantly elevated by LPS induced sepsis. Treatment with a high dose of the 
selective COX-2i celecoxib – serving as positive control – attenuated LPS 
induced PG increase: 6-keto-PGF1α, PGF2α and 13,14-dihydro-15-keto-PGE1 
were below the limit of quantification (LOQ). PGE2 (p< 0.01) and 13,14-dihydro-
15-keto-PGF2α (p< 0.01) were massively decreased in comparison to the LPS 
group (Fig.  8.2). Treatment with the polyphenols (i. p. 100 mg/kg) did not result 
in decreased PG levels in comparison to the LPS group (Fig.  8.2). The PGE2 
levels were even elevated (p< 0.01) following resveratrol administration. For the 
polyphenol ε-viniferin, high levels of PGF2α (p< 0.001), 13,14-dihydro-15-keto-
PGF2α (p< 0.001), 13,14-dihydro-15-keto-PGE1 (p< 0.01) and the non-
enzymatically formed autoxidation marker 8-iPF2α (p< 0.001) were detected. 
It is noteworthy, that the COX blockade by the celecoxib group did not shunt 
oxylipin formation towards the CYP- or LOX pathway of the AA cascade (Fig.  
8.3, Tab. 11.7) as described in earlier studies [20]. The epoxy- and dihydroxy-
fatty acid (FA) metabolites were even decreased in the CYP pathway (Fig.  8.3, 
Tab. 11.7). A similar decrease was observed for the sum of linoleic acid (LA) 
derived epoxy-metabolites in the apigenin (p< 0.05) and the resveratrol (p 
<0.01) group and the sum of DiHETrEs in the case of apigenin (p< 0.05), as 
exemplary shown in Fig.  8.3 for the metabolites of LA and AA. 
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Fig.  8.3: Sum of LA and AA plasma epoxy fatty acid and dihydroxy fatty acid levels in acute 
(24 h) LPS-induced sepsis in mice. The test compounds were administered 2 h prior 
induction of sepsis by LPS (100 mg/kg bw, i. p.). Shown are mean ± SE. (n= 4-8, 
ANOVA followed by Dunnett‘s test *p<0.05, **p<0.01, ***p<0.001). 
 
The kidney PG levels 24 h after LPS injection showed a similar trend as in 
plasma. Slightly increased PG levels were observed in the LPS group (Fig.  8.4, 
Tab. 11.8). The selective COX-2 inhibitor celecoxib lowered PG concentrations 
in comparison to the LPS group (PGE2α metabolite 13,14-dihydro-15-keto-
PGE2α (p< 0.01), PGE1 metabolite 13,14-dihydro-15-keto-PGE1 <LOQ.). Kidney 
levels of PGE2 (p< 0.001), PGF2α (p< 0.001), 6-keto-PGF1α (p< 0.05), 
13,14-dihydro-15-keto-PGE1 (p< 0.001) and 8-iPF2α (p< 0.001) in the resveratrol 
group were increased in comparison to the animals only receiving LPS. 6-keto-
PGF1α (p< 0.001), 13,14-dihydro-15-keto-PGE1 (p< 0.001) and 8-iPF2α (p< 0.01) 
kidney levels were elevated in the ε-viniferin treated mice (Fig.  8.4). 
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Fig.  8.4: Kidney PG levels in acute (24 h) LPS induced sepsis in mice. The test compounds 
were administered 2 h prior to the induction of sepsis by LPS (100 mg/kg bw, i. p.). 
Shown are mean ± SE. (n= 4-8, ANOVA followed by Dunnett‘s test *p<0.05, 
**p<0.01, ***p<0.001).  
 
Clinical chemistry markers of kidney function (plasma creatinine and urea 
levels) were moderately increased in the LPS group, while treatment with 
celecoxib and ε-viniferin caused an elevation of both parameters (Fig.  8.5) 
indicating worsening of renal function. The chemoattractant and pro-
inflammatory molecule MCP-1 was measured by qPCR in renal tissue and 
revealed elevated mRNA levels in the LPS group (p< 0.05 LPS versus vehicle 
group). Combined treatment with LPS and celecoxib or polyphenols did not 
affect MCP-1 levels in comparison to the LPS group (Fig.  8.6). The pro-
inflammatory IL-6 mRNA expression in the kidney was about 10-fold increased 
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due to LPS injection in comparison to vehicle control (p> 0.05). Treatment with 
apigenin, resveratrol and genistein resulted in similar IL-6 mRNA elevation as in 
the LPS group, whereas celecoxib und ε-viniferin caused further increase of 
IL-6 mRNA expression compared to the LPS group (celecoxib 9-fold, ε-viniferin 
28 fold in comparison to LPS group, Fig.  8.6). 
 
Fig.  8.5: Plasma urea and creatinine levels as well as plasma AST, ALT and LDH activites in 
acute (24 h) LPS-induced sepsis in mice. The test compounds were administered 
2 h prior to the induction of sepsis LPS (100 mg/kg bw, i. p.). Shown are mean ± SE. 
(n= 4-8, ANOVA followed by Dunnett‘s test *p<0.05, **p<0.01, ***p<0.001). 
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Fig.  8.6: Kidney MCP-1 and IL-6 mRNA levels in acute (24 h) LPS induced sepsis in mice. 
The test compounds were administered 2 h prior to the induction of sepsis by LPS 
(100 mg/kg bw, i. p.). Shown are mean ± SE. (n= 3-5, ANOVA followed by Dunnett‘s 
test *p<0.05, **p<0.01, ***p<0.001). 
 
In the liver tissue no change in PG levels was observed between the LPS and 
the control group (Fig.  8.7, Tab. 11.9). Consistently, only a slight increase in 
plasma ALT activity and a moderate increase in AST activity were observed 
(Fig.  8.5). The mice treated with celecoxib, ε-viniferin and genistein showed 
elevated AST and ALT activities in plasma, thereby indicating aggravated liver 
injury of the high dose (Fig.  8.5). 
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Fig.  8.7: Liver PG levels 24 h in acute (24 h) LPS induced sepsis in mice. The test 
compounds were administered 2 h prior to the induction of sepsis by LPS 
(100 mg/kg bw, i. p.). Shown are mean ± SE. (n= 4-8, ANOVA followed by Dunnett‘s 
test *p<0.05, **p<0.01, ***p<0.001). 
 
8.4 Discussion 
The current concept is that several food ingredients elicit effects on human 
health by a modulation of the activity of enzymes of the AA cascade [21]. 
Particularly for food polyphenols a large number of studies report a potentially 
beneficial reduction of COX-2 activity [3]. The aim of the present work was to 
reevaluate these findings, analyzing the effects of a library of polyphenols on 
COX-2 in three in vitro test systems and in a robust in vivo inflammation model. 
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EGCG, resveratrol, ε-viniferin and hopeaphenol inhibited COX-1 and COX-2 in 
the cell free assay (Tab. 8.1). The most potent polyphenol tested was 
resveratrol with an IC50 of 0.49 µM (COX-1) and 0.43 µM (COX-2) (Tab. 8.1). 
The potency is consistent with previous studies reporting IC50 values for 
resveratrol ranging from 0.5 to 0.9 µM in the case of COX-1 and from 1.0 to 3.1 
in the case of COX-2 [16, 22, 23]. Thus, our data support the hypothesis that 
polyphenols could indeed act as COXi. It is remarkable that the polyphenols 
inhibited COX-2 at potency levels comparable to those of the NSAID 
indomethacin (0.36 µM) and the selective COX-2i celecoxib (0.24 µM) in this 
test system (Tab. 7.5). Both compounds are frequently used in the clinic for 
analgetic treatment of patients [24]. Taking the tyrosyl radical involved in the 
enzyme catalysis and the radical scavenging properties of polyphenols into 
account the inhibition of COX by polyphenols is discussed as being a rather 
unspecific mechanism [25, 26]. However, the polyphenols naringenin, genistein 
and apigenin with a strong antioxidative capacity [27, 28] showed no effect on 
COX. Hence, the inhibition by EGCG, resveratrol, ε-viniferin and hopeaphenol 
seems not to be based on a fully unspecific mechanism. 
In order to evaluate the biological relevance of enzyme inhibitors, cell assays 
are more predictive because the enzyme acts in its intact cellular compartment 
(ER) and changes at the expression level can be monitored. Moreover, the 
uptake of the inhibitor into the cell is taken into account. When studying 
biological questions in cellular systems, it is crucial to choose an adequate cell 
line. COX-2 expression is increased in many types of cancer, e. g. colon, breast 
or lung cancer, and, thus, some cell lines derived thereof, such as the colon 
adenocarcinoma derived cell line HCA-7, abundantly express COX-2 [29]. 
Therefore, these HCA-7 cells were selected as a cell culture model for the in 
vitro studies of the effects of polyphenols on COX-2 activity. 
In HCA-7 cells, only naringenin, nobiletin, genistein, apigenin and resveratrol 
affected COX-2 dependent PGE2 formation (Tab. 8.1). In the case of 
resveratrol, the unchanged COX-2 protein levels after 24 hours suggest that 
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resveratrol acts by inhibiting COX-2 activity, which is consistent with earlier 
findings [17]. However, at longer incubation times (48 h and 96 h) resveratrol 
has been reported to decrease COX-2 expression [17]. The slight change in 
PGE2 formation and the unchanged COX-2 protein levels after incubation with 
apigenin are comparable to a previous study [6]. Interestingly, the effects of 
genistein, nobiletin and naringenin can be in part explained by a decreased 
COX-2 expression (Tab. 8.1). This mode of action is supported by the lack of 
effect on the COX-2 activity in the cell-free enzyme assay. However, the effects 
only occurred at high concentrations of the compounds. Among the compounds 
tested only resveratrol effectively decreased the PGE2 formation in HCA-7 cells. 
However, with its IC50 of 4.7 µM resveratrol was more than 10-fold lower than 
that of celecoxib (IC50 0.29 µM) and indomethacin (IC50 0.58 µM) (Tab. 7.5), 
which may be explained by a low metabolic stability of resveratrol [30]. Based 
on these data, it seems unlikely that polyphenols could affect COX-2 expression 
and PGE2 formation of cancer cells in vivo. 
An up-regulated expression of COX-2 in monocytes, macrophages and other 
cells plays a key role in acute inflammation [31]. This makes COX-2 to one of 
the main drug targets in inflammation. Although cell line models, e. g. the 
murine macrophage cell line RAW 264.7, are often used to study effects on 
COX-2 during inflammatory processes in vitro [7, 8, 12, 14], LPS stimulated 
primary human monocytes better reflect the in vivo situation in patients. In 
stimulated primary human monocytes, all tested polyphenols potently inhibited 
LPS induced PGE2 production except for EGCG, ε-viniferin and hopeaphenol. 
Resveratrol, apigenin, genistein and wogonin were the most potent polyphenols 
with IC50 values below 10 µM. Although comparison of different cellular systems 
has its limitations, these results are consistent with earlier studies in RAW 264.7 
cells reporting an IC50 value of 8 µM and reduced COX-2 levels for apigenin, 
reduced PGE2 formation and COX-2 levels for genistein as well as a lack of 
effect of EGCG on PGE2 levels with even a slight increase in COX-2 protein 
levels [10]. Incubation of LPS stimulated murine macrophages with wogonin 
resulted in a suppression of COX-2 protein expression and an IC50 of 0.3 µM 
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[8], whereas for naringenin and nobiletin decreased COX-2 protein levels were 
found in LPS stimulated RAW 264.7 cells [7, 9]. The decreased COX-2 protein 
levels for naringenin and apigenin in combination with the absence of inhibitory 
effects in the enzyme assay suggest that these polyphenols reduce PGE2 
production in primary monocytes by down-regulation of COX-2 expression. As 
described earlier [11], resveratrol acts by two different mechanisms, the down-
regulation of COX-2 protein and the inhibition of the COX-2 activity (Tab. 8.1, 
Fig.  8.1). In comparison with pharmaceutically used COX inhibitors, the 
polyphenols are about 100 to 1000-fold less potent, the celecoxib, indomethacin 
and dexamethasone IC50 values being 14, 10 and 1.6 nM, respectively (Tab. 
7.5). Nevertheless, plasma concentrations close to their IC50 value in the µM 
range seem to be realistic following the intake of a high dose of polyphenols 
[32]. In order to evaluate potential health effects of polyphenols on COX-2 a 
robust in vivo model with a highly induced expression of COX-2 and elevated 
PGE2 levels was selected. The LPS induced sepsis model is a reliable and 
often used animal model to study the effects of compounds on the AA cascade 
and in this context in particular on the COX-2 mediated branch [33, 34, Chapter 
6]. However, this does not intend to utilize polyphenols to treat sepsis. 
Compounds were administered i. p. to prevent low intestinal absorption and 
tested in a high dose to ensure that even low to moderate inhibitory effects can 
be detected. Similar high doses have been used in previous studies 
investigating the effect of apigenin and resveratrol or celecoxib on LPS induced 
sepsis [20, 35, 36]. It should be noted that celecoxib and ε-viniferin caused 
moderate elevation of liver function parameters AST, ALT, and LDH indicating 
liver function impairment (Fig.  8.5). As previously described, celecoxib reduced 
plasma and kidney PG levels significantly [20], thus demonstrating as a positive 
control that the chosen experimental model allows to detect the modulation of 
COX-2 in vivo. None of the polyphenols tested attenuated the PG levels. Taking 
the high dose administered into account, this observation suggests that their 
potential to affect COX-2 in vivo is negligible. Resveratrol, as well as its dimer 
increased the PGE2 plasma concentration, which might indicate that the 
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stilbene might even aggravate at high concentrations the inflammatory process 
(Fig.  8.2). 
The targeted metabolomics approach enables the parallel detection of a large 
number of products being part of the COX pathway. This allowed us to 
characterize the COX-2 inhibition in more detail. In animals treated with 
celecoxib not only PGE2, but also the plasma metabolites of PGI2 (6-keto-
PGF1α), PGE1 (13,14-dihydro-15-keto-PGE1) and PGF2α (13,14-dihydro-15-keto-
PGF2α) were decreased, thereby additionally supporting an inhibition of COX-2 
by celecoxib. However, all these metabolites were not lowered by treatment 
with polyphenols (Fig.  8.2), thus substantiating the fact that the polyphenols 
cannot modulate COX-2 in vivo. 
The targeted metabolomics approach led to an interesting additional finding: 
Both apigenin and resveratrol reduced the levels of the CYP derived epoxy-FAs 
and their hydrolysis products (dihydroxy-FAs, Fig.  8.3). This indicates that 
CYPs are inhibited by these compounds, a mode of action of polyphenols that is 
well known for drug metabolizing CYPs [37]. This unexpected activity of the 
compounds should be addressed in further studies. 
The treatment with polyphenols did not attenuate tissue inflammation of the 
kidney or systemic liver function and renal function impairment as measured by 
clinical chemistry in the LPS sepsis model (Fig.  8.5, Fig.  8.6). Thus, it has to 
be concluded that the food ingredients do not alleviate the inflammation and 
organ damage caused by acute sepsis under the conditions of our study. The 
outcome of earlier studies analyzing the effects of polyphenols on LPS induced 
sepsis were inconsistent: Nicholas et al. [36] reported a reduced LPS-induced 
mortality following administration of apigenin. Larossa et al. [35] observed no 
effect on the levels of a number of inflammatory biomarkers after resveratrol 
treatment, which is consistent with the findings in our study. 
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8.5 Conclusions 
Overall our data support earlier findings that food polyphenols inhibit COX-2 in 
vitro. However, if more biological relevant systems are used, the efficacies of 
these natural products compared to drugs are lower (factor 10 in cancer cells, 
factor 100-1000 in primary monocytes). In vivo, even a high dose of 
polyphenols had no effect on COX-2 activity during acute inflammation in the 
LPS sepsis model. Taking the poor bioavailability of polyphenols [38] into 
account, it seems highly unlikely that the highest dose, that can possibly be 
ingested would modulate acute inflammation. However, direct effects in the 
gastrointestinal tract might take place, as reduced COX-2 expression and PGE2 
production have been observed for resveratrol in different murine colitis models 
[39, 40]. 
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9 Chapter 9 
Concluding Remarks and Future Perspectives 
 
Within this thesis, the potential anti-inflammatory effects of polyphenols by 
inhibition of cyclooxygenase-2 (COX-2) were investigated. The bioavailability of 
dietary ingredients is an important factor regarding the effectiveness to elicit 
biological actions. The first part of this thesis deals therefore with the 
metabolism and intestinal absorption of the resveratrol oligomers hopeaphenol 
and ε-viniferin. Hopeaphenol showed a unique metabolic stability regarding 
glucuronidation by human and rat liver microsomes (Chapter 2). Therefore, the 
tetramer seems to be no substrate for glucuronosyltransferases. Although 
conjugation with glucuronic acid is a major metabolic pathway for polyphenols, 
further studies are needed to elucidate its fate in other metabolic pathways such 
as conversion by cytochrome P 450 monooxygenases or sulfotransferases. The 
intestinal absorption of the resveratrol oligomers was studied in a Caco-2 
cellular transwell model (Chapter 3). Although a minor portion of both oligomers 
was detected in the cellular fraction, neither ε-viniferin nor hopeaphenol were 
able to pass the Caco-2 cell monolayer. This observation suggests low oral 
bioavailability for both compounds. However, to investigate the bioavailability in 
more detail, further experiments, preferably supplementation studies in humans 
are necessary. In these studies the quantification of compound and metabolites 
in plasma or tissues is a major challenge, due to lack of standards and 
isotopically labeled internal standards. 
In the second part of this thesis effects of polyphenols on the COX branch of the 
arachidonic acid (AA) cascade were investigated. Different animal models of 
inflammation were characterized for changes in oxylipin levels to identify a 
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suitable in vivo model for studying the effects of polyphenols on COX-2 
(Chapter 5 and 6). In the selected models a general increase of lipid mediators 
during acute inflammation was observed. The extent, however, differed 
considerably between the models. Even the two sepsis models showed different 
effects of the acute inflammation on systemic oxylipin levels. The increase in 
plasma prostaglandin (PG) and other lipid mediator concentrations was more 
pronounced in the LPS-induced murine sepsis in comparison to sepsis induced 
by cecal ligation and puncture (CLP). It would be of high scientific value to 
investigate if the changes in oxylipin pattern observed during experimental 
sepsis resemble the situation in septic patients. In particular, it is of high interest 
to answer the question which model is the most predictive one for oxylipin levels 
in septic patients. This would allow developing new treatment strategies which 
target the AA cascade in sepsis. 
The investigation of a small library of polyphenols in different in vitro test 
systems supported earlier findings that polyphenols are able to modulate 
COX-2 activity in vitro (Chapter 8). However, pretreatment with a high dose of 
polyphenols in an animal model of acute inflammation revealed that they did not 
affect COX-2 activity. The positive control celecoxib resulted in decreased PG 
levels, demonstrating that effects on COX-2 can be detected within the chosen 
model. Thus, a modulation of the activity of this branch of the AA cascade by 
polyphenols does not seem to be a relevant in vivo mechanism during acute 
inflammation. Dosage and route of administration are critical parameters for the 
investigation of effects of compounds in animal models. In this study the 
compounds were administered i. p. at a high dose. This approach was chosen 
to bypass low intestinal absorption. Based on the assumption that this strategy 
allows to detect even moderate effects of compounds with a low bioavailability, 
the study clearly demonstrates that a single dose of polyphenols has no 
beneficial effects on acute inflammation. It remains to be elucidated if 
polyphenols can elicit beneficial effects on diseases characterized by chronic or 
less severe inflammation. Moreover, repeated administration of polyphenols 
may enhance the potential effects of these compounds. 
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Overall this thesis demonstrates that it is not possible to transfer the in vitro 
modulation of COX-2 by polyphenols to an efficacy in vivo. Nevertheless, the 
compounds may act on other targets involved in the development of 
inflammation. 
Although epidemiological data suggest that the protective effects of fruits and 
vegetables are mediated by polyphenols, up to now evidence is missing that a 
single compound or a class of substances is responsible for the effects. Further 
research is needed to elucidate if the beneficial health effects of fruits and 
vegetables can be explained by single ingredients. Another possible 
explanation for the protective effects would be that they are mediated by the 
complex natural mixture of the different ingredients present in fruits and 
vegetables. Studies in animals and patients, which investigate the effects of the 
dietary intake of whole fruits and vegetables on chronic inflammation, would 
address this aspect. 
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10 Summary 
The dietary intake of fruits and vegetables is associated with beneficial effects 
on human health. Polyphenols are discussed to play a key role in this process. 
Several in vitro studies propose an anti-inflammatory potential of polyphenols 
mediated by a modulation of the cyclooxygenase-2 (COX-2) activity. The 
bioavailability of polyphenols is a key factor for their potential effects in vivo. 
The compounds can only elicit biological effects if the substance reaches the 
target cell or tissue in a sufficient concentration. 
This thesis aims to investigate the effects of polyphenols mediated by a 
modulation of COX-2 activity. For this purpose a tiered approach was applied: 
1. Investigation of bioavailability and chemical stability. (Chapter 2-3) 
2. Development of an analytical methodology for the investigation of COX-2 
inhibition in in vitro. (Chapter 7) 
3. Determination of COX-2 inhibitory potential of polyphenols in vitro. 
(Chapter 8) 
4. Identification of an in vivo model and analytical technique for studying 
effects on COX-2 in vivo. (Chapter 4-6) 
5. Investigation of the most potent polyphenols in the in vivo model. 
(Chapter 8) 
Investigation of the metabolic and chemical stability of resveratrol and its 
oligomers revealed a unique stability for the tetramer hopeaphenol. Microsomal 
incubation of hopeaphenol and ε-viniferin showed that hopeaphenol, in contrast 
to resveratrol and ε-viniferin, is no substrate for glucuronosyltransferases. This 
metabolic stability towards glucuronidation may result in an increased 
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bioavailability of this polyphenol. However, neither hopeaphenol nor ε-viniferin 
showed a flux through the Caco-2-cell monolayer, a commonly used cell-line 
model for intestinal absorption. Because significant amounts of hopeaphenol 
and ε-viniferin were detected in the cellular fraction, these compounds may act 
on the intestine. Overall the data suggest that it is unlikely that the oligomers 
pass the human intestinal barrier in biologically relevant amounts. 
In order to study effects of polyphenols on COX-2, a reliable and preferably fast 
read-out for COX activity assays is necessary. For this purpose, a fast online-
solid phase extraction-LC-MS method for the quantification of TxB2, PGE2, and 
PGD2 was developed. This method allows the quantification of COX products in 
7.1 min per sample, including online sample preparation. Regarding sensitivity 
and accuracy in biological matrices, the presented method is comparable or 
even better than described approaches. 
In the next step the method was applied as read-out to characterize the effects 
of selected polyphenols on COX-2 in three in vitro test systems: (i) an enzyme 
assay, (ii) a cancer cell line and (iii) primary human monocytes stimulated with 
lipopolysaccharide (LPS). These studies supported that polyphenols are indeed 
able to modulate COX-2 activity in vitro. Apigenin, wogonin, resveratrol and 
genistein were found to be the most potent polyphenols tested in the primary 
monocytes. However, their inhibitory potencies were 100 to 1000-fold lower in 
comparison to pharmaceuticals. 
Apart from TxB2, PGE2 and PGD2 several other metabolites are formed in the 
COX branch in vivo. Therefore, targeted metabolomics is an ideal tool to 
investigate if the observed effects of polyphenols on COX-2 are of in vivo 
relevance. Additionally, this approach enables to detect effects of polyphenols 
on the other branches of the AA cascade. Applying this technique, different 
inflammation models were characterized regarding their oxylipin pattern to 
identify an in vivo model which allows investigating COX-2 activity modulation of 
polyphenols in vivo. In an animal model for inflammatory bowel disease a 
general increase of plasma oxylipins derived from the lipoxygenase and 
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cytochrome P450 branch of the AA cascade was observed during the acute 
phase of inflammation. However, no increased plasma COX metabolites could 
be detected. In the chronic phase of colitis neither COX metabolites nor lipid 
mediators derived from other pathways were elevated. Thus, systemic oxylipin 
levels are no suitable markers for chronic inflammation within this model. In two 
commonly used animal models of sepsis, the LPS induced murine sepsis model 
and the cecal ligation and puncture (CLP) model, changes in COX metabolites 
were more pronounced. Plasma prostaglandin (PG) levels were dramatically 
elevated. In the LPS model PGE2 concentration was found at 2100% of the 
control. PG increase was lower after CLP induced sepsis (97% increase in 
PGE2). Additionally to the PG levels, plasma epoxy-fatty acid (FA), dihydroxy-
FA and most of the hydroxy-FA levels were elevated in both models of sepsis. 
The pronounced changes in the COX branch during LPS induced sepsis 
demonstrate that this model is suitable for the investigation of effects of 
polyphenols on COX-2 activity in vivo. 
The most potent polyphenols in vitro, resveratrol, apigenin, genistein and 
ε viniferin, were tested for their ability to act on COX-2 in vivo in the LPS 
induced sepsis model. Pretreatment with polyphenols (100 mg/kg bw i. p.) failed 
to decrease plasma and tissue PG levels, whereas the positive control 
celecoxib significantly reduced LPS induced PG formation. Thus, despite the 
moderate in vitro activity, polyphenols were not able to inhibit COX-2 activity in 
vivo. These data suggest that an effect of polyphenols on COX-2 during acute 
inflammation seems rather unlikely, even if a high dose is ingested. 
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11 Appendix 
Chapter 4 
 
 
Fig.  11.1: Ex-vivo degradation/formation of TxB2, prostaglandins (PGs) and trihomes in human 
whole blood after blood withdrawal. Blood of a healthy human volunteer was 
collected in EDTA tubes, pooled and left for 5 min, 30 min, 60 min or 120 min either 
at room temperature (RT) or on ice. After centrifugation (1200 x g, 15 min, 4 °C), the 
plasma was immediately frozen (-80 °C) and the oxylipin concentration was 
analyzed within 5 days (Oasis SPE). The resulting concentrations after different 
periods of time in sample preparation are compared to those with direct sample 
preparation (t(5 min, RT)). In comparison to 5 min storage at RT the concentration of the 
PGs was significantly decreased already 5 min after storage on ice. After 30 min (ice 
and RT) the PG levels were increased before they finally decreased again after 60 
min. The concentrations of TxB2, 20-COOH-LTB4 and trihomes were stable up to 
120 min either on ice or at RT. Shown are mean ± SD (n=4). 
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Fig.  11.2: Ex-vivo degradation/ formation of diols in human whole blood after blood withdrawal. 
Blood of a healthy human volunteer was collected in EDTA tubes, pooled and left for 
5 min, 30 min, 60 min or 120 min either at room temperature (RT) or on ice. After 
centrifugation (1200 x g, 15 min, 4 °C), the plasma was immediately frozen (-80 °C) 
and the oxylipin concentration was analyzed within 5 days (Oasis SPE)The resulting 
concentrations after different periods of time in sample preparation are compared to 
those with direct sample preparation (t(5 min, RT)). Shown are mean ± SD (n=4).  
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Fig.  11.3: Ex-vivo degradation/ formation of alcohols and epoxy fatty acids in human whole blood after 
blood withdrawal. Blood of a healthy human volunteer was collected in EDTA tubes, pooled 
and left for 5 min, 30 min, 60 min or 120 min either at room temperature (RT) or on ice. After 
centrifugation (1200 x g, 15 min, 4 °C), the plasma was immediately frozen (-80 °C) and the 
oxylipin concentration was analyzed within 5 days (Oasis SPE). The resulting concentrations 
after different periods of time in sample preparation are compared to those with direct sample 
preparation (t(5 min, RT)). While concentrations of 11- and 15-HETE halved after 60 min on ice or 
at RT, the levels of further alcohols were stable up to 120 min. The concentrations of 11(12)- 
and 14(15)-EpETrE were halved after 60 min of storage either on ice or at RT. The other 
epoxides were not affected up to 120 min of storage. Shown are mean ± SD (n=4). 
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Fig.  11.4: Ex-vivo degradation/ formation of oxylipins in freshly centrifuged human plasma. Blood of a 
healthy human volunteer was collected in EDTA tubes, pooled and centrifuged (1200 x g, 15 min, 4 °C) 
after 5 min at room temperature (RT). The resulting plasma was left with the cell pellet for 0 min, 30 min or 
60 min on ice before freezing at -80 °C till analysis. Oxylipin concentrations were analyzed within 5 days 
(Oasis SPE). The resulting concentrations after different periods of time in sample preparation are 
compared to those with direct sample preparation (t(0 min)). While the concentrations of 11- and 15-HETE 
halved in the first 30 min after centrifugation, most other alcohols showed no losses. The levels of PGE2 
and PGF2α significantly decreased in the first 30 min of storage while TxB2, 20-COOH-LTB4, 6-keto-PGF1α 
and the trihomes showed no changes up to 60 min. The detected diols and most of the epoxides showed 
no or only minor losses during this storage. However, the concentrations of all EpETrEs decreased within 
the first 30 min. Shown are mean ± SD (n=4). 
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Chapter 5, 6, 8 
Tab. 11.1: Parameters of the LC-MS method used for the quantification of oxylipins in chapter 
5, 6 and 8. Shown are the analytes with their mass transitions for quantification in 
the scheduled SRM mode, electronic MS parameters (declustering potential (DP), 
collision energy (CE), collision exit potential (CXP)), retention time (tR) and the 
calibration range (lower limit of quantification (LLOQ), upper limit of quantification 
(ULOQ)). 
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Chapter 6 
Tab. 11.2: Plasma concentration of oxylipins (>LOQ) 24 h after induction of sepsis by i. p. LPS 
injection or CLP survery. Statistical differences were determined by one-way ANOVA 
followed by Tukeys post-test test (*p<0.05, **p<0.01, ***p<0.001). 
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Tab. 11.3: Liver tissue concentration of oxylipins (>LOQ) 24 h after induction of sepsis by i. p. 
LPS injection or CLP survery. Statistical differences were determined by one-way 
ANOVA followed by Tukeys post-test test (*p<0.05, **p<0.01, ***p<0.001). 
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Tab. 11.3 continued 
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Tab. 11.4: Kidney tissue concentration of oxylipins (>LOQ) 24 h after induction of sepsis by i. p. 
LPS injection or CLP survery. Statistical differences were determined by one-way 
ANOVA followed by Tukeys post-test test (*p<0.05, **p<0.01, ***p<0.001). 
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Tab. 11.5: Heart tissue concentration of oxylipins (>LOQ) 24 h after induction of sepsis by i. p. 
LPS injection or CLP survery. Statistical differences were determined by one-way 
ANOVA followed by Tukeys post-test test (*p<0.05, **p<0.01, ***p<0.001). 
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Tab. 11.6 Lung tissue concentration of oxylipins (>LOQ) 24 h after induction of sepsis by i. p. 
LPS injection or CLP survery. Statistical differences were determined by one-way 
ANOVA followed by Tukeys post-test test (*p<0.05, **p<0.01, ***p<0.001). 
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Chapter 8 
Tab. 11.7: Oxylipin concentrations in plasma 24 h after LPS treatment. 
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Tab. 11.8: Oxylipin concentrations in kidney tissue 24 h after LPS treatment. 
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Tab. 11.9: Oxylipin concentrations in liver tissue 24 h after LPS treatment. 
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12 Abbreviations 
AA  arachidonic acid 
ACN  acetonitrile 
AKI acute kidney injury 
ALT alanine transaminase 
AMPP N-(4-aminomethylphenyl) pyridinium 
AST aspartate transaminase 
BCA bicinchoninic acid 
BHT butylated hydroxytoluene 
BSA bovine serum albumin 
CAD collisionally activated dissociation 
CE collision energy 
CLP cecal puncture ligation 
COX cyclooxygenase 
Ctrl. control 
CXP collision exit potential 
CYP cytochrome P450 monooxygenase 
DAI disease activity index 
DHA docosahexaenoic acid 
DiHDPE dihydroxy docosopentaenoic acid 
DiHETE dihydroxy eicosatetraenoic acid 
DiHETrE dihydroxy eicosatrienoic acid 
DiHODE dihydroxy octadecadienoic acid 
DiHOME dihydroxy octadecenoic acid 
DMEM Dulbecco’s Modified Eagle Medium 
ABBREVIATIONS 
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DMSO dimethyl sulfoxide 
DP declustering potential 
DSS dextran sulfate sodium 
Dyn. range dynamic range 
EDTA ethylenediaminetetraacetic acid 
EET epoxy-AA 
EIA enzyme immune assay 
EKODE epoxy-keto-octadecenoic acid 
EP entrance potential 
EPA eicosapentaenoic acid 
EpDPE epoxy docosapentaenoic acid 
EpETE epoxy eicosatetraenoic acid 
EpETrE epoxy eicosatrienoic acid 
EpODE epoxy octadecadienoic acid 
EpOME epoxy octadecenoic acid 
ESI electrospray ionization 
FA fatty acid 
FBS fetal bovine serum 
FCS fetal calf serum 
FWHM full width at half maximum 
GUS glucuronidase 
HAc acetic acid 
HDHA hydroxy docosahexaenoic acid 
HEPE hydroxy eicosapentaenoic acid 
HEPES 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid 
HETE hydroxy eicosatetraenoic acid 
HETrE hydroxyl eicosatrienoic acid 
HLM human liver microsomes 
HODE hydroxy octadecadienoic acid 
HOTrE hydroxy octadecatrienoic acid 
ABBREVIATIONS 
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HpETE hydroperoxyeicosatetraenoic acid; hydroperoxy-AA 
HRMS high resolution MS 
IL interleukin 
iP isoprostane 
IS internal standard 
LC  liquid chromatography 
LDH lactate dehydrogenase 
LLE liquid liquid extraction 
LLOQ lower limit of quantification 
LOD limit of detection 
LOQ limit of quantification 
LOX lipoxygenase 
LPS lipopolysaccharide 
LT leukotriene 
LY lucifer yellow 
m/z mass to charge ratio 
MeOH methanol 
mPGES mircosomal prostaglandin E synthase 
MRM multiple reaction monitoring 
MS  mass spectrometry 
n.d. not detected 
NSAID non-steroidal anti-inflammatory drug  
PAGE polyacrylamide gel electrophoresis 
Papp apparent permeability coefficient 
PBS phosphate buffered saline 
PFB pentafluorobenzyl 
PG prostaglandin 
PUFA polyunsaturated fatty acid 
RIPA radioimmunoprecipitation assay buffer 
RLM  rat liver microsomes  
ABBREVIATIONS 
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RPMI Roswell Park Memorial Institute medium 
SD standard deviation 
SDS sodium dodecyl sulfate 
SE standard error mean 
sEH soluble epoxide hydrolase 
SOP standard operating procedure 
SPE solid phase extraction 
SRM selected reaction monitoring 
TBST tris buffered saline tween 
TEER trans-epithelial electrical resistance 
TNF tumor nekrose factor 
TRIS tris(hydroxymethyl)aminomethane 
Tx thromboxane 
TxAS thromboxane A synthase 
UC ulcerative colitis 
UDP uridine 5’-diphosphate 
UDPGA uridine 5’-diphosphoglucuronic acid 
UGT UDP-glucuronosyltransferase 
ULOQ Upper limit of quantification 
UV ultraviolet absorbance detection 
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